Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,966152,maximal rate of transport,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [h],12,85,DB01032,Probenecid
,966152,transport constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [h],12,86,DB01032,Probenecid
,966152,transport constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [l],32,87,DB01032,Probenecid
,966152,Michaelis constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [l],32,88,DB01032,Probenecid
,966152,Michaelis constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),M,7 x,89,DB01032,Probenecid
,966152,Ki,"The value of Ki, the dissociation constant for the transport carrier-inhibitor complex, was 23 mug/ml (8 x10-5 M).",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[μg] / [ml],23,90,DB01032,Probenecid
,966152,dissociation constant,"The value of Ki, the dissociation constant for the transport carrier-inhibitor complex, was 23 mug/ml (8 x10-5 M).",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[μg] / [ml],23,91,DB01032,Probenecid
,966152,dissociation constant,"The value of Ki, the dissociation constant for the transport carrier-inhibitor complex, was 23 mug/ml (8 x10-5 M).",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),M,8 x10-5,92,DB01032,Probenecid
,1553347,concentrations,Plasma probenecid concentrations during low-dose and high-dose infusion were 56.9 +/- 12 and 248 +/- 42 micrograms/ml.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],56.9,427,DB01032,Probenecid
,1553347,concentrations,Plasma probenecid concentrations during low-dose and high-dose infusion were 56.9 +/- 12 and 248 +/- 42 micrograms/ml.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],248,428,DB01032,Probenecid
,1553347,terminal half-life,Postinfusion data showed that the zidovudine terminal half-life during high-dose probenecid treatment was longer than that with low-dose probenecid treatment (58.2 +/- 4.6 vs 39.0 +/- 9.1 min).,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),min,58.2,429,DB01032,Probenecid
,1553347,terminal half-life,Postinfusion data showed that the zidovudine terminal half-life during high-dose probenecid treatment was longer than that with low-dose probenecid treatment (58.2 +/- 4.6 vs 39.0 +/- 9.1 min).,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),min,39.0,430,DB01032,Probenecid
,1553347,volume of distribution,The volume of distribution of zidovudine also decreased (1.76 +/- 0.27 vs. 1.10 +/- 0.095 L/kg) as a result of probenecid coadministration.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[l] / [kg],1.76,431,DB01032,Probenecid
,1553347,volume of distribution,The volume of distribution of zidovudine also decreased (1.76 +/- 0.27 vs. 1.10 +/- 0.095 L/kg) as a result of probenecid coadministration.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[l] / [kg],1.10,432,DB01032,Probenecid
,1553347,Michaelis-type constants,"Michaelis-type constants for probenecid inhibition of zidovudine renal and nonrenal clearances were 73 and 55 micrograms/ml, respectively.",Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],73,433,DB01032,Probenecid
,1553347,Michaelis-type constants,"Michaelis-type constants for probenecid inhibition of zidovudine renal and nonrenal clearances were 73 and 55 micrograms/ml, respectively.",Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],55,434,DB01032,Probenecid
,2571484,total plasma clearance,"In this study the elimination kinetics of cilastatin in rats at doses of 5, 10, 20, 50, 100, and 200 mg/kg iv were demonstrated to be dose dependent, with total plasma clearance and non-renal clearance falling from 20.2 +/- 3.1 ml/min/kg and 17.7 +/- 3.3 ml/min/kg (mean +/- S.D.) at the 5 mg/kg dose to 11.4 +/- 1.2 ml/min/kg and 5.30 +/- 1.2 ml/min/kg, respectively, at the 200 mg/kg dose, whereas the volume of distribution of the drug remained unchanged.",Dose-dependent kinetics of cilastatin in laboratory animals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],20.2,2224,DB01032,Probenecid
,2571484,non-renal clearance,"In this study the elimination kinetics of cilastatin in rats at doses of 5, 10, 20, 50, 100, and 200 mg/kg iv were demonstrated to be dose dependent, with total plasma clearance and non-renal clearance falling from 20.2 +/- 3.1 ml/min/kg and 17.7 +/- 3.3 ml/min/kg (mean +/- S.D.) at the 5 mg/kg dose to 11.4 +/- 1.2 ml/min/kg and 5.30 +/- 1.2 ml/min/kg, respectively, at the 200 mg/kg dose, whereas the volume of distribution of the drug remained unchanged.",Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],17.7,2225,DB01032,Probenecid
,2571484,non-renal clearance,"In this study the elimination kinetics of cilastatin in rats at doses of 5, 10, 20, 50, 100, and 200 mg/kg iv were demonstrated to be dose dependent, with total plasma clearance and non-renal clearance falling from 20.2 +/- 3.1 ml/min/kg and 17.7 +/- 3.3 ml/min/kg (mean +/- S.D.) at the 5 mg/kg dose to 11.4 +/- 1.2 ml/min/kg and 5.30 +/- 1.2 ml/min/kg, respectively, at the 200 mg/kg dose, whereas the volume of distribution of the drug remained unchanged.",Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],5.30,2226,DB01032,Probenecid
,2571484,fm,The fm values decreased from 0.915 at the 10 mg/kg dose to 0.626 at the 100 mg/kg dose.,Dose-dependent kinetics of cilastatin in laboratory animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),,0.915,2227,DB01032,Probenecid
,2571484,fm,The fm values decreased from 0.915 at the 10 mg/kg dose to 0.626 at the 100 mg/kg dose.,Dose-dependent kinetics of cilastatin in laboratory animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),,0.626,2228,DB01032,Probenecid
,2571484,renal clearance,The renal clearance of cilastatin increased from 2.50 +/- 0.40 ml/min/kg at the lowest dose to 6.10 +/- 0.50 ml/min/kg at the highest dose as the dose increased.,Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],2.50,2229,DB01032,Probenecid
,2571484,renal clearance,The renal clearance of cilastatin increased from 2.50 +/- 0.40 ml/min/kg at the lowest dose to 6.10 +/- 0.50 ml/min/kg at the highest dose as the dose increased.,Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],6.10,2230,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],23,3710,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],56,3711,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],103,3712,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],102,3713,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],27,3714,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],74,3715,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],115,3716,DB01032,Probenecid
,15830485,peak serum concentrations,"Mean peak serum concentrations of antibiotic activity after cephalothin infusions were 23, 56, 103, and 102 mug/ml, respectively, and after cefoxitin infusions they were 27, 74, 115, and 125 mug/ml, respectively.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),[μg] / [ml],125,3717,DB01032,Probenecid
,15830485,terminal serum half-life,"Probenecid treatment prolonged the terminal serum half-life of cephalothin-like activity from 0.52 to 1.0 h, and of cefoxitin from 0.68 to 1.4 h.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),h,0.52 to 1.0,3718,DB01032,Probenecid
,15830485,terminal serum half-life,"Probenecid treatment prolonged the terminal serum half-life of cephalothin-like activity from 0.52 to 1.0 h, and of cefoxitin from 0.68 to 1.4 h.","Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830485/),h,0.68 to 1.4,3719,DB01032,Probenecid
,7471606,plasma concentration,Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the probenecid.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,2.5,4012,DB01032,Probenecid
,7471606,plasma concentration,Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the probenecid.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,9.05,4013,DB01032,Probenecid
,7471606,plasma concentration,Probenecid reached an average plasma concentration of 71.3 mg/1.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,71.3,4014,DB01032,Probenecid
,15564947,clearance,Probenecid pretreatment resulted in a decrease in the clearance of M6G from 8.3 +/- 1 l/h to 6.7 +/- 1.3 l/h (factor of 0.8; P < 0.05 vs. placebo cotreatment).,Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564947/),[l] / [h],8.3,4294,DB01032,Probenecid
,15564947,clearance,Probenecid pretreatment resulted in a decrease in the clearance of M6G from 8.3 +/- 1 l/h to 6.7 +/- 1.3 l/h (factor of 0.8; P < 0.05 vs. placebo cotreatment).,Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564947/),[l] / [h],6.7,4295,DB01032,Probenecid
,4020675,half-life,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,4.30,4627,DB01032,Probenecid
,4020675,half-life,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,2.51,4628,DB01032,Probenecid
,4020675,clearance,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],178,4629,DB01032,Probenecid
,4020675,clearance,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],329,4630,DB01032,Probenecid
,4020675,volume of distribution,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,65,4631,DB01032,Probenecid
,4020675,volume of distribution,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,69,4632,DB01032,Probenecid
,4020675,Urinary excretion,Urinary excretion of acetaminophen glucuronide during 24 hr was decreased (84 +/- 9 vs.,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),,84,4633,DB01032,Probenecid
,4020675,excretion,260 +/- 21 mg of acetaminophen as glucuronide; P less than .001) and acetaminophen sulfate excretion was increased (323 +/- 25 vs.,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),,323,4634,DB01032,Probenecid
,4020675,half-life,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,33.0,4635,DB01032,Probenecid
,4020675,half-life,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,14.3,4636,DB01032,Probenecid
,4020675,clearance,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],44.7,4637,DB01032,Probenecid
,4020675,clearance,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],80.3,4638,DB01032,Probenecid
,4020675,volume of distribution,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,111,4639,DB01032,Probenecid
,4020675,volume of distribution,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,111,4640,DB01032,Probenecid
,9110063,bioavailability,The bioavailability of oral ganciclovir averages 6-9%.,Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9110063/),%,6-9,8164,DB01032,Probenecid
,6947405,distribution serum half-life (T1/2 alpha),The mean distribution serum half-life (T1/2 alpha) was 0.11-0.12 h and the mean elimination serum half-life (T1/2 beta) was 0.79-0.89 h.,Pharmacokinetics of azlocillin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),h,0.11-0.12,9486,DB01032,Probenecid
,6947405,elimination serum half-life (T1/2 beta),The mean distribution serum half-life (T1/2 alpha) was 0.11-0.12 h and the mean elimination serum half-life (T1/2 beta) was 0.79-0.89 h.,Pharmacokinetics of azlocillin in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),h,0.79-0.89,9487,DB01032,Probenecid
,6947405,volume of the central compartment (Vc),The volume of the central compartment (Vc) was 7.36-8.01 1/1.73 m2 and the apparent volume of distribution (Vdss) was 14.12-14.32 1/1.73 m2.,Pharmacokinetics of azlocillin in healthy subjects. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[1] / [1.73·m2],7.36-8.01,9488,DB01032,Probenecid
,6947405,apparent volume of distribution (Vdss),The volume of the central compartment (Vc) was 7.36-8.01 1/1.73 m2 and the apparent volume of distribution (Vdss) was 14.12-14.32 1/1.73 m2.,Pharmacokinetics of azlocillin in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[1] / [1.73·m2],14.12-14.32,9489,DB01032,Probenecid
,6947405,T1/2 beta,The mean T1/2 beta after a 30 min i.v. infusion of 80 mg/kg to the same healthy subjects was 1.10 h.,Pharmacokinetics of azlocillin in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),h,1.10,9490,DB01032,Probenecid
,6947405,Serum clearances (Cs),"Serum clearances (Cs) for 15, 30 and 80 mg/kg were 251.1, 214.0 and 152.9 ml/min/1.73 m2 and renal clearance (Cr) were 99.7, 145.2 and 94.1 ml/min/1.73 m2, respectively.",Pharmacokinetics of azlocillin in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[ml] / [1.73·m2·min],251.1,9491,DB01032,Probenecid
,6947405,Serum clearances (Cs),"Serum clearances (Cs) for 15, 30 and 80 mg/kg were 251.1, 214.0 and 152.9 ml/min/1.73 m2 and renal clearance (Cr) were 99.7, 145.2 and 94.1 ml/min/1.73 m2, respectively.",Pharmacokinetics of azlocillin in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[ml] / [1.73·m2·min],214.0,9492,DB01032,Probenecid
,6947405,Serum clearances (Cs),"Serum clearances (Cs) for 15, 30 and 80 mg/kg were 251.1, 214.0 and 152.9 ml/min/1.73 m2 and renal clearance (Cr) were 99.7, 145.2 and 94.1 ml/min/1.73 m2, respectively.",Pharmacokinetics of azlocillin in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[ml] / [1.73·m2·min],152.9,9493,DB01032,Probenecid
,6947405,renal clearance (Cr),"Serum clearances (Cs) for 15, 30 and 80 mg/kg were 251.1, 214.0 and 152.9 ml/min/1.73 m2 and renal clearance (Cr) were 99.7, 145.2 and 94.1 ml/min/1.73 m2, respectively.",Pharmacokinetics of azlocillin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[ml] / [1.73·m2·min],99.7,9494,DB01032,Probenecid
,6947405,renal clearance (Cr),"Serum clearances (Cs) for 15, 30 and 80 mg/kg were 251.1, 214.0 and 152.9 ml/min/1.73 m2 and renal clearance (Cr) were 99.7, 145.2 and 94.1 ml/min/1.73 m2, respectively.",Pharmacokinetics of azlocillin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[ml] / [1.73·m2·min],145.2,9495,DB01032,Probenecid
,6947405,renal clearance (Cr),"Serum clearances (Cs) for 15, 30 and 80 mg/kg were 251.1, 214.0 and 152.9 ml/min/1.73 m2 and renal clearance (Cr) were 99.7, 145.2 and 94.1 ml/min/1.73 m2, respectively.",Pharmacokinetics of azlocillin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6947405/),[ml] / [1.73·m2·min],94.1,9496,DB01032,Probenecid
,9527780,Renal clearance (CLR),"Renal clearance (CLR) for the unbound drug (approximately 400 ml/min) was greater than the glomerular filtration rate (GFR) (approximately 109 ml/min) for both epimers, suggesting that both epimers are secreted at the renal tubules.",Stereoselective disposition of sulbenicillin in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527780/),[ml] / [min],400,12162,DB01032,Probenecid
,9527780,CLR,"CLR was greater for the S-epimer (37.5 and 49.8 ml/min for R-SBPC and S-SBPC, respectively), which was simply due to the greater fu of the S-epimer in plasma.",Stereoselective disposition of sulbenicillin in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527780/),[ml] / [min],37.5,12163,DB01032,Probenecid
,9527780,CLR,"CLR was greater for the S-epimer (37.5 and 49.8 ml/min for R-SBPC and S-SBPC, respectively), which was simply due to the greater fu of the S-epimer in plasma.",Stereoselective disposition of sulbenicillin in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527780/),[ml] / [min],49.8,12164,DB01032,Probenecid
,9527780,total body clearance,"In contrast, total body clearance was greater for the R-epimer (67.8 and 56.3 ml/min for R-SBPC and S-SBPC, respectively) because of the stereoselective degradation of the R-epimer in plasma.",Stereoselective disposition of sulbenicillin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527780/),[ml] / [min],67.8,12165,DB01032,Probenecid
,9527780,total body clearance,"In contrast, total body clearance was greater for the R-epimer (67.8 and 56.3 ml/min for R-SBPC and S-SBPC, respectively) because of the stereoselective degradation of the R-epimer in plasma.",Stereoselective disposition of sulbenicillin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527780/),[ml] / [min],56.3,12166,DB01032,Probenecid
,1762074,total clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],2.4,12876,DB01032,Probenecid
,1762074,total clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],2.3,12877,DB01032,Probenecid
,1762074,total clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.8,12878,DB01032,Probenecid
,1762074,renal clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.7,12879,DB01032,Probenecid
,1762074,renal clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.8,12880,DB01032,Probenecid
,1762074,renal clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.5,12881,DB01032,Probenecid
,1762074,renal clearance,"The renal clearance of AZT was approximately equal to renal plasma flow of rats (1.5 l/hr/kg), suggesting that in addition to filtration, AZT is also efficiently secreted in the kidney of the rat.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.5,12882,DB01032,Probenecid
,1762074,volume of distribution at steady state,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [kg],1.3,12883,DB01032,Probenecid
,1762074,volume of distribution at steady state,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [kg],1.0,12884,DB01032,Probenecid
,1762074,volume of distribution at steady state,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [kg],0.84,12885,DB01032,Probenecid
,1762074,elimination half-life,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),h,0.55,12886,DB01032,Probenecid
,1762074,elimination half-life,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),h,0.44,12887,DB01032,Probenecid
,1762074,elimination half-life,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),h,0.46,12888,DB01032,Probenecid
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),%,70,12889,DB01032,Probenecid
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),%,79,12890,DB01032,Probenecid
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),%,83,12891,DB01032,Probenecid
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),,0,12892,DB01032,Probenecid
excess,6490225,peak concentrations,"At the end of the infusion, peak concentrations in excess of 100 micrograms/ml were recorded for amoxycillin and 14 micrograms/ml for clavulanic acid.",Parenteral augmentin: pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6490225/),[μg] / [ml],100,13074,DB01032,Probenecid
,6490225,peak concentrations,"At the end of the infusion, peak concentrations in excess of 100 micrograms/ml were recorded for amoxycillin and 14 micrograms/ml for clavulanic acid.",Parenteral augmentin: pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6490225/),[μg] / [ml],14,13075,DB01032,Probenecid
,10664994,t1/2(alpha)),"The pharmacokinetic parameters of 99Tcm-PAH (t1/2(alpha)) = 2.5 min, t1/2(beta) = 41.7 min, Cl = 5.22 ml.min-1, Kel = 5.1 x 10(-4) min-1) differ from those of 99Tcm-DTPA.",99Tcm-p-aminohippuric acid as a new renal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664994/),min,2.5,16151,DB01032,Probenecid
,10664994,t1/2(beta),"The pharmacokinetic parameters of 99Tcm-PAH (t1/2(alpha)) = 2.5 min, t1/2(beta) = 41.7 min, Cl = 5.22 ml.min-1, Kel = 5.1 x 10(-4) min-1) differ from those of 99Tcm-DTPA.",99Tcm-p-aminohippuric acid as a new renal agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664994/),min,41.7,16152,DB01032,Probenecid
,10664994,Cl,"The pharmacokinetic parameters of 99Tcm-PAH (t1/2(alpha)) = 2.5 min, t1/2(beta) = 41.7 min, Cl = 5.22 ml.min-1, Kel = 5.1 x 10(-4) min-1) differ from those of 99Tcm-DTPA.",99Tcm-p-aminohippuric acid as a new renal agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664994/),[ml] / [min],5.22,16153,DB01032,Probenecid
,10664994,Kel,"The pharmacokinetic parameters of 99Tcm-PAH (t1/2(alpha)) = 2.5 min, t1/2(beta) = 41.7 min, Cl = 5.22 ml.min-1, Kel = 5.1 x 10(-4) min-1) differ from those of 99Tcm-DTPA.",99Tcm-p-aminohippuric acid as a new renal agent. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664994/),,5.1 x 10(-4),16154,DB01032,Probenecid
,7912178,t1/2,"In NMRI mice t1/2, CL, and V2 were 1-4 hr, 0.6-1 liter/kg/hr, and 1-4 liters/kg following 3, 10, or 30 mg/kg.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),h,1-4,16912,DB01032,Probenecid
,7912178,CL,"In NMRI mice t1/2, CL, and V2 were 1-4 hr, 0.6-1 liter/kg/hr, and 1-4 liters/kg following 3, 10, or 30 mg/kg.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [h·kg],0.6-1,16913,DB01032,Probenecid
,7912178,V2,"In NMRI mice t1/2, CL, and V2 were 1-4 hr, 0.6-1 liter/kg/hr, and 1-4 liters/kg following 3, 10, or 30 mg/kg.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [kg],1-4,16914,DB01032,Probenecid
,7912178,t1/2,"In Wistar and Sprague-Dawley rats, the mean +/- SD values of t1/2, CL, and Vz were 0.8 +/- 0.35 hr, 3.2 +/- 1.0 liters/kg/hr, and 4.0 +/- 1.1 liters/kg, respectively.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),h,0.8,16915,DB01032,Probenecid
,7912178,CL,"In Wistar and Sprague-Dawley rats, the mean +/- SD values of t1/2, CL, and Vz were 0.8 +/- 0.35 hr, 3.2 +/- 1.0 liters/kg/hr, and 4.0 +/- 1.1 liters/kg, respectively.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [h·kg],3.2,16916,DB01032,Probenecid
,7912178,Vz,"In Wistar and Sprague-Dawley rats, the mean +/- SD values of t1/2, CL, and Vz were 0.8 +/- 0.35 hr, 3.2 +/- 1.0 liters/kg/hr, and 4.0 +/- 1.1 liters/kg, respectively.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [kg],4.0,16917,DB01032,Probenecid
,7912178,CLR,The CLR was 0.90 +/- 0.20 liter/kg/hr.,"Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [h·kg],0.90,16918,DB01032,Probenecid
,7912178,t1/2,"In beagle dogs, t1/2 and Vz were 1-3 hr and 1-3 liters/kg, respectively.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),h,1-3,16919,DB01032,Probenecid
,7912178,Vz,"In beagle dogs, t1/2 and Vz were 1-3 hr and 1-3 liters/kg, respectively.","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [kg],1-3,16920,DB01032,Probenecid
,7912178,CL,"The CL was determined to be 1.5 +/- 0.4 liters/kg/hr (N = 18) following 2 days of infusion (0.2-1 mg/kg/hr), but after 1 month CL had decreased significantly (p < 0.0001) to 1.0 +/- 0.1 liter/kg/hr.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [h·kg],1.5,16921,DB01032,Probenecid
,7912178,CL,"The CL was determined to be 1.5 +/- 0.4 liters/kg/hr (N = 18) following 2 days of infusion (0.2-1 mg/kg/hr), but after 1 month CL had decreased significantly (p < 0.0001) to 1.0 +/- 0.1 liter/kg/hr.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912178/),[l] / [h·kg],1.0,16922,DB01032,Probenecid
,3941391,mean,"Intestinal perfusion studies were performed in six healthy volunteers during i.v. furosemide administration (mean serum concentration, 3.74 +/- 0.64 microgram/ml).",Clearance of furosemide by the gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[μg] / [ml],3.74,17356,DB01032,Probenecid
,3941391,serum concentration,"Intestinal perfusion studies were performed in six healthy volunteers during i.v. furosemide administration (mean serum concentration, 3.74 +/- 0.64 microgram/ml).",Clearance of furosemide by the gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[μg] / [ml],3.74,17357,DB01032,Probenecid
,3941391,clearance,Furosemide clearance for the total gastrointestinal tract was 2.1 +/- 0.4 ml/min (mean +/- S.E.M.) compared to a renal clearance of 93.1 +/- 4.6 ml/min.,Clearance of furosemide by the gastrointestinal tract. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[ml] / [min],2.1,17358,DB01032,Probenecid
,3941391,renal clearance,Furosemide clearance for the total gastrointestinal tract was 2.1 +/- 0.4 ml/min (mean +/- S.E.M.) compared to a renal clearance of 93.1 +/- 4.6 ml/min.,Clearance of furosemide by the gastrointestinal tract. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[ml] / [min],93.1,17359,DB01032,Probenecid
,18087819,cumulative biliary excretion amounts,"When belotecan was injected as a bolus dose of 5 mg/kg after probenecid was infused at a rate of 42.8 mg/2 mL/h/kg, the cumulative biliary excretion amounts and biliary clearance (CL(b)) of belotecan decreased (28.29 +/- 2.83 versus 19.96 +/- 1.45% of dose and 161.01 +/- 26.95 versus 92.66 +/- 1.45 mL/min/kg), whereas the systemic pharmacokinetics did not change.",Effect of probenecid on the biliary excretion of belotecan. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18087819/),[ml] / [kg·min],28.29,17375,DB01032,Probenecid
,18087819,biliary clearance (CL(b)),"When belotecan was injected as a bolus dose of 5 mg/kg after probenecid was infused at a rate of 42.8 mg/2 mL/h/kg, the cumulative biliary excretion amounts and biliary clearance (CL(b)) of belotecan decreased (28.29 +/- 2.83 versus 19.96 +/- 1.45% of dose and 161.01 +/- 26.95 versus 92.66 +/- 1.45 mL/min/kg), whereas the systemic pharmacokinetics did not change.",Effect of probenecid on the biliary excretion of belotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18087819/),[ml] / [kg·min],161.01,17376,DB01032,Probenecid
,18087819,biliary clearance (CL(b)),"When belotecan was injected as a bolus dose of 5 mg/kg after probenecid was infused at a rate of 42.8 mg/2 mL/h/kg, the cumulative biliary excretion amounts and biliary clearance (CL(b)) of belotecan decreased (28.29 +/- 2.83 versus 19.96 +/- 1.45% of dose and 161.01 +/- 26.95 versus 92.66 +/- 1.45 mL/min/kg), whereas the systemic pharmacokinetics did not change.",Effect of probenecid on the biliary excretion of belotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18087819/),[ml] / [kg·min],92.66,17377,DB01032,Probenecid
,11139459,target plasma concentration,Two groups of rats received an exponential infusion of M3G over 4 h to reach a target plasma concentration of 65 microM on two consecutive days.,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),μM,65,18889,DB01032,Probenecid
,11139459,influx clearance into the brain,"The process that appears to be mainly influenced by probenecid is influx clearance into the brain (0.11 microl min(-1) g-brain(-1) vs 0.17 microl min(-1) g-brain(-1), in the absence vs presence of probenecid, P:<0.001).",Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),[μl] / [g-brain·min],0.11,18890,DB01032,Probenecid
,11139459,influx clearance into the brain,"The process that appears to be mainly influenced by probenecid is influx clearance into the brain (0.11 microl min(-1) g-brain(-1) vs 0.17 microl min(-1) g-brain(-1), in the absence vs presence of probenecid, P:<0.001).",Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),[μl] / [g-brain·min],0.17,18891,DB01032,Probenecid
,11139459,efflux clearance,The efflux clearance was 1.15 microl min(-1) g-brain(-1).,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),[μl] / [g-brain·min],1.15,18892,DB01032,Probenecid
,11139459,half-life,The half-life of M3G was 81+/-25 min in brain ECF vs 22+/-2 min in blood (P<0.0001).,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),min,81,18893,DB01032,Probenecid
,11139459,half-life,The half-life of M3G was 81+/-25 min in brain ECF vs 22+/-2 min in blood (P<0.0001).,Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139459/),min,22,18894,DB01032,Probenecid
,27266990,unbound area under the concentration curve,"After 23 μmol/kg i.p. bolus injection, the prodrugs' unbound area under the concentration curve in brain was 0.3 nmol/g × min, whereas the parent drugs could not reach the brain.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[nM] / [g·min],0.3,19802,DB01032,Probenecid
,27266990,unbound brain concentrations,"The unbound brain concentrations of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[pM] / [g],521.4,19803,DB01032,Probenecid
,27266990,unbound brain concentrations,"The unbound brain concentrations of the prodrugs after 100 μM in situ mouse brain perfusion were 521.4 ± 46.9 and 126.9 ± 19.9 pmol/g for prodrugs 1 and 2, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),[pM] / [g],126.9,19804,DB01032,Probenecid
,27266990,concentrations,"The combination of competing transporter substrates for LAT1, l-tryptophan, and for organic anion transporting polypeptides, probenecid, decreased the brain concentrations to 352.4 ± 44.5 and 70.9 ± 7.0 pmol/g, respectively.",Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27266990/),,35,19805,DB01032,Probenecid
,8908728,peak norfloxacin plasma level,The peak norfloxacin plasma level of 90.52 +/- 3.18 micrograms/ml attained in the probenecid pre-treated febrile goats was higher than that in the febrile (75.46 +/- 0.72 micrograms/ml) or afebrile goats (62.25 +/- 1.23 micrograms/ml).,The effect of induced fever on the biokinetics of norfloxacin and its interaction with probenecid in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908728/),[μg] / [ml],90.52,20220,DB01032,Probenecid
,8908728,peak norfloxacin plasma level,The peak norfloxacin plasma level of 90.52 +/- 3.18 micrograms/ml attained in the probenecid pre-treated febrile goats was higher than that in the febrile (75.46 +/- 0.72 micrograms/ml) or afebrile goats (62.25 +/- 1.23 micrograms/ml).,The effect of induced fever on the biokinetics of norfloxacin and its interaction with probenecid in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908728/),[μg] / [ml],75.46,20221,DB01032,Probenecid
,8908728,peak norfloxacin plasma level,The peak norfloxacin plasma level of 90.52 +/- 3.18 micrograms/ml attained in the probenecid pre-treated febrile goats was higher than that in the febrile (75.46 +/- 0.72 micrograms/ml) or afebrile goats (62.25 +/- 1.23 micrograms/ml).,The effect of induced fever on the biokinetics of norfloxacin and its interaction with probenecid in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908728/),[μg] / [ml],62.25,20222,DB01032,Probenecid
,6328337,Renal clearance,Renal clearance of SA-446 (CSA) was 2.24 +/- 0.34 ml/g X min and was significantly higher than GFR.,Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6328337/),[ml] / [g·min],2.24,20235,DB01032,Probenecid
over,6328337,clearance ratio (CSA/GFR),The clearance ratio (CSA/GFR) of over 1.0 was indicative of a net tubular secretion.,Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6328337/),,1.0,20236,DB01032,Probenecid
,6328337,CSA,CSA decreased significantly from 2.24 +/- 0.34 to 0.71 +/- 0.14 ml/g X min.,Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6328337/),[ml] / [g·min],2.24,20237,DB01032,Probenecid
,6328337,CSA,CSA decreased significantly from 2.24 +/- 0.34 to 0.71 +/- 0.14 ml/g X min.,Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6328337/),[ml] / [g·min],0.71,20238,DB01032,Probenecid
,688724,AUC,"There was an increase in the mean AUC of indomethacin in plasma from 2,553 +/- 213 hr ng/ml to 4,181 +/- 384 hr ng/ml when probenecid was given, but there was no change in the plasma half-life of indomethacin.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[h·ng] / [ml],"2,553",21057,DB01032,Probenecid
,688724,AUC,"There was an increase in the mean AUC of indomethacin in plasma from 2,553 +/- 213 hr ng/ml to 4,181 +/- 384 hr ng/ml when probenecid was given, but there was no change in the plasma half-life of indomethacin.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[h·ng] / [ml],"4,181",21058,DB01032,Probenecid
,688724,plasma clearance,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [h·kg],174,21059,DB01032,Probenecid
,688724,plasma clearance,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [h·kg],107,21060,DB01032,Probenecid
,688724,apparent volume of distribution,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[l] / [kg],"0,927",21061,DB01032,Probenecid
,688724,apparent volume of distribution,"There was a reduction in the mean plasma clearance of indomethacin from 174 +/- 21 ml/kg/hr to 107 +/- 14 ml/kg/hr when probenecid was added to the indomethacin therapy and a decrease in the apparent volume of distribution from 0,927 +/- 0.16 L/kg to 0.613 +/- 0.13 L/kg.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[l] / [kg],0.613,21062,DB01032,Probenecid
,688724,urinary excretion,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[μg] / [d],"8,967",21063,DB01032,Probenecid
,688724,urinary excretion,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[μg] / [d],"4,760",21064,DB01032,Probenecid
,688724,renal clearance,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [min],271,21065,DB01032,Probenecid
,688724,renal clearance,"There was no change in the amount of free indomethacin excreted in the urine during probenecid therapy but there was a reduction in the urinary excretion of free plus glucuronide conjugate of indomethacin from 8,967 +/- 867 microgram/day to 4,760 +/- 674 microgram/day, with a fall in the mean renal clearance of indomethacin glucuronide from 271 +/- 48 ml/min to 126 +/- 57.0 ml/min.",The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688724/),[ml] / [min],126,21066,DB01032,Probenecid
,7379446,diuresis at steady state,Continuous intravenous infusion of furosemide (8 mg/hr) to 6 healthy subjects induced an average diuresis at steady state of 667 +/- 144 ml/30 min (+/- SD) with a mean plasma concentration of furosemide of 623 +/- 209 ng/ml.,Renal tubular secretion and effects of furosemide. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[ml] / [30·min],667,22404,DB01032,Probenecid
,7379446,plasma concentration,Continuous intravenous infusion of furosemide (8 mg/hr) to 6 healthy subjects induced an average diuresis at steady state of 667 +/- 144 ml/30 min (+/- SD) with a mean plasma concentration of furosemide of 623 +/- 209 ng/ml.,Renal tubular secretion and effects of furosemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[ng] / [ml],623,22405,DB01032,Probenecid
,7379446,urinary output,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],50.4,22406,DB01032,Probenecid
,7379446,urinary output,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],47.7,22407,DB01032,Probenecid
,7379446,urinary output,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],5.4,22408,DB01032,Probenecid
,7379446,Na,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],47.7,22409,DB01032,Probenecid
,7379446,Na,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],5.4,22410,DB01032,Probenecid
,1447340,renal excretion rate,"Probenecid co-medication reduces the renal excretion rate of flumequine acyl glucuronide from 662 to 447 micrograms/min (p = 0.00080), but not the percentage of glucuronidation.",Direct-gradient high-performance liquid chromatographic analysis and preliminary pharmacokinetics of flumequine and flumequine acyl glucuronide in humans: effect of probenecid. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447340/),[μg] / [min],662,22746,DB01032,Probenecid
,8150753,Cmax,"The Cmax ranged between 16.3 and 133 mg/L, with corresponding AUC values ranging between 34 and 263 mg.h/L.",Pharmacokinetics of cefepime: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),[mg] / [l],16.3 and 133,23388,DB01032,Probenecid
,8150753,AUC,"The Cmax ranged between 16.3 and 133 mg/L, with corresponding AUC values ranging between 34 and 263 mg.h/L.",Pharmacokinetics of cefepime: a review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),[h·mg] / [l],34 and 263,23389,DB01032,Probenecid
,8150753,elimination half-life (T1/2),The elimination half-life (T1/2) was approximately 2 h and was dose-independent.,Pharmacokinetics of cefepime: a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),h,2,23390,DB01032,Probenecid
,8150753,Total clearance (Cltot),Total clearance (Cltot) for all doses ranged between 122 and 136 mL/min.,Pharmacokinetics of cefepime: a review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),[ml] / [min],122 and 136,23391,DB01032,Probenecid
,8150753,Renal clearance (Clren),"Renal clearance (Clren) varied between 96 and 116 mL/min, suggesting that cefepime is eliminated mainly by glomerular filtration.",Pharmacokinetics of cefepime: a review. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),[ml] / [min],96 and 116,23392,DB01032,Probenecid
,8150753,Tmax,"Following single im doses of between 250 and 2000 mg, absorption was rapid and the Tmax was attained in 1-1.6 h.",Pharmacokinetics of cefepime: a review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),h,1-1.6,23393,DB01032,Probenecid
,8150753,T1/2,The T1/2 was approximately 2 h and independent of dose.,Pharmacokinetics of cefepime: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),h,2,23394,DB01032,Probenecid
,8150753,bioavailability,The bioavailability following im administration of 2000 mg was 100%.,Pharmacokinetics of cefepime: a review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),%,100,23395,DB01032,Probenecid
,8150753,Binding,Binding to plasma proteins was 16%.,Pharmacokinetics of cefepime: a review. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),%,16,23396,DB01032,Probenecid
,8150753,volume of distribution at steady-state (Vdss),The volume of distribution at steady-state (Vdss) varied between 18 and 22 L and was dose-independent.,Pharmacokinetics of cefepime: a review. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150753/),l,18 and 22,23397,DB01032,Probenecid
,10741624,apparent oral clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[l] / [h],14.7,24634,DB01032,Probenecid
,10741624,apparent oral clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[l] / [h],10.8,24635,DB01032,Probenecid
,10741624,renal clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],196.8,24636,DB01032,Probenecid
,10741624,renal clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],141.8,24637,DB01032,Probenecid
,10741624,net renal clearance by tubular secretion,"The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 +/- 62.9 to 93.0 +/- 31.1 mL/min.",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],151.4,24638,DB01032,Probenecid
,10741624,net renal clearance by tubular secretion,"The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 +/- 62.9 to 93.0 +/- 31.1 mL/min.",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],93.0,24639,DB01032,Probenecid
,4455125,peak serum levels,"After a 30-min infusion, peak serum levels of BL-P1654 (72.8 mug/ml [standard deviation] +/- 5.9) were 50% greater than those of ampicillin (53.6 +/- 8.9).",Human pharmacokinetics of BL-P1654 compared with ampicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4455125/),[μg] / [ml],72.8,25333,DB01032,Probenecid
,4455125,peak serum levels,"After a 30-min infusion, peak serum levels of BL-P1654 (72.8 mug/ml [standard deviation] +/- 5.9) were 50% greater than those of ampicillin (53.6 +/- 8.9).",Human pharmacokinetics of BL-P1654 compared with ampicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4455125/),[μg] / [ml],53.6,25334,DB01032,Probenecid
,4455125,peak serum levels,"At 75 min after the 1-g intramuscular injection of BL-P1654, peak serum levels averaged 28.4 +/- 10.3 mug/ml.",Human pharmacokinetics of BL-P1654 compared with ampicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4455125/),[μg] / [ml],28.4,25335,DB01032,Probenecid
,4455125,half-life,"The half-life of BL-P1654 (2.04 h) was significantly longer than for ampicillin (1.15 h), and the renal clearances of BL-P1654 and ampicillin were 79 versus 244 ml/min per 1.73 m(2), respectively.",Human pharmacokinetics of BL-P1654 compared with ampicillin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4455125/),h,2.04,25336,DB01032,Probenecid
,4455125,half-life,"The half-life of BL-P1654 (2.04 h) was significantly longer than for ampicillin (1.15 h), and the renal clearances of BL-P1654 and ampicillin were 79 versus 244 ml/min per 1.73 m(2), respectively.",Human pharmacokinetics of BL-P1654 compared with ampicillin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4455125/),h,1.15,25337,DB01032,Probenecid
,4455125,renal clearances,"The half-life of BL-P1654 (2.04 h) was significantly longer than for ampicillin (1.15 h), and the renal clearances of BL-P1654 and ampicillin were 79 versus 244 ml/min per 1.73 m(2), respectively.",Human pharmacokinetics of BL-P1654 compared with ampicillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4455125/),[1.73·min·ml] / [m(2],79,25338,DB01032,Probenecid
,4455125,renal clearances,"The half-life of BL-P1654 (2.04 h) was significantly longer than for ampicillin (1.15 h), and the renal clearances of BL-P1654 and ampicillin were 79 versus 244 ml/min per 1.73 m(2), respectively.",Human pharmacokinetics of BL-P1654 compared with ampicillin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4455125/),[1.73·min·ml] / [m(2],244,25339,DB01032,Probenecid
less,2109576,excretion ratios,"In dogs, on the other hand, the excretion ratios were less than unity (0.608 and 0.456) both without and with probenecid, and so were not affected by probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.608,26050,DB01032,Probenecid
,2109576,excretion ratios,"In dogs, on the other hand, the excretion ratios were less than unity (0.608 and 0.456) both without and with probenecid, and so were not affected by probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.456,26051,DB01032,Probenecid
,2109576,excretion ratio,"The excretion ratio without probenecid was 1.13, which was significantly decreased to 0.750 with probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,1.13,26052,DB01032,Probenecid
,2109576,excretion ratio,"The excretion ratio without probenecid was 1.13, which was significantly decreased to 0.750 with probenecid.","Renal handling of fleroxacin in rabbits, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109576/),,0.750,26053,DB01032,Probenecid
,32482623,half-life,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h,7.6,26063,DB01032,Probenecid
,32482623,bioavailability,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),%,3.2,26064,DB01032,Probenecid
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,0.19,26065,DB01032,Probenecid
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,2.5,26066,DB01032,Probenecid
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,3.8,26067,DB01032,Probenecid
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,2.7,26068,DB01032,Probenecid
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,10.5,26069,DB01032,Probenecid
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,26.6,26070,DB01032,Probenecid
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.8,26071,DB01032,Probenecid
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,6.2,26072,DB01032,Probenecid
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,10.5,26073,DB01032,Probenecid
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1,26074,DB01032,Probenecid
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.4,26075,DB01032,Probenecid
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.4,26076,DB01032,Probenecid
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.6,26077,DB01032,Probenecid
,3377315,elimination half-life (t1/2),The following mean values +/- SD were found: elimination half-life (t1/2) was 83.8 +/- 8.6 minutes after IV administration and significantly longer 116.8 +/- 20.5 minutes (P less than 0.001) after IM administration at 10 mg/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,83.8,27734,DB01032,Probenecid
,3377315,elimination half-life (t1/2),The following mean values +/- SD were found: elimination half-life (t1/2) was 83.8 +/- 8.6 minutes after IV administration and significantly longer 116.8 +/- 20.5 minutes (P less than 0.001) after IM administration at 10 mg/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,116.8,27735,DB01032,Probenecid
,3377315,t1/2,The t1/2 was increased to 141.3 +/- 24.4 minutes by the coadministration of probenecid and to 145.0 +/- 48.2 minutes by doubling the IM dosage to 20 mg/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,141.3,27736,DB01032,Probenecid
,3377315,t1/2,The t1/2 was increased to 141.3 +/- 24.4 minutes by the coadministration of probenecid and to 145.0 +/- 48.2 minutes by doubling the IM dosage to 20 mg/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,145.0,27737,DB01032,Probenecid
,3377315,total body clearance,The total body clearance was 3.39 +/- 0.42 ml/min/kg and the renal clearance 2.37 +/- 0.74 ml/min/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),[ml] / [kg·min],3.39,27738,DB01032,Probenecid
,3377315,renal clearance,The total body clearance was 3.39 +/- 0.42 ml/min/kg and the renal clearance 2.37 +/- 0.74 ml/min/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),[ml] / [kg·min],2.37,27739,DB01032,Probenecid
,3377315,specific volume of distribution,The specific volume of distribution was 0.2990 +/- 0.0510 L/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),[l] / [kg],0.2990,27740,DB01032,Probenecid
,3377315,mean residence time (MRT),The average mean residence time (MRT) was 94.0 +/- 12.3 minutes after IV administration and 137.6 +/- 19.9 minutes after IM administration of ceftriaxone at 10 mg/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,94.0,27741,DB01032,Probenecid
,3377315,mean residence time (MRT),The average mean residence time (MRT) was 94.0 +/- 12.3 minutes after IV administration and 137.6 +/- 19.9 minutes after IM administration of ceftriaxone at 10 mg/kg.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,137.6,27742,DB01032,Probenecid
,3377315,MRT,The MRT was increased to 198 +/- 48.8 minutes by the coadministration of probenecid and to 191.0 +/- 59.4 minutes by doubling the IM dose.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,198,27743,DB01032,Probenecid
,3377315,MRT,The MRT was increased to 198 +/- 48.8 minutes by the coadministration of probenecid and to 191.0 +/- 59.4 minutes by doubling the IM dose.,Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),min,191.0,27744,DB01032,Probenecid
,3377315,Bioavailability,"Bioavailability of ceftriaxone after IM administration at 10 mg/kg and at 20 mg/kg was 78% and 83%, respectively.",Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),%,78,27745,DB01032,Probenecid
,3377315,Bioavailability,"Bioavailability of ceftriaxone after IM administration at 10 mg/kg and at 20 mg/kg was 78% and 83%, respectively.",Pharmacokinetics and bioavailability of ceftriaxone administered intravenously and intramuscularly to calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377315/),%,83,27746,DB01032,Probenecid
,3292102,body clearance,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [h·kg],0.7,28702,DB01032,Probenecid
,3292102,steady-state volume of distribution,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [kg],0.8,28703,DB01032,Probenecid
,3292102,elimination half-life,The elimination half-life of unchanged captopril was approximately 2 hours.,Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),h,2,28704,DB01032,Probenecid
,3292102,bioavailability,"In healthy subjects, about 70 to 75% of an oral dose is absorbed and the bioavailability of captopril is approximately 65%.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),%,65,28705,DB01032,Probenecid
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB01032,Probenecid
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB01032,Probenecid
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB01032,Probenecid
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB01032,Probenecid
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB01032,Probenecid
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB01032,Probenecid
,9118583,terminal phase half-life,"A sustained release dosage form is available, which may be beneficial due to the short terminal phase half-life of tiaprofenic acid (3 to 6 hours).",Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118583/),h,3 to 6,32056,DB01032,Probenecid
,9869572,renal clearance (CLR),"In control rabbits, the renal clearance (CLR) of DA-1131 and the glomerular filtration rate based on creatinine clearance (CLCR) were 6.14 +/- 2.09 and 2.26 +/- 0.589 ml/min/kg, respectively.","Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869572/),[ml] / [kg·min],6.14,35287,DB01032,Probenecid
,9869572,renal clearance (CLR),"In control rabbits, the renal clearance (CLR) of DA-1131 and the glomerular filtration rate based on creatinine clearance (CLCR) were 6.14 +/- 2.09 and 2.26 +/- 0.589 ml/min/kg, respectively.","Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869572/),[ml] / [kg·min],2.26,35288,DB01032,Probenecid
,9869572,CLR,"The CLR of DA-1131 (3. 87 +/- 0.543 ml/min/kg) decreased significantly with treatment with probenecid in rabbits, indicating that the renal tubular secretion of DA-1131 was inhibited by probenecid.","Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869572/),[ml] / [kg·min],3. 87,35289,DB01032,Probenecid
,9869572,CLR,"However, in control rats, the CLR of DA-1131 (5.80 +/- 1.94 ml/min/kg) was comparable to the CLCR (4.29 +/- 1.64 ml/min/kg), indicating that DA-1131 was mainly excreted by glomerular filtration in rats.","Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869572/),[ml] / [kg·min],5.80,35290,DB01032,Probenecid
,9869572,CLR,"However, in control rats, the CLR of DA-1131 (5.80 +/- 1.94 ml/min/kg) was comparable to the CLCR (4.29 +/- 1.64 ml/min/kg), indicating that DA-1131 was mainly excreted by glomerular filtration in rats.","Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869572/),[ml] / [kg·min],4.29,35291,DB01032,Probenecid
,9869572,CLR,"Therefore, it could be expected that the CLR of DA-1131 could not be affected by treatment with probenecid in rats; this was proved by a similar CLR of DA-1131 with treatment with (6.93 +/- 0.675 ml/min/kg) or without (5.80 +/- 1.94 ml/min/kg) probenecid.","Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869572/),[ml] / [kg·min],6.93,35292,DB01032,Probenecid
,9869572,CLR,"Therefore, it could be expected that the CLR of DA-1131 could not be affected by treatment with probenecid in rats; this was proved by a similar CLR of DA-1131 with treatment with (6.93 +/- 0.675 ml/min/kg) or without (5.80 +/- 1.94 ml/min/kg) probenecid.","Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869572/),[ml] / [kg·min],5.80,35293,DB01032,Probenecid
,8257956,Plasma protein binding,"Plasma protein binding of probenecid was high, being somewhat higher in males (90.7 +/- 1.4%) than in females (87.9 +/- 1.4%; p = 0.0019).",Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257956/),%,90.7,36608,DB01032,Probenecid
,8257956,Plasma protein binding,"Plasma protein binding of probenecid was high, being somewhat higher in males (90.7 +/- 1.4%) than in females (87.9 +/- 1.4%; p = 0.0019).",Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257956/),%,87.9,36609,DB01032,Probenecid
,8257956,height of the plateau value,The height of the plateau value depended on the individual and varied between 250 and 800 micrograms/min (15-50 mg/h).,Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257956/),[μg] / [min],250 and 800,36610,DB01032,Probenecid
,8257956,height of the plateau value,The height of the plateau value depended on the individual and varied between 250 and 800 micrograms/min (15-50 mg/h).,Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257956/),,15-50,36611,DB01032,Probenecid
,6313357,peak plasma concentration,An ampicillin mean peak plasma concentration of 23.1 mg/l was found typically 1.5 h after dosing; the mean peak plasma concentration of sulbactam (10.0 mg/l) occurred at the same time.,Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313357/),[mg] / [l],23.1,43384,DB01032,Probenecid
,6313357,peak plasma concentration,An ampicillin mean peak plasma concentration of 23.1 mg/l was found typically 1.5 h after dosing; the mean peak plasma concentration of sulbactam (10.0 mg/l) occurred at the same time.,Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313357/),[mg] / [l],10.0,43385,DB01032,Probenecid
,6313357,plasma half-life,The mean plasma half-life of ampicillin was 1.45 h and that of sulbactam 1.3 h.,Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313357/),h,1.45,43386,DB01032,Probenecid
,6313357,plasma half-life,The mean plasma half-life of ampicillin was 1.45 h and that of sulbactam 1.3 h.,Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313357/),h,1.3,43387,DB01032,Probenecid
,6313357,urinary recovery,The mean urinary recovery of ampicillin was 65% and that of sulbactam 62%.,Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313357/),%,65,43388,DB01032,Probenecid
,6313357,urinary recovery,The mean urinary recovery of ampicillin was 65% and that of sulbactam 62%.,Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6313357/),%,62,43389,DB01032,Probenecid
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.83,43396,DB01032,Probenecid
,20347037,clearance,"Clofarabine clearance was significantly reduced upon co-administration with, cimetidine (0.83+/-0.22-->0.32+/-0.058mL/min).",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [min],0.32,43397,DB01032,Probenecid
,20347037,clearance,"In vivo data correlated with IPK results as clofarabine clearance decreased 61% (20.2-7.80mL/min/kg), upon co-administration with cimetidine in rats.",Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20347037/),[ml] / [kg·min],20.2-7.80,43398,DB01032,Probenecid
,15825306,peak concentrations,Average peak concentrations of ampicillin in the serum after doses equimolar to 250 mg of ampicillin were 6.8 mug/ml at 56 min with pivampicillin and 1.96 mug/ml at 1 h 24 min with ampicillin.,Clinical pharmacology of pivampicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15825306/),[μg] / [ml],6.8,44868,DB01032,Probenecid
,15825306,peak concentrations,Average peak concentrations of ampicillin in the serum after doses equimolar to 250 mg of ampicillin were 6.8 mug/ml at 56 min with pivampicillin and 1.96 mug/ml at 1 h 24 min with ampicillin.,Clinical pharmacology of pivampicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15825306/),[μg] / [ml],1.96,44869,DB01032,Probenecid
,15825306,maximal concentration,"The maximal concentration after pivampicillin treatment was also higher than that recorded when twice the equimolar dose of ampicillin, which averaged 3.2 mug/ml at 1 h 42 min, was used.",Clinical pharmacology of pivampicillin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15825306/),[μg] / [ml],3.2,44870,DB01032,Probenecid
,15825306,urinary excretion,"The urinary excretion of ampicillin, expressed as a percentage of the administered dose, averaged 67 to 73 and 25 to 29% after administration of pivampicillin and ampicillin, respectively.",Clinical pharmacology of pivampicillin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15825306/),%,67 to 73,44871,DB01032,Probenecid
,15825306,urinary excretion,"The urinary excretion of ampicillin, expressed as a percentage of the administered dose, averaged 67 to 73 and 25 to 29% after administration of pivampicillin and ampicillin, respectively.",Clinical pharmacology of pivampicillin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15825306/),%,25 to 29,44872,DB01032,Probenecid
,8342300,elimination half-life (t1/2 beta),Both enantiomers disappeared rapidly from plasma with an elimination half-life (t1/2 beta) of 0.35-0.38 h.,Enantiomer-enantiomer interaction of a uricosuric antihypertensive diuretic (DBCA) in renal tubular secretion and stereoselective inhibition by probenecid in the cynomolgus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342300/),h,0.35-0.38,44904,DB01032,Probenecid
,8342300,Unbound fractions,Unbound fractions were 18.9% for the (R)(+)-enantiomer and 10.2% for the (S)(-)-enantiomer.,Enantiomer-enantiomer interaction of a uricosuric antihypertensive diuretic (DBCA) in renal tubular secretion and stereoselective inhibition by probenecid in the cynomolgus monkey. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342300/),%,18.9,44905,DB01032,Probenecid
,8342300,Unbound fractions,Unbound fractions were 18.9% for the (R)(+)-enantiomer and 10.2% for the (S)(-)-enantiomer.,Enantiomer-enantiomer interaction of a uricosuric antihypertensive diuretic (DBCA) in renal tubular secretion and stereoselective inhibition by probenecid in the cynomolgus monkey. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342300/),%,10.2,44906,DB01032,Probenecid
,23436258,elimination half-life (t(1/2) β),"Oseltamivir shows dose linear kinetics, and oseltamivir carboxylate has an elimination half-life (t(1/2) β) after oral administration in healthy individuals of approximately 7.7 hours.",Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,7.7,44925,DB01032,Probenecid
,23436258,t(1/2) β,Zanamivir distributes in an apparent volume of distribution approximating that of extracellular water and is rapidly eliminated (t(1/2) β of approximately 3.0 hours).,Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,3.0,44926,DB01032,Probenecid
,23436258,t(1/2) β,Peramivir is slowly eliminated (t(1/2) β of 7.7-20.8 hours) and is prescribed as either a once-daily injection or as a single infusion.,Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23436258/),h,7.7-20.8,44927,DB01032,Probenecid
,2203580,terminal phase half-life,"Sustained release dosage forms are available, which may be beneficial due to the short terminal phase half-life of ketoprofen (1 to 3h).",Clinical pharmacokinetics of ketoprofen and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203580/),h,1 to 3,46734,DB01032,Probenecid
,6460974,peak serum levels,"Following the intravenous loading dose, mean peak serum levels of 101 micrograms/ml for mezlocillin and 91.5 micrograms/ml for ampicillin were recorded.",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),[μg] / [ml],101,48374,DB01032,Probenecid
,6460974,peak serum levels,"Following the intravenous loading dose, mean peak serum levels of 101 micrograms/ml for mezlocillin and 91.5 micrograms/ml for ampicillin were recorded.",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),[μg] / [ml],91.5,48375,DB01032,Probenecid
,6460974,ultimate half-life t 1/2,The ultimate half-life t 1/2 of mezlocillin (46.4 min) was slightly shorter than that of ampicillin (52.4 min).,[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),min,46.4,48376,DB01032,Probenecid
,6460974,ultimate half-life t 1/2,The ultimate half-life t 1/2 of mezlocillin (46.4 min) was slightly shorter than that of ampicillin (52.4 min).,[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),min,52.4,48377,DB01032,Probenecid
,6460974,total volume of distribution,"Similarly, the total volume of distribution of mezlocillin (24.1 l) was slightly inferior to that of ampicillin (29.4 l).",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),l,24.1,48378,DB01032,Probenecid
,6460974,total volume of distribution,"Similarly, the total volume of distribution of mezlocillin (24.1 l) was slightly inferior to that of ampicillin (29.4 l).",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),l,29.4,48379,DB01032,Probenecid
,6460974,renal clearance,"The total clearances of the two antibiotics were not significantly different, but the renal clearance of mezlocillin (186.6 ml/min/1.73 m2) was significantly lower than that of ampicillin (309.5 ml/min/1.73 m2).",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),[ml] / [1.73·m2·min],186.6,48380,DB01032,Probenecid
,6460974,renal clearance,"The total clearances of the two antibiotics were not significantly different, but the renal clearance of mezlocillin (186.6 ml/min/1.73 m2) was significantly lower than that of ampicillin (309.5 ml/min/1.73 m2).",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),[ml] / [1.73·m2·min],309.5,48381,DB01032,Probenecid
,6460974,peak serum levels,"Following intramuscular injection, the mean peak serum levels obtained were 15.6 microgram/ml with mezlocillin and 15.1 micrograms/ml with ampicillin.",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),[μg] / [ml],15.6,48382,DB01032,Probenecid
,6460974,peak serum levels,"Following intramuscular injection, the mean peak serum levels obtained were 15.6 microgram/ml with mezlocillin and 15.1 micrograms/ml with ampicillin.",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),[μg] / [ml],15.1,48383,DB01032,Probenecid
,6460974,half-lives,The half-lives of the antibiotics were 50.0 min and 57.2 min respectively.,[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),min,50.0,48384,DB01032,Probenecid
,6460974,half-lives,The half-lives of the antibiotics were 50.0 min and 57.2 min respectively.,[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),min,57.2,48385,DB01032,Probenecid
,6460974,bioavailable fractions,"The bioavailable fractions of mezlocillin and ampicillin, as measured from the areas under the serum concentration curves wer 63 % and 75 % respectively of the values determined after intravenous injection.",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),%,63,48386,DB01032,Probenecid
,6460974,bioavailable fractions,"The bioavailable fractions of mezlocillin and ampicillin, as measured from the areas under the serum concentration curves wer 63 % and 75 % respectively of the values determined after intravenous injection.",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),%,75,48387,DB01032,Probenecid
,6460974,ultimate half-life,"However, the ultimate half-life was not significantly altered (50.5 min without, and 52.0 min with probenecid).",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),min,50.5,48388,DB01032,Probenecid
,6460974,ultimate half-life,"However, the ultimate half-life was not significantly altered (50.5 min without, and 52.0 min with probenecid).",[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6460974/),min,52.0,48389,DB01032,Probenecid
,3946913,half-life,Probenecid given IV was characterized by a rapid disposition phase with a mean half-life of 14.0 minutes and a subsequent slower elimination phase with a mean half-life of 87.8 minutes in 5 of 6 mares.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,14.0,48431,DB01032,Probenecid
,3946913,half-life,Probenecid given IV was characterized by a rapid disposition phase with a mean half-life of 14.0 minutes and a subsequent slower elimination phase with a mean half-life of 87.8 minutes in 5 of 6 mares.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,87.8,48432,DB01032,Probenecid
,3946913,half-life of the elimination phase,"In the remaining mare, a rapid disposition phase was not observed, and the half-life of the elimination phase was slower (172 minutes).",Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,172,48433,DB01032,Probenecid
,3946913,mean residence time,The mean residence time of probenecid averaged 116 minutes for all 6 mares and 89.2 minutes for the 5 mares with biphasic disposition.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,116,48434,DB01032,Probenecid
,3946913,mean residence time,The mean residence time of probenecid averaged 116 minutes for all 6 mares and 89.2 minutes for the 5 mares with biphasic disposition.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,89.2,48435,DB01032,Probenecid
,3946913,total plasma clearance,"The total plasma clearance of probenecid averaged 1.18 +/- 0.49 ml/min/kg, whereas renal clearance accounted for 42.6 +/- 9.3% of the total clearance.",Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),[ml] / [kg·min],1.18,48436,DB01032,Probenecid
,3946913,steady-state volume of distribution,The steady-state volume of distribution of probenecid averaged 116 +/- 28.2 ml/kg.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),[ml] / [kg],116,48437,DB01032,Probenecid
,3946913,maximum plasma probenecid concentration,The maximum plasma probenecid concentration after 10 mg/kg orally averaged nearly 30 micrograms/ml.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),[μg] / [ml],30,48438,DB01032,Probenecid
,3946913,half-life,The half-life of probenecid after oral administration was approximately 120 minutes.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,120,48439,DB01032,Probenecid
greater,3946913,Oral bioavailability,Oral bioavailability was good with greater than 90% of the dose absorbed.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),%,90,48440,DB01032,Probenecid
,2808215,half-life,The half-life of meropenem was approximately 1 h and the urinary recovery of unchanged drug was 79%.,The pharmacokinetics of meropenem in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808215/),h,1,49369,DB01032,Probenecid
,2808215,urinary recovery of unchanged drug,The half-life of meropenem was approximately 1 h and the urinary recovery of unchanged drug was 79%.,The pharmacokinetics of meropenem in volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808215/),%,79,49370,DB01032,Probenecid
,12708933,serum peak,"In patients who received cefazolin once daily, the average serum peak and trough concentrations on day 1 were 146.53 and 2.02 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],146.53,49393,DB01032,Probenecid
,12708933,trough concentrations,"In patients who received cefazolin once daily, the average serum peak and trough concentrations on day 1 were 146.53 and 2.02 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],2.02,49394,DB01032,Probenecid
,12708933,Peak,"Peak and trough concentrations on day 5 were 148.30 and 2.67 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],148.30,49395,DB01032,Probenecid
,12708933,trough concentrations,"Peak and trough concentrations on day 5 were 148.30 and 2.67 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],2.67,49396,DB01032,Probenecid
,12708933,peak,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],122.15,49397,DB01032,Probenecid
,12708933,trough concentrations,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],18.65,49398,DB01032,Probenecid
,12708933,trough concentrations,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],136.51,49399,DB01032,Probenecid
,12708933,trough concentrations,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],16.98,49400,DB01032,Probenecid
,2362917,AUCAZT,Administration of 500 mg probenecid every 6 hr prior to and during AZT dosing resulted in an increase in the average AUCAZT from 89 micrograms.,Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),μg,89,50481,DB01032,Probenecid
,2362917,CLR,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],4.76,50482,DB01032,Probenecid
,2362917,CLR,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],2.98,50483,DB01032,Probenecid
,2362917,CLTOT/F,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],28.7,50484,DB01032,Probenecid
,2362917,CLTOT/F,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],2.98,50485,DB01032,Probenecid
,2362917,CLTOT/F,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],14.1,50486,DB01032,Probenecid
,2362917,CLR,"The CLR of GAZT decreased from an average of 11.3 ml/min/kg (control) to 2.63 ml/min/kg during probenecid treatment, resulting in a greater than 3.5-fold increase in AUCGAZT.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],11.3,50487,DB01032,Probenecid
,2362917,CLR,"The CLR of GAZT decreased from an average of 11.3 ml/min/kg (control) to 2.63 ml/min/kg during probenecid treatment, resulting in a greater than 3.5-fold increase in AUCGAZT.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],2.63,50488,DB01032,Probenecid
,15848954,apparent elimination half-life,PTZ was eliminated with the apparent elimination half-life of 13.0 min after microinjection into the parietal cortex area 2 region of the rat brain.,In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),min,13.0,53252,DB01032,Probenecid
,15848954,apparent efflux clearance,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[μl] / [brain·g·min],137,53253,DB01032,Probenecid
,15848954,elimination rate constant,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),1/[min],5.35 x 10(-2),53254,DB01032,Probenecid
,15848954,distribution volume,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[ml] / [brain·g],2.56,53255,DB01032,Probenecid
,23529922,initial uptake clearance,"The initial uptake clearance of M-III by rat kidney slices was 0.295 and 0.0114 ml/min/g at 37 °C and 4 °C, respectively.","Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529922/),[ml] / [g·min],0.295,54416,DB01032,Probenecid
,23529922,initial uptake clearance,"The initial uptake clearance of M-III by rat kidney slices was 0.295 and 0.0114 ml/min/g at 37 °C and 4 °C, respectively.","Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529922/),[ml] / [g·min],0.0114,54417,DB01032,Probenecid
,23529922,K(m),The Eadie-Hofstee plot of M-III uptake at 37 °C revealed two-component transport processes with K(m) values being 6.48 and 724 µmol/l.,"Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529922/),[μM] / [l],6.48,54418,DB01032,Probenecid
,23529922,K(m),The Eadie-Hofstee plot of M-III uptake at 37 °C revealed two-component transport processes with K(m) values being 6.48 and 724 µmol/l.,"Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529922/),[μM] / [l],724,54419,DB01032,Probenecid
,23529922,initial uptake clearance,"In contrast, in dog kidney slices, the initial uptake clearance of M-III was 8.70 × 10(-3) and 9.00 × 10(-3) ml/min/g at 37 °C and 4 °C, respectively, and the uptake was not inhibited by PBC.","Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529922/),[ml] / [g·min],8.70 × 10(-3),54420,DB01032,Probenecid
,23529922,initial uptake clearance,"In contrast, in dog kidney slices, the initial uptake clearance of M-III was 8.70 × 10(-3) and 9.00 × 10(-3) ml/min/g at 37 °C and 4 °C, respectively, and the uptake was not inhibited by PBC.","Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529922/),[ml] / [g·min],9.00 × 10(-3),54421,DB01032,Probenecid
,2732141,Cmax,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],117,57047,DB01032,Probenecid
,2732141,T1/2 beta,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,36,57048,DB01032,Probenecid
,2732141,Vss,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),,181,57049,DB01032,Probenecid
,2732141,AUC,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l·min],2179,57050,DB01032,Probenecid
,2732141,Cmax,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],116,57051,DB01032,Probenecid
,2732141,T1/2 beta,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,47,57052,DB01032,Probenecid
,2732141,Vss,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),,141,57053,DB01032,Probenecid
,2732141,AUC,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l·min],4540,57054,DB01032,Probenecid
,2732141,Cmax,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],15,57055,DB01032,Probenecid
,2732141,Tmax,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,30,57056,DB01032,Probenecid
,2732141,T1/2abs,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,14,57057,DB01032,Probenecid
,2732141,T1/2 beta,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,61,57058,DB01032,Probenecid
,2732141,AUC,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l·min],2117,57059,DB01032,Probenecid
,2732141,urinary recoveries,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),%,33,57060,DB01032,Probenecid
,2732141,Css,"At steady state during continuous infusion, mean values were Css 12.7 mg/l, Vss 131 and T1/2 beta after steady state was 22 min.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],12.7,57061,DB01032,Probenecid
,2732141,Vss,"At steady state during continuous infusion, mean values were Css 12.7 mg/l, Vss 131 and T1/2 beta after steady state was 22 min.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),,131,57062,DB01032,Probenecid
,2732141,T1/2 beta after steady state,"At steady state during continuous infusion, mean values were Css 12.7 mg/l, Vss 131 and T1/2 beta after steady state was 22 min.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,22,57063,DB01032,Probenecid
,27638508,Km,"Taurine and GCDCA-S were substrates of OAT1 and OAT3, with Km values of 379 ± 58 and 64.3 ± 3.9 μM, respectively.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,379,59228,DB01032,Probenecid
,27638508,Km,"Taurine and GCDCA-S were substrates of OAT1 and OAT3, with Km values of 379 ± 58 and 64.3 ± 3.9 μM, respectively.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,64.3,59229,DB01032,Probenecid
,27638508,Ki,"The Ki values of probenecid for the OAT1- and OAT3-mediated uptake of taurine and GCDCA-S (9.49 ± 1.27 and 7.40 ± 0.70 μM, respectively) were similar to those of their typical substrate drugs.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,9.49,59230,DB01032,Probenecid
,27638508,Ki,"The Ki values of probenecid for the OAT1- and OAT3-mediated uptake of taurine and GCDCA-S (9.49 ± 1.27 and 7.40 ± 0.70 μM, respectively) were similar to those of their typical substrate drugs.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,7.40,59231,DB01032,Probenecid
,8585661,bioavailable (F,"It was administered intragastrically at a dose rate of 13.5 mg/kg of body weight to ponies and horses, and was highly bioavailable (F = 41.0%), compared with other penicillins in adult horses.",Pharmacokinetics of bacampicillin in equids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585661/),%,41.0,59386,DB01032,Probenecid
,8585661,peak ampicillin plasma concentration,"The high peak ampicillin plasma concentration of 6.1 +/- 0.5 micrograms/ml achieved and persistence of the antibiotic at concentration of 0.3 +/- 0.1 microgram/ml 6 hours after its intragastric administration, suggest that bacampicillin hydrochloride may reach suitable bactericidal concentrations for treatment of infections caused by susceptible microorganisms.",Pharmacokinetics of bacampicillin in equids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585661/),[μg] / [ml],6.1,59387,DB01032,Probenecid
,3342285,maximum free fraction,"The unbound fraction was found to increase non-linearly with increasing total concentration, yielding a maximum free fraction of 49 per cent.",Dose-dependent pharmacokinetics of probenecid in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342285/),%,49,59653,DB01032,Probenecid
,3342285,maximal rate of elimination (Vm),The maximal rate of elimination (Vm) remained unchanged between different doses irrespective of whether it was calculated in total or free concentrations (mean 187.2 +/- 8.3 (SD) microgram min-1).,Dose-dependent pharmacokinetics of probenecid in the rat. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342285/),[μg] / [min],187.2,59654,DB01032,Probenecid
,3342285,"unbound Michaelis-Menten constant (Km,u)","The Michaelis-Menten constant (Km) decreased slightly with increasing dose, while the unbound Michaelis-Menten constant (Km,u) did not change between the doses (mean 37.1 +/- 1.3 (SD) microgram ml-1).",Dose-dependent pharmacokinetics of probenecid in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342285/),[μg] / [ml],37.1,59655,DB01032,Probenecid
,3342285,volume of distribution of the central compartment (Vc),"The volume of distribution of the central compartment (Vc) did not alter when the dose was increased from 50 to 100 mg kg-1 (mean 56.5 +/- 4.3 (SD) ml), but the unbound volume of distribution of the central compartment (Vc,u) decreased from 186.5 +/- 15.6 (SD) to 89.8 +/- 6.9 (SD) ml, which is in accordance with the reduction to be expected for drugs that only distribute in the extracellular fluid.",Dose-dependent pharmacokinetics of probenecid in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342285/),m,56.5,59656,DB01032,Probenecid
,3342285,"unbound volume of distribution of the central compartment (Vc,u)","The volume of distribution of the central compartment (Vc) did not alter when the dose was increased from 50 to 100 mg kg-1 (mean 56.5 +/- 4.3 (SD) ml), but the unbound volume of distribution of the central compartment (Vc,u) decreased from 186.5 +/- 15.6 (SD) to 89.8 +/- 6.9 (SD) ml, which is in accordance with the reduction to be expected for drugs that only distribute in the extracellular fluid.",Dose-dependent pharmacokinetics of probenecid in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342285/),ml,186.5,59657,DB01032,Probenecid
,3342285,"unbound volume of distribution of the central compartment (Vc,u)","The volume of distribution of the central compartment (Vc) did not alter when the dose was increased from 50 to 100 mg kg-1 (mean 56.5 +/- 4.3 (SD) ml), but the unbound volume of distribution of the central compartment (Vc,u) decreased from 186.5 +/- 15.6 (SD) to 89.8 +/- 6.9 (SD) ml, which is in accordance with the reduction to be expected for drugs that only distribute in the extracellular fluid.",Dose-dependent pharmacokinetics of probenecid in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342285/),ml,89.8,59658,DB01032,Probenecid
,23025519,Maximum cidofovir plasma concentrations,"Maximum cidofovir plasma concentrations, which averaged approximately 1 μg/mL, were significantly below the 36 μg/mL 50% effective concentration in vitro for cidofovir against BKV.",Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23025519/),[μg] / [ml],1,60148,DB01032,Probenecid
,23025519,Maximum cidofovir plasma concentrations,"Maximum cidofovir plasma concentrations, which averaged approximately 1 μg/mL, were significantly below the 36 μg/mL 50% effective concentration in vitro for cidofovir against BKV.",Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23025519/),[μg] / [m],36,60149,DB01032,Probenecid
,23025519,overall disposition half-life,"The plasma concentration of cidofovir declined with an overall disposition half-life of 5.1 ± 3.5 and 5.3 ± 2.9 h in the absence and in the presence of probenecid, respectively (P > 0.05).",Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23025519/),h,5.1,60150,DB01032,Probenecid
,23025519,overall disposition half-life,"The plasma concentration of cidofovir declined with an overall disposition half-life of 5.1 ± 3.5 and 5.3 ± 2.9 h in the absence and in the presence of probenecid, respectively (P > 0.05).",Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23025519/),h,5.3,60151,DB01032,Probenecid
,1788980,Plasma protein binding,2. Plasma protein binding was similar in both sexes: 99.3-99.5% in males and 99.4-99.6% in females.,Sex differences in excretion of zenarestat in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788980/),%,99.3-99.5,62762,DB01032,Probenecid
,1788980,Plasma protein binding,2. Plasma protein binding was similar in both sexes: 99.3-99.5% in males and 99.4-99.6% in females.,Sex differences in excretion of zenarestat in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788980/),%,99.4-99.6,62763,DB01032,Probenecid
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],1.8,66819,DB01032,Probenecid
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],0.6,66820,DB01032,Probenecid
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],0.3,66821,DB01032,Probenecid
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],0.18,66822,DB01032,Probenecid
,28990653,inhibition constant (Ki ),The in-vitro inhibition constant (Ki ) value for paritaprevir vs EE on average was 20 μm and was consistent with a competitive inhibition mechanism.,Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28990653/),μm,20,68856,DB01032,Probenecid
,12355579,Cl(r),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.60,69848,DB01032,Probenecid
,12355579,Cl(r),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.28,69849,DB01032,Probenecid
,12355579,Cl(r),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.08,69850,DB01032,Probenecid
,12355579,Cl(t),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.78,69851,DB01032,Probenecid
,12355579,Cl(t),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.51,69852,DB01032,Probenecid
,12355579,Cl(t),"The mean Cl(r) values were, respectively, 4.60+/-0.42, 4.28+/-0.52 and 4.08+/-0.67 ml/min, practically equivalent to the Cl(t) values (4.78+/-0.38, 4.51+/-0.36 and 4.21+/-0.56 ml/min), confirming that the drug is mainly eliminated via renal excretion.",Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],4.21,69853,DB01032,Probenecid
,12355579,total clearance,Probenecid provoked a statistically significant dose-dependent reduction in the total clearance of acamprosate (from 5.8+/-0.7 ml/min in the control group to 2.6+/-0.1 ml/min in the animals treated with 66 mg/kg of probenecid) demonstrating the existence of a tubular secretion process on the renal excretion of acamprosate in the rat.,Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],5.8,69854,DB01032,Probenecid
,12355579,total clearance,Probenecid provoked a statistically significant dose-dependent reduction in the total clearance of acamprosate (from 5.8+/-0.7 ml/min in the control group to 2.6+/-0.1 ml/min in the animals treated with 66 mg/kg of probenecid) demonstrating the existence of a tubular secretion process on the renal excretion of acamprosate in the rat.,Disposition of acamprosate in the rat: influence of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12355579/),[ml] / [min],2.6,69855,DB01032,Probenecid
,27163499,t1/2,"Probenecid prolonged the t1/2 of KUC-7322 from 1.6 to 3.4 hours and decreased the renal clearance and cumulative fraction of KUC-7322 excreted in urine from 18.5 to 4.9 L/h and from 64.7% to 49.7%, respectively.","Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163499/),h,1,70148,DB01032,Probenecid
,27163499,renal clearance,"Probenecid prolonged the t1/2 of KUC-7322 from 1.6 to 3.4 hours and decreased the renal clearance and cumulative fraction of KUC-7322 excreted in urine from 18.5 to 4.9 L/h and from 64.7% to 49.7%, respectively.","Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163499/),[l] / [h],18.5,70149,DB01032,Probenecid
,9755846,renal clearance (CL(R)),"The renal clearance (CL(R)) of DA-1131 in dogs without probenecid (3.18+/-0.247 ml/min/kg) was considerably smaller than the reported creatinine clearance (CL(CR)) in dogs, 6.13 ml/min/kg, indicating that renal tubular reabsorption of the drug was observed in dogs.","No effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in dogs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755846/),[ml] / [kg·min],3.18,71182,DB01032,Probenecid
,9755846,CLR,"However, the CLR of DA-1131 was not significantly different (3.18+/-0.247 versus 3.29+/-0.698 ml/min/kg) by treatment with probenecid indicating that the tubular reabsorption of DA-1131 was not inhibited by probenecid.","No effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in dogs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755846/),[ml] / [kg·min],3.18,71183,DB01032,Probenecid
,9755846,CLR,"However, the CLR of DA-1131 was not significantly different (3.18+/-0.247 versus 3.29+/-0.698 ml/min/kg) by treatment with probenecid indicating that the tubular reabsorption of DA-1131 was not inhibited by probenecid.","No effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in dogs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9755846/),[ml] / [kg·min],3.29,71184,DB01032,Probenecid
,8436544,elimination half-life,"After bolus intravenous dosing with 20 mg/kg, the elimination half-life of FK037 varied in the species; with values of 0.27, 0.30, 0.97, 1.29 and 1.76 hours in mice, rats, rabbits, dogs and monkeys, respectively.","Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),h,0.27,71205,DB01032,Probenecid
,8436544,elimination half-life,"After bolus intravenous dosing with 20 mg/kg, the elimination half-life of FK037 varied in the species; with values of 0.27, 0.30, 0.97, 1.29 and 1.76 hours in mice, rats, rabbits, dogs and monkeys, respectively.","Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),h,0.30,71206,DB01032,Probenecid
,8436544,elimination half-life,"After bolus intravenous dosing with 20 mg/kg, the elimination half-life of FK037 varied in the species; with values of 0.27, 0.30, 0.97, 1.29 and 1.76 hours in mice, rats, rabbits, dogs and monkeys, respectively.","Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),h,0.97,71207,DB01032,Probenecid
,8436544,elimination half-life,"After bolus intravenous dosing with 20 mg/kg, the elimination half-life of FK037 varied in the species; with values of 0.27, 0.30, 0.97, 1.29 and 1.76 hours in mice, rats, rabbits, dogs and monkeys, respectively.","Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),h,1.29,71208,DB01032,Probenecid
,8436544,elimination half-life,"After bolus intravenous dosing with 20 mg/kg, the elimination half-life of FK037 varied in the species; with values of 0.27, 0.30, 0.97, 1.29 and 1.76 hours in mice, rats, rabbits, dogs and monkeys, respectively.","Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),h,1.76,71209,DB01032,Probenecid
,8436544,volume of distribution,The volume of distribution ranged between 260 ml/kg in rats and 390 ml/kg in dogs.,"Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),[ml] / [kg],260,71210,DB01032,Probenecid
,8436544,volume of distribution,The volume of distribution ranged between 260 ml/kg in rats and 390 ml/kg in dogs.,"Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),[ml] / [kg],390,71211,DB01032,Probenecid
,8436544,penetration percentage,The penetration percentage ranged from 14.2 to 16.0% for these drugs with no significant differences.,"Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),%,14.2 to 16.0,71212,DB01032,Probenecid
,8436544,Biliary excretion,"Biliary excretion was low, 0.79% in rats.","Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),%,0.79,71213,DB01032,Probenecid
,8436544,Serum protein binding,Serum protein binding was low (8.8 to 17.6%) in all the species studied.,"Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436544/),%,8.8 to 17.6,71214,DB01032,Probenecid
,1452971,clearance ratio,"However, the clearance ratio in the treatment group was significantly increased from 11.72 to 17.27.","The effects of probenecid on the excretion kinetics of stanozolol, an anabolic steroid, in rats. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1452971/),,11.72,71750,DB01032,Probenecid
,1452971,clearance ratio,"However, the clearance ratio in the treatment group was significantly increased from 11.72 to 17.27.","The effects of probenecid on the excretion kinetics of stanozolol, an anabolic steroid, in rats. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1452971/),,17.27,71751,DB01032,Probenecid
,7752308,volume of distribution at steady-state Vd(ss),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),[l] / [kg],0.2,72297,DB01032,Probenecid
,7752308,volume of distribution by the area method Vd(area),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),[l] / [kg],0.38,72298,DB01032,Probenecid
,7752308,mean residence time (MRT),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),h,6.5,72299,DB01032,Probenecid
,7752308,mean residence time in peripheral tissues (MRTp),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),h,2.6,72300,DB01032,Probenecid
,7752308,total body clearance (Cl),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),[l] / [h·kg],0.032,72301,DB01032,Probenecid
,7752308,elimination rate constant (beta),"For treatment with ceftiofur sodium alone, the mean volume of distribution at steady-state Vd(ss) was 0.2 +/- 0.06 L/kg, the mean volume of distribution by the area method Vd(area) was 0.38 +/- 0.22 L/kg, mean residence time (MRT) was 6.5 +/- 1.8 h, mean residence time in peripheral tissues (MRTp) was 2.6 +/- 1.0 h, total body clearance (Cl) was 0.032 +/- 0.013 L/kg/h and elimination rate constant (beta) was 0.097 +/- 0.044 h-1 (mean +/- standard deviation).",The effects on the pharmacokinetics of intravenous ceftiofur sodium in dairy cattle of simultaneous intravenous acetyl salicylate (aspirin) or probenecid. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752308/),1/[h],0.097,72302,DB01032,Probenecid
,1595963,volume of distribution at steady state,Significant (P less than or equal to 0.05) increase was evident in the 12-hour mean concentration of phenylbutazone (11.45 +/- 1.66 micrograms/ml without probenecid; 14.56 +/- 1.20 micrograms/ml with probenecid) along with significant (P less than or equal to 0.05) reduction in its volume of distribution at steady state associated with concurrent probenecid administration (218.6 +/- 11.52 ml/kg without probenecid; 169.4 +/- 9.25 ml/kg with probenecid).,Effect of probenecid on the pharmacokinetics of flunixin meglumine and phenylbutazone in healthy mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595963/),[ml] / [kg],218.6,74500,DB01032,Probenecid
,1595963,volume of distribution at steady state,Significant (P less than or equal to 0.05) increase was evident in the 12-hour mean concentration of phenylbutazone (11.45 +/- 1.66 micrograms/ml without probenecid; 14.56 +/- 1.20 micrograms/ml with probenecid) along with significant (P less than or equal to 0.05) reduction in its volume of distribution at steady state associated with concurrent probenecid administration (218.6 +/- 11.52 ml/kg without probenecid; 169.4 +/- 9.25 ml/kg with probenecid).,Effect of probenecid on the pharmacokinetics of flunixin meglumine and phenylbutazone in healthy mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595963/),[ml] / [kg],169.4,74501,DB01032,Probenecid
,10628898,absolute bioavailability,The absolute bioavailability of the active metabolite from orally administered oseltamivir is 80%.,Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),%,80,74584,DB01032,Probenecid
,10628898,apparent half-life,"After peak plasma concentrations are attained, the concentration of the active metabolite declines with an apparent half-life of 6 to 10 hours.",Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628898/),h,6 to 10,74585,DB01032,Probenecid
≥,26673740,transport ratio,"Using efflux transport studies, we show that bumetanide is a transported substrate of human OAT3, exhibiting a transport ratio of ≥1.5, which is attenuated by OAT3 inhibitors.",In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26673740/),,1.5,75347,DB01032,Probenecid
,7297018,Peak serum levels,Peak serum levels after 1000 and 500 mg intravenously was 221 and 91 micrograms/ml.,Kinetics and renal handling of cefonicid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),[μg] / [ml],221,76457,DB01032,Probenecid
,7297018,Peak serum levels,Peak serum levels after 1000 and 500 mg intravenously was 221 and 91 micrograms/ml.,Kinetics and renal handling of cefonicid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),[μg] / [ml],91,76458,DB01032,Probenecid
,7297018,half-life (t1/2),The half-life (t1/2) was the same for both regimens (3.5 hr).,Kinetics and renal handling of cefonicid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),h,3.5,76459,DB01032,Probenecid
,7297018,peak serum levels,Intramuscular injection of the 1000- and 500-mg doses resulted in peak serum levels of 112 and 40 micrograms/ml.,Kinetics and renal handling of cefonicid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),[μg] / [ml],112,76460,DB01032,Probenecid
,7297018,peak serum levels,Intramuscular injection of the 1000- and 500-mg doses resulted in peak serum levels of 112 and 40 micrograms/ml.,Kinetics and renal handling of cefonicid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),[μg] / [ml],40,76461,DB01032,Probenecid
,7297018,peak serum level,"When probenecid was given with the 500-mg dose, the peak serum level was 61 micrograms/ml and the time to peak level rose from 1.3 to 2.5 hr.",Kinetics and renal handling of cefonicid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),[μg] / [ml],61,76462,DB01032,Probenecid
,7297018,time to peak level,"When probenecid was given with the 500-mg dose, the peak serum level was 61 micrograms/ml and the time to peak level rose from 1.3 to 2.5 hr.",Kinetics and renal handling of cefonicid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),h,1.3,76463,DB01032,Probenecid
,7297018,time to peak level,"When probenecid was given with the 500-mg dose, the peak serum level was 61 micrograms/ml and the time to peak level rose from 1.3 to 2.5 hr.",Kinetics and renal handling of cefonicid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),h,2.5,76464,DB01032,Probenecid
,7297018,t1/2,The t1/2 after 1000 and 500 mg alone was much the same at 4.8 and 4.9 hr.,Kinetics and renal handling of cefonicid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),h,4.8,76465,DB01032,Probenecid
,7297018,t1/2,The t1/2 after 1000 and 500 mg alone was much the same at 4.8 and 4.9 hr.,Kinetics and renal handling of cefonicid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),h,4.9,76466,DB01032,Probenecid
,7297018,t1/2,The addition of probenecid to the 500-mg dose extended the t1/2 and 7.5 hr.,Kinetics and renal handling of cefonicid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297018/),h,7.5,76467,DB01032,Probenecid
,742871,peak serum concentrations,"Mean peak serum concentrations of 4.9, 13.3, and 30.2 mug/ml were assayed at 30 to 50 min, and measurable levels were present up to 4, 6, and 8 h, respectively, after dosing.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[μg] / [ml],4.9,77178,DB01032,Probenecid
,742871,peak serum concentrations,"Mean peak serum concentrations of 4.9, 13.3, and 30.2 mug/ml were assayed at 30 to 50 min, and measurable levels were present up to 4, 6, and 8 h, respectively, after dosing.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[μg] / [ml],13.3,77179,DB01032,Probenecid
,742871,peak serum concentrations,"Mean peak serum concentrations of 4.9, 13.3, and 30.2 mug/ml were assayed at 30 to 50 min, and measurable levels were present up to 4, 6, and 8 h, respectively, after dosing.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[μg] / [ml],30.2,77180,DB01032,Probenecid
,742871,serum concentrations,"Single intravenous bolus doses of 1.0, 2.0, 4.0, and 6.0 g were given to four groups of five subjects, and mean serum concentrations of 70.7, 199.5, 330.7, and 451.8 mug/ml were measured at the end of the injections.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[μg] / [ml],70.7,77181,DB01032,Probenecid
,742871,serum concentrations,"Single intravenous bolus doses of 1.0, 2.0, 4.0, and 6.0 g were given to four groups of five subjects, and mean serum concentrations of 70.7, 199.5, 330.7, and 451.8 mug/ml were measured at the end of the injections.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[μg] / [ml],199.5,77182,DB01032,Probenecid
,742871,serum concentrations,"Single intravenous bolus doses of 1.0, 2.0, 4.0, and 6.0 g were given to four groups of five subjects, and mean serum concentrations of 70.7, 199.5, 330.7, and 451.8 mug/ml were measured at the end of the injections.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[μg] / [ml],330.7,77183,DB01032,Probenecid
,742871,serum concentrations,"Single intravenous bolus doses of 1.0, 2.0, 4.0, and 6.0 g were given to four groups of five subjects, and mean serum concentrations of 70.7, 199.5, 330.7, and 451.8 mug/ml were measured at the end of the injections.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[μg] / [ml],451.8,77184,DB01032,Probenecid
,742871,terminal serum half-life,"The antibiotic had a mean terminal serum half-life of 60 to 80 min after the intramuscular doses and 36 to 63 min after intravenous administrations, depending on the dose.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),min,60 to 80,77185,DB01032,Probenecid
,742871,terminal serum half-life,"The antibiotic had a mean terminal serum half-life of 60 to 80 min after the intramuscular doses and 36 to 63 min after intravenous administrations, depending on the dose.",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),min,36 to 63,77186,DB01032,Probenecid
,742871,apparent distribution volume,"The apparent distribution volume was 20 to 24 liters/1.73 m(2), and distribution volume at steady state was 16 to 19 liters/1.73 m(2).",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[1.73·l] / [m(2],20 to 24,77187,DB01032,Probenecid
,742871,distribution volume at steady state,"The apparent distribution volume was 20 to 24 liters/1.73 m(2), and distribution volume at steady state was 16 to 19 liters/1.73 m(2).",Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),[1.73·l] / [m(2],16 to 19,77188,DB01032,Probenecid
,742871,urinary recovery in 24 h,Mean urinary recovery in 24 h was 74 to 89% for the intravenous doses and 57 to 59% for the intramuscular doses.,Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),%,74 to 89,77189,DB01032,Probenecid
,742871,urinary recovery in 24 h,Mean urinary recovery in 24 h was 74 to 89% for the intravenous doses and 57 to 59% for the intramuscular doses.,Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/742871/),%,57 to 59,77190,DB01032,Probenecid
,6583194,half life in the beta-phase,The half life in the beta-phase was about 1 h in 48 subjects with normal renal function and about 80 min in one subject with a glomerular filtration rate (GFR) of about 50 ml/min/1 X 73 m2.,Pharmacokinetics of imipenem in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583194/),h,1,77225,DB01032,Probenecid
,6583194,half life in the beta-phase,The half life in the beta-phase was about 1 h in 48 subjects with normal renal function and about 80 min in one subject with a glomerular filtration rate (GFR) of about 50 ml/min/1 X 73 m2.,Pharmacokinetics of imipenem in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583194/),min,80,77226,DB01032,Probenecid
,6583194,volume of distribution in the central compartment,The volume of distribution in the central compartment was about 101.,Pharmacokinetics of imipenem in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583194/),,101,77227,DB01032,Probenecid
,3162904,half-life,"The half-life of both enoxacin and 4-oxo-enoxacin was 5-6 h; during treatment with 400 and 600 mg bd, the plasma concentrations exceeded MIC values for most bacteria isolated in respiratory tract infections, including most Pseudomonas aeruginosa strains; Streptococcus pneumoniae was an exception.",Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162904/),h,5-6,77760,DB01032,Probenecid
,3162904,Diffusion,Diffusion from plasma to sputum was approximately 100%.,Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162904/),%,100,77761,DB01032,Probenecid
,34019417,IC50,"Compound 18, with the most potent activity (IC50 = 74 nM), high BBB permeability (Pe = 19.1 × 10-6 cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound.",Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson's Disease. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019417/),nM,74,78978,DB01032,Probenecid
,34019417,Pe,"Compound 18, with the most potent activity (IC50 = 74 nM), high BBB permeability (Pe = 19.1 × 10-6 cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound.",Optimization of N-Phenylpropenoyl-l-amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson's Disease. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34019417/),[cm] / [s],19.1 × 10-6,78979,DB01032,Probenecid
,18370547,Elimination half-life,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),h,4.86,79240,DB01032,Probenecid
,18370547,Elimination half-life,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),h,5.26,79241,DB01032,Probenecid
,18370547,mean residence time,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),h,5.26,79242,DB01032,Probenecid
,18370547,mean residence time,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),h,7.23,79243,DB01032,Probenecid
,18370547,mean residence time,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),h,7.95,79244,DB01032,Probenecid
,18370547,area under the curve,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),[mg] / [h·l],10.28,79245,DB01032,Probenecid
,18370547,area under the curve,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),[mg] / [h·l],11.9,79246,DB01032,Probenecid
,18370547,total clearance,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),[l] / [h],19.66,79247,DB01032,Probenecid
,18370547,total clearance,"Elimination half-life, mean residence time and area under the curve were significantly increased (4.86 vs 5.26h; 7.23 vs 7.95h; 10.28 vs 11.9 mg/L . h) [p < 0.01], whereas the total clearance was decreased (19.66 vs 16.95 L/h) [p < 0.01] in the presence of probenecid.",Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370547/),[l] / [h],16.95,79248,DB01032,Probenecid
,7654491,"t1/2,z","Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,2.01,80763,DB01032,Probenecid
,7654491,"t1/2,z","Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,3.40,80764,DB01032,Probenecid
,7654491,oral clearance,"Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],164,80765,DB01032,Probenecid
,7654491,oral clearance,"Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],58.3,80766,DB01032,Probenecid
,7654491,tmax,"Probenecid significantly increased the tmax of the metabolite frusemide acyl glucuronide from 1.4 to 2.6 h, but had no effect on the tlag, Cmax, t1/2,z and plasma protein binding.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,1.4,80767,DB01032,Probenecid
,7654491,tmax,"Probenecid significantly increased the tmax of the metabolite frusemide acyl glucuronide from 1.4 to 2.6 h, but had no effect on the tlag, Cmax, t1/2,z and plasma protein binding.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,2.6,80768,DB01032,Probenecid
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,39.2,80769,DB01032,Probenecid
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,34.4,80770,DB01032,Probenecid
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,12.1,80771,DB01032,Probenecid
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,11.8,80772,DB01032,Probenecid
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],128,80773,DB01032,Probenecid
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],44.0,80774,DB01032,Probenecid
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],552,80775,DB01032,Probenecid
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],158,80776,DB01032,Probenecid
,7654491,non-renal clearance,"The non-renal clearance of frusemide (36.7 +/- 21.0 vs 15.2 +/- 13.4 ml min-1, P = 0.0068) was also decreased.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],36.7,80777,DB01032,Probenecid
,7654491,non-renal clearance,"The non-renal clearance of frusemide (36.7 +/- 21.0 vs 15.2 +/- 13.4 ml min-1, P = 0.0068) was also decreased.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],15.2,80778,DB01032,Probenecid
,3874742,bioavailability,"Probenecid decreased total plasma clearance of zomepirac by 64%, which resulted in an increase in bioavailability from 0.55 without probenecid to 0.84 when given concurrently.",Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3874742/),,0.55,81793,DB01032,Probenecid
,3874742,bioavailability,"Probenecid decreased total plasma clearance of zomepirac by 64%, which resulted in an increase in bioavailability from 0.55 without probenecid to 0.84 when given concurrently.",Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3874742/),,0.84,81794,DB01032,Probenecid
,3874742,ratio of the total clearance/bioavailability,"The ratio of the total clearance/bioavailability of zomepirac in control subjects was 682 +/- 246 ml/min, which is double the value reported in previous studies of zomepirac disposition.",Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3874742/),[ml] / [min],682,81795,DB01032,Probenecid
,3286083,t1/2 alpha,"After intravenous injection plasma concentrations follow a 2-compartment open model, with a t1/2 alpha of 0.20 hours.",Clinical pharmacokinetics of aztreonam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),h,0.20,81889,DB01032,Probenecid
,3286083,Volume of distribution at steady-state (Vdss),Volume of distribution at steady-state (Vdss) after intravenous or intramuscular injection is about 0.16 L/kg (0.42 L/kg for the free drug).,Clinical pharmacokinetics of aztreonam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),[l] / [kg],0.16,81890,DB01032,Probenecid
,3286083,Volume of distribution at steady-state (Vdss),Volume of distribution at steady-state (Vdss) after intravenous or intramuscular injection is about 0.16 L/kg (0.42 L/kg for the free drug).,Clinical pharmacokinetics of aztreonam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),[l] / [kg],0.42,81891,DB01032,Probenecid
,3286083,Plasma binding,Plasma binding in healthy subjects is about 56% and is not concentration dependent.,Clinical pharmacokinetics of aztreonam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),%,56,81892,DB01032,Probenecid
,3286083,Total plasma clearance,"Total plasma clearance in healthy adults is about 140 ml/min (8.4 L/h) or 2 ml/min/kg (0.12 L/h/kg), and terminal half-life is 1.7 hours.",Clinical pharmacokinetics of aztreonam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),[ml] / [min],140,81893,DB01032,Probenecid
,3286083,Total plasma clearance,"Total plasma clearance in healthy adults is about 140 ml/min (8.4 L/h) or 2 ml/min/kg (0.12 L/h/kg), and terminal half-life is 1.7 hours.",Clinical pharmacokinetics of aztreonam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),[ml] / [kg·min],2,81894,DB01032,Probenecid
,3286083,terminal half-life,"Total plasma clearance in healthy adults is about 140 ml/min (8.4 L/h) or 2 ml/min/kg (0.12 L/h/kg), and terminal half-life is 1.7 hours.",Clinical pharmacokinetics of aztreonam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),h,1.7,81895,DB01032,Probenecid
,3286083,clearance,"In children clearance is similar to that in adults when expressed as a function of bodyweight, but in neonates, especially in low birthweight infants, it is less [about 1 ml/min/kg (0.06 L/h/kg)].",Clinical pharmacokinetics of aztreonam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),[ml] / [kg·min],1,81896,DB01032,Probenecid
,3286083,clearance,"In children clearance is similar to that in adults when expressed as a function of bodyweight, but in neonates, especially in low birthweight infants, it is less [about 1 ml/min/kg (0.06 L/h/kg)].",Clinical pharmacokinetics of aztreonam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286083/),[l] / [h·kg],0.06,81897,DB01032,Probenecid
,1879255,Time to peak concentration,Time to peak concentration varied widely between 0.5 and 4 h in both CF subjects and controls.,Probenecid pharmacokinetics in cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879255/),h,0.5 and 4,82790,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,14.1,82801,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,36.3,82802,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,9.3,82803,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,42.1,82804,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,47.9,82805,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,47.6,82806,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,78.6,82807,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,83.1,82808,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,44.1,82809,DB01032,Probenecid
,16433034,urinary recoveries (UR,"Mean AUC0(0-infinityS) (microg x h/ml) and urinary recoveries (UR, %, 0-24 h) were 14.1 and 36.3 in mice, 9.3 and 42.1 in rats, 47.9 and 47.6 in rabbits, 78.6 and 83.1 in dogs and 44.1 and 51.0 in monkeys, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,51.0,82810,DB01032,Probenecid
,16433034,Serum protein binding rates,"Serum protein binding rates (%) of doripenem were 25.2 in mice, 35.2 in rats, 11.8 in rabbits, 10.2 in dogs, 6.1 in monkeys and 8.1 in humans, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,25.2,82811,DB01032,Probenecid
,16433034,Serum protein binding rates,"Serum protein binding rates (%) of doripenem were 25.2 in mice, 35.2 in rats, 11.8 in rabbits, 10.2 in dogs, 6.1 in monkeys and 8.1 in humans, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,35.2,82812,DB01032,Probenecid
,16433034,Serum protein binding rates,"Serum protein binding rates (%) of doripenem were 25.2 in mice, 35.2 in rats, 11.8 in rabbits, 10.2 in dogs, 6.1 in monkeys and 8.1 in humans, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,11.8,82813,DB01032,Probenecid
,16433034,Serum protein binding rates,"Serum protein binding rates (%) of doripenem were 25.2 in mice, 35.2 in rats, 11.8 in rabbits, 10.2 in dogs, 6.1 in monkeys and 8.1 in humans, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,10.2,82814,DB01032,Probenecid
,16433034,Serum protein binding rates,"Serum protein binding rates (%) of doripenem were 25.2 in mice, 35.2 in rats, 11.8 in rabbits, 10.2 in dogs, 6.1 in monkeys and 8.1 in humans, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,6.1,82815,DB01032,Probenecid
,16433034,Serum protein binding rates,"Serum protein binding rates (%) of doripenem were 25.2 in mice, 35.2 in rats, 11.8 in rabbits, 10.2 in dogs, 6.1 in monkeys and 8.1 in humans, respectively.","Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433034/),%,8.1,82816,DB01032,Probenecid
,11095580,apparent intrinsic clearance,"However, PRB decreased the apparent intrinsic clearance of VPA (1.81 +/- 0.58 versus 1.23 +/- 0.23 ml/min; P =.025) by competitively inhibiting VPA elimination.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[ml] / [min],1.81,83248,DB01032,Probenecid
,11095580,apparent intrinsic clearance,"However, PRB decreased the apparent intrinsic clearance of VPA (1.81 +/- 0.58 versus 1.23 +/- 0.23 ml/min; P =.025) by competitively inhibiting VPA elimination.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[ml] / [min],1.23,83249,DB01032,Probenecid
,11095580,V(max),"VG formation (V(max) = 0.80 +/- 0.06 microg/min/mg of protein; K(m) = 173 +/- 28.8 microg/ml) was impaired by PRB in a competitive manner (K(i) = 876 +/- 559 microg/ml), consistent with the in vivo data.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[μg] / [mg·min],0.80,83250,DB01032,Probenecid
,11095580,K(m),"VG formation (V(max) = 0.80 +/- 0.06 microg/min/mg of protein; K(m) = 173 +/- 28.8 microg/ml) was impaired by PRB in a competitive manner (K(i) = 876 +/- 559 microg/ml), consistent with the in vivo data.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[μg] / [ml],173,83251,DB01032,Probenecid
,11095580,K(i),"VG formation (V(max) = 0.80 +/- 0.06 microg/min/mg of protein; K(m) = 173 +/- 28.8 microg/ml) was impaired by PRB in a competitive manner (K(i) = 876 +/- 559 microg/ml), consistent with the in vivo data.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[μg] / [ml],876,83252,DB01032,Probenecid
,20519552,K(m),In vitro studies conducted to characterize the transporters involved demonstrated PNU-288034 uptake by human organic anion transporter 3 (OAT3; K(m) = 44 +/- 5 microM) and human multidrug and toxin extrusion protein 1 (hMATE1; K(m) = 340 +/- 55 microM).,Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519552/),μM,44,83674,DB01032,Probenecid
,20519552,K(m),In vitro studies conducted to characterize the transporters involved demonstrated PNU-288034 uptake by human organic anion transporter 3 (OAT3; K(m) = 44 +/- 5 microM) and human multidrug and toxin extrusion protein 1 (hMATE1; K(m) = 340 +/- 55 microM).,Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20519552/),μM,340,83675,DB01032,Probenecid
,11193895,Vmax,"The transport of CPT in Caco-2 cell lines (validated model of intestinal drug transport) was concentration dependent and saturable (Vmax: 34 x 10(-5) cm/sec and Km: 20 microM), and was temperature dependent with an activation energy (Ea) of 11.7 kcal/mole.",Pharmacokinetics of orally administered camptothecins. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[cm] / [s],34 x 10(-5),85169,DB01032,Probenecid
,11193895,Km,"The transport of CPT in Caco-2 cell lines (validated model of intestinal drug transport) was concentration dependent and saturable (Vmax: 34 x 10(-5) cm/sec and Km: 20 microM), and was temperature dependent with an activation energy (Ea) of 11.7 kcal/mole.",Pharmacokinetics of orally administered camptothecins. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),μM,20,85170,DB01032,Probenecid
,11193895,activation energy (Ea),"The transport of CPT in Caco-2 cell lines (validated model of intestinal drug transport) was concentration dependent and saturable (Vmax: 34 x 10(-5) cm/sec and Km: 20 microM), and was temperature dependent with an activation energy (Ea) of 11.7 kcal/mole.",Pharmacokinetics of orally administered camptothecins. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[kcal] / [mole],11.7,85171,DB01032,Probenecid
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],8.57,85172,DB01032,Probenecid
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],5.06,85173,DB01032,Probenecid
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],6.44,85174,DB01032,Probenecid
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],4.81,85175,DB01032,Probenecid
,11193895,specific activities,"The mean (+/- SD) specific activities (pmoles/min/mg) were: liver (8.57 +/- 10.4, n = 8), duodenum (5.06 +/- 3.7, n = 4), jejunum (6.44 +/- 2.8, n = 5), ileum (4.81 +/- 2.4, n = 5), colon (1.93 +/- 1.5, n = 6), and rectum (0.82, n = 1).",Pharmacokinetics of orally administered camptothecins. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193895/),[pmoles] / [mg·min],1.93,85176,DB01032,Probenecid
,7103460,renal clearance,"In the absence of probenecid, the renal clearance (248 +/- 80 ml/min per 1.73 m2) accounted for 83% of the total clearance (300 +/- 69 ml/min per 1.73 m2) and was almost threefold greater than the estimated creatinine clearance (90 +/- 48 ml/min per 1.73 m2).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[ml] / [1.73·m2·min],248,85514,DB01032,Probenecid
,7103460,total clearance,"In the absence of probenecid, the renal clearance (248 +/- 80 ml/min per 1.73 m2) accounted for 83% of the total clearance (300 +/- 69 ml/min per 1.73 m2) and was almost threefold greater than the estimated creatinine clearance (90 +/- 48 ml/min per 1.73 m2).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[ml] / [1.73·m2·min],300,85515,DB01032,Probenecid
,7103460,renal clearance,"After probenecid administration, there was a 32% decline in renal clearance (248 to 168 ml/min per 1.73 m2; P less than or equal to 0.05), a 40% increase in the area under the curve (91.3 to 127.6 nmol.h/ml; P less than 0.05), and an 18% increase in the terminal plasma half-life (2.3 to 2.7 h; P less than 0.01).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[ml] / [1.73·m2·min],248 to 168,85516,DB01032,Probenecid
,7103460,area under the curve,"After probenecid administration, there was a 32% decline in renal clearance (248 to 168 ml/min per 1.73 m2; P less than or equal to 0.05), a 40% increase in the area under the curve (91.3 to 127.6 nmol.h/ml; P less than 0.05), and an 18% increase in the terminal plasma half-life (2.3 to 2.7 h; P less than 0.01).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[h·nM] / [ml],91.3 to 127.6,85517,DB01032,Probenecid
,7103460,terminal plasma half-life,"After probenecid administration, there was a 32% decline in renal clearance (248 to 168 ml/min per 1.73 m2; P less than or equal to 0.05), a 40% increase in the area under the curve (91.3 to 127.6 nmol.h/ml; P less than 0.05), and an 18% increase in the terminal plasma half-life (2.3 to 2.7 h; P less than 0.01).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),h,2.3 to 2.7,85518,DB01032,Probenecid
,16343289,clearances (Clp,"Plasma 99mTc-MAG3 clearances (Clp, ml/min/kg) were 7.9 +/- 0.5, 3.3 +/- 0.5 and 4.8 +/- 1.3 in control, 15 min and 24 h after probenecid administration respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),[ml] / [kg·min],7.9,86176,DB01032,Probenecid
,16343289,clearances (Clp,"Plasma 99mTc-MAG3 clearances (Clp, ml/min/kg) were 7.9 +/- 0.5, 3.3 +/- 0.5 and 4.8 +/- 1.3 in control, 15 min and 24 h after probenecid administration respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),[ml] / [kg·min],3.3,86177,DB01032,Probenecid
,16343289,clearances (Clp,"Plasma 99mTc-MAG3 clearances (Clp, ml/min/kg) were 7.9 +/- 0.5, 3.3 +/- 0.5 and 4.8 +/- 1.3 in control, 15 min and 24 h after probenecid administration respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),[ml] / [kg·min],4.8,86178,DB01032,Probenecid
,16343289,biological half-lives at elimination phase (t(1/2),"Similarly, the biological half-lives at elimination phase (t(1/2), h) were 0.61 +/- 0.09, 0.79 +/- 0.11 and 0.74 +/- 0.12, and volumes of distribution at steady state (Vdss, L/kg) were 0.29 +/- 0.04, 0.20 +/- 0.05 and 0.25 +/- 0.06 respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),h,0.61,86179,DB01032,Probenecid
,16343289,biological half-lives at elimination phase (t(1/2),"Similarly, the biological half-lives at elimination phase (t(1/2), h) were 0.61 +/- 0.09, 0.79 +/- 0.11 and 0.74 +/- 0.12, and volumes of distribution at steady state (Vdss, L/kg) were 0.29 +/- 0.04, 0.20 +/- 0.05 and 0.25 +/- 0.06 respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),h,0.79,86180,DB01032,Probenecid
,16343289,biological half-lives at elimination phase (t(1/2),"Similarly, the biological half-lives at elimination phase (t(1/2), h) were 0.61 +/- 0.09, 0.79 +/- 0.11 and 0.74 +/- 0.12, and volumes of distribution at steady state (Vdss, L/kg) were 0.29 +/- 0.04, 0.20 +/- 0.05 and 0.25 +/- 0.06 respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),h,0.74,86181,DB01032,Probenecid
,16343289,volumes of distribution at steady state (Vdss,"Similarly, the biological half-lives at elimination phase (t(1/2), h) were 0.61 +/- 0.09, 0.79 +/- 0.11 and 0.74 +/- 0.12, and volumes of distribution at steady state (Vdss, L/kg) were 0.29 +/- 0.04, 0.20 +/- 0.05 and 0.25 +/- 0.06 respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),[l] / [kg],0.29,86182,DB01032,Probenecid
,16343289,volumes of distribution at steady state (Vdss,"Similarly, the biological half-lives at elimination phase (t(1/2), h) were 0.61 +/- 0.09, 0.79 +/- 0.11 and 0.74 +/- 0.12, and volumes of distribution at steady state (Vdss, L/kg) were 0.29 +/- 0.04, 0.20 +/- 0.05 and 0.25 +/- 0.06 respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),[l] / [kg],0.20,86183,DB01032,Probenecid
,16343289,volumes of distribution at steady state (Vdss,"Similarly, the biological half-lives at elimination phase (t(1/2), h) were 0.61 +/- 0.09, 0.79 +/- 0.11 and 0.74 +/- 0.12, and volumes of distribution at steady state (Vdss, L/kg) were 0.29 +/- 0.04, 0.20 +/- 0.05 and 0.25 +/- 0.06 respectively.",Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),[l] / [kg],0.25,86184,DB01032,Probenecid
,16343289,maximum Clp inhibition (Imax),The maximum Clp inhibition (Imax) by probenecid and the plasma probenecid concentration that induced 50% of Imax (I50) were estimated to be 72 +/- 12% and 13 +/- 8 microg/ml respectively.,Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),%,72,86185,DB01032,Probenecid
,16343289,Imax (I50),The maximum Clp inhibition (Imax) by probenecid and the plasma probenecid concentration that induced 50% of Imax (I50) were estimated to be 72 +/- 12% and 13 +/- 8 microg/ml respectively.,Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343289/),[μg] / [ml],13,86186,DB01032,Probenecid
,8115734,elimination half life,"In normal eyes, the elimination half life was 2.2 hours with a distribution volume of 1.2 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),h,2.2,86434,DB01032,Probenecid
,8115734,distribution volume,"In normal eyes, the elimination half life was 2.2 hours with a distribution volume of 1.2 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),ml,1.2,86435,DB01032,Probenecid
,8115734,half life,"In aphakic vitrectomized eyes, the half life was 1 hour and the distribution volume was 1.4 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),h,1,86436,DB01032,Probenecid
,8115734,distribution volume,"In aphakic vitrectomized eyes, the half life was 1 hour and the distribution volume was 1.4 ml.",Clearance and distribution of ciprofloxacin after intravitreal injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8115734/),ml,1.4,86437,DB01032,Probenecid
,21285173,renal urate clearance,"Addition of probenecid 500 mg/day to allopurinol therapy decreased plasma urate concentrations by 25%, from mean 0.37 mmol/l (95% CI 0.33-0.41) to mean 0.28 mmol/l (95% CI 0.24-0.32) (p < 0.001); and increased renal urate clearance by 62%, from mean 6.0 ml/min (95% CI 4.5-7.5) to mean 9.6 ml/min (95% CI 6.9-12.3) (p < 0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],6.0,86741,DB01032,Probenecid
,21285173,renal urate clearance,"Addition of probenecid 500 mg/day to allopurinol therapy decreased plasma urate concentrations by 25%, from mean 0.37 mmol/l (95% CI 0.33-0.41) to mean 0.28 mmol/l (95% CI 0.24-0.32) (p < 0.001); and increased renal urate clearance by 62%, from mean 6.0 ml/min (95% CI 4.5-7.5) to mean 9.6 ml/min (95% CI 6.9-12.3) (p < 0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],9.6,86742,DB01032,Probenecid
,21285173,steady-state plasma oxypurinol concentrations,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[mg] / [l],11.1,86743,DB01032,Probenecid
,21285173,steady-state plasma oxypurinol concentrations,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[mg] / [l],8.2,86744,DB01032,Probenecid
,21285173,renal oxypurinol clearance,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],12.7,86745,DB01032,Probenecid
,21285173,renal oxypurinol clearance,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],16.1,86746,DB01032,Probenecid
,20219852,renal clearance,"When JBP485 and cephalexin were coadministered, both the decrease in accumulative renal excretion (81.9-68.1% of JBP485 and 91.8-74.5% of cephalexin) and in renal clearance (2.89-1.87 ml/min/kg JBP485 and 2.23-1.58 ml/min/kg cephalexin) indicated that transporter(s) other than H(+)/peptide transporter (PEPT) 2 are involved in the process of excretion.",Pharmacokinetic interaction between JBP485 and cephalexin in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20219852/),[ml] / [kg·min],2.89-1.87,87099,DB01032,Probenecid
,20219852,renal clearance,"When JBP485 and cephalexin were coadministered, both the decrease in accumulative renal excretion (81.9-68.1% of JBP485 and 91.8-74.5% of cephalexin) and in renal clearance (2.89-1.87 ml/min/kg JBP485 and 2.23-1.58 ml/min/kg cephalexin) indicated that transporter(s) other than H(+)/peptide transporter (PEPT) 2 are involved in the process of excretion.",Pharmacokinetic interaction between JBP485 and cephalexin in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20219852/),[ml] / [kg·min],2.23-1.58,87100,DB01032,Probenecid
,6097173,MIC,"The geometric mean MIC of sulbactam for 20 pretreatment isolates of N. gonorrhoeae was 1.37 microgram/ml (range, 0.25 to 8.0 micrograms/ml).",Therapeutic trial and pharmacokinetics of sulbactam for uncomplicated gonorrhea in men. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6097173/),[μg] / [ml],1.37,87175,DB01032,Probenecid
,17250987,retention times,"The retention times of Armillarisin A and the internal standard, probenecid, were 1.63 and 1.78 min, respectively.",Quantitation of Armillarisin A in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17250987/),min,1.63,87620,DB01032,Probenecid
,17250987,retention times,"The retention times of Armillarisin A and the internal standard, probenecid, were 1.63 and 1.78 min, respectively.",Quantitation of Armillarisin A in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17250987/),min,1.78,87621,DB01032,Probenecid
,7768255,steady state plasma concentration,The steady state plasma concentration of diflunisal was significantly higher during the probenecid treatment phase as compared to the control phase (104.0 vs. 63.1 micrograms.ml-1).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[μg] / [ml],104.0,90887,DB01032,Probenecid
,7768255,steady state plasma concentration,The steady state plasma concentration of diflunisal was significantly higher during the probenecid treatment phase as compared to the control phase (104.0 vs. 63.1 micrograms.ml-1).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[μg] / [ml],63.1,90888,DB01032,Probenecid
,7768255,plasma clearance,This was the result of a significant decrease in the plasma clearance of diflunisal from 5.8 (control) to 3.4 ml.min-1 (probenecid co-administration).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[ml] / [min],5.8,90889,DB01032,Probenecid
,7768255,plasma clearance,This was the result of a significant decrease in the plasma clearance of diflunisal from 5.8 (control) to 3.4 ml.min-1 (probenecid co-administration).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[ml] / [min],3.4,90890,DB01032,Probenecid
,1621740,maximum plasma concentration (Cmax),"In one study in children, following the administration of 15 mg/kg of loracarbef suspension, the mean maximum plasma concentration (Cmax) was 20.3 micrograms/mL.",Pharmacokinetic profile of loracarbef. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1621740/),[μg] / [ml],20.3,93712,DB01032,Probenecid
,7259928,steady state levels,"3 Cefoxitin was administered by intravenous infusion, subsequent to a loading dose, to produce steady state levels in the region of 10 microgram/ml, in one volunteer.",The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7259928/),[μg] / [ml],10,93819,DB01032,Probenecid
,10148,(,"Following intravenous administration an initial rapid elimination of drug from the plasma was observed [(t1/2)alpha approximately 0.4 hr, (t1/2)beta approximately 4 hr].","The biotransformation of (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy) acetic acid (MK-196) in the chimpanzee. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10148/),h,0.4,95774,DB01032,Probenecid
,10148,t1/2)alpha,"Following intravenous administration an initial rapid elimination of drug from the plasma was observed [(t1/2)alpha approximately 0.4 hr, (t1/2)beta approximately 4 hr].","The biotransformation of (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy) acetic acid (MK-196) in the chimpanzee. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10148/),h,0.4,95775,DB01032,Probenecid
,10148,t1/2)beta,"Following intravenous administration an initial rapid elimination of drug from the plasma was observed [(t1/2)alpha approximately 0.4 hr, (t1/2)beta approximately 4 hr].","The biotransformation of (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy) acetic acid (MK-196) in the chimpanzee. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10148/),h,4,95776,DB01032,Probenecid
,6218568,peak serum level,"After intravenous bolus injection of 1 g of moxalactam, the peak serum level was 201.0 micrograms/ml, the half-life (beta-phase) was 126 min, and the cumulative urinary excretion during a 10-hr period was 90.5% of the dose.","Moxalactam--absorption, excretion, distribution, and metabolism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6218568/),[μg] / [ml],201.0,96743,DB01032,Probenecid
,6218568,half-life (beta-phase),"After intravenous bolus injection of 1 g of moxalactam, the peak serum level was 201.0 micrograms/ml, the half-life (beta-phase) was 126 min, and the cumulative urinary excretion during a 10-hr period was 90.5% of the dose.","Moxalactam--absorption, excretion, distribution, and metabolism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6218568/),min,126,96744,DB01032,Probenecid
,6218568,Concentrations,Concentrations in sputum were 1.84-2.11 micrograms/ml in individuals given 1 g by intravenous slow bolus injection.,"Moxalactam--absorption, excretion, distribution, and metabolism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6218568/),[μg] / [ml],1.84-2.11,96745,DB01032,Probenecid
,89025,peak serum level,"Bleomycin (1 mg/kg, ip) reached a peak serum level of 0.7-1.0 microgram/ml in 54 +/- 4 min (mean +/- SE) and was eliminated with a t 1/2 of 32 +/- 1 min.","Disposition of the pulmonary toxin, bleomycin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),[μg] / [ml],0.7-1.0,98552,DB01032,Probenecid
,89025,t 1/2,"Bleomycin (1 mg/kg, ip) reached a peak serum level of 0.7-1.0 microgram/ml in 54 +/- 4 min (mean +/- SE) and was eliminated with a t 1/2 of 32 +/- 1 min.","Disposition of the pulmonary toxin, bleomycin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),min,32,98553,DB01032,Probenecid
,89025,apparent volume of distribution,The apparent volume of distribution in rats was 184 +/- 11 ml/kg.,"Disposition of the pulmonary toxin, bleomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),[ml] / [kg],184,98554,DB01032,Probenecid
,29920736,renal clearance,"Mean (standard deviation) renal clearance of mirogabalin (l h-1 ) was substantially slower after probenecid [6.67 (1.53)] or cimetidine [7.17 (1.68)] coadministration, compared with mirogabalin alone [11.3 (2.39)].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],6.67,100144,DB01032,Probenecid
,29920736,renal clearance,"Mean (standard deviation) renal clearance of mirogabalin (l h-1 ) was substantially slower after probenecid [6.67 (1.53)] or cimetidine [7.17 (1.68)] coadministration, compared with mirogabalin alone [11.3 (2.39)].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],7.17,100145,DB01032,Probenecid
,29920736,renal clearance,"Mean (standard deviation) renal clearance of mirogabalin (l h-1 ) was substantially slower after probenecid [6.67 (1.53)] or cimetidine [7.17 (1.68)] coadministration, compared with mirogabalin alone [11.3 (2.39)].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],11.3,100146,DB01032,Probenecid
,29920736,apparent total body clearance,"Coadministration of probenecid or cimetidine decreased mirogabalin mean (standard deviation) apparent total body clearance [10.5 (2.33) and 12.8 (2.67) l h-1 , respectively, vs. 18.4 (3.93) for mirogabalin alone].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],10.5,100147,DB01032,Probenecid
,29920736,apparent total body clearance,"Coadministration of probenecid or cimetidine decreased mirogabalin mean (standard deviation) apparent total body clearance [10.5 (2.33) and 12.8 (2.67) l h-1 , respectively, vs. 18.4 (3.93) for mirogabalin alone].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),[l] / [h],12.8,100148,DB01032,Probenecid
,29920736,apparent total body clearance,"Coadministration of probenecid or cimetidine decreased mirogabalin mean (standard deviation) apparent total body clearance [10.5 (2.33) and 12.8 (2.67) l h-1 , respectively, vs. 18.4 (3.93) for mirogabalin alone].","Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920736/),,18.4,100149,DB01032,Probenecid
,6311084,peak concentration,"The mean calculated peak concentration, area under the curve from zero to infinity, and half-life without probenecid were 78.1 micrograms/ml, 77.2 micrograms .",Effect of probenecid on the pharmacokinetics of cefmenoxime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311084/),[μg] / [ml],78.1,100743,DB01032,Probenecid
,6311084,area under the curve from zero to infinity,"The mean calculated peak concentration, area under the curve from zero to infinity, and half-life without probenecid were 78.1 micrograms/ml, 77.2 micrograms .",Effect of probenecid on the pharmacokinetics of cefmenoxime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311084/),μg,77.2,100744,DB01032,Probenecid
,6311084,corrected renal drug clearance,"The mean corrected renal drug clearance was 159 and 66 ml/min without and with probenecid, respectively.",Effect of probenecid on the pharmacokinetics of cefmenoxime. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311084/),[ml] / [min],159,100745,DB01032,Probenecid
,6311084,corrected renal drug clearance,"The mean corrected renal drug clearance was 159 and 66 ml/min without and with probenecid, respectively.",Effect of probenecid on the pharmacokinetics of cefmenoxime. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311084/),[ml] / [min],66,100746,DB01032,Probenecid
,2052528,renal clearance,"At a steady-state serum concentration of 0.45 mM, probenecid had no significant effect on the serum concentrations or renal clearance of inorganic sulfate, whereas at a serum concentration of 1.4 mM, probenecid treatment caused a significant decrease in serum sulfate concentrations (0.57 +/- 0.11 vs 0.96 +/- 0.19 mM in controls, mean +/- SD, n = 6, P less than 0.001) due to an increase in the renal clearance of sulfate (3.88 +/- 1.18 vs 2.13 +/- 0.84 ml/min/kg in controls, P less than 0.01).",Sulfate homeostasis. Probenecid-induced alterations of inorganic sulfate in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052528/),[ml] / [kg·min],3.88,101646,DB01032,Probenecid
,2052528,renal clearance,"At a steady-state serum concentration of 0.45 mM, probenecid had no significant effect on the serum concentrations or renal clearance of inorganic sulfate, whereas at a serum concentration of 1.4 mM, probenecid treatment caused a significant decrease in serum sulfate concentrations (0.57 +/- 0.11 vs 0.96 +/- 0.19 mM in controls, mean +/- SD, n = 6, P less than 0.001) due to an increase in the renal clearance of sulfate (3.88 +/- 1.18 vs 2.13 +/- 0.84 ml/min/kg in controls, P less than 0.01).",Sulfate homeostasis. Probenecid-induced alterations of inorganic sulfate in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052528/),[ml] / [kg·min],2.13,101647,DB01032,Probenecid
,2052528,fraction,"The fraction of the filtered sulfate that was reabsorbed was significantly decreased (0.38 +/- 0.23, vs 0.74 +/- 0.09 in controls, P less than 0.01).",Sulfate homeostasis. Probenecid-induced alterations of inorganic sulfate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052528/),,0.38,101648,DB01032,Probenecid
,2052528,fraction,"The fraction of the filtered sulfate that was reabsorbed was significantly decreased (0.38 +/- 0.23, vs 0.74 +/- 0.09 in controls, P less than 0.01).",Sulfate homeostasis. Probenecid-induced alterations of inorganic sulfate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052528/),,0.74,101649,DB01032,Probenecid
,31760750,IC50,"The present study showed that drugs such as probenecid and glimepiride displayed potent inhibition toward the OAT3-mediated SVAG transport, with IC50 values of 4.9 and 0.8 μM, respectively.","Interaction of Organic Anion Transporter 3-Mediated Uptake of Steviol Acyl Glucuronide, a Major Metabolite of Rebaudioside A, with Selected Drugs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31760750/),μM,4.9,101951,DB01032,Probenecid
,31760750,IC50,"The present study showed that drugs such as probenecid and glimepiride displayed potent inhibition toward the OAT3-mediated SVAG transport, with IC50 values of 4.9 and 0.8 μM, respectively.","Interaction of Organic Anion Transporter 3-Mediated Uptake of Steviol Acyl Glucuronide, a Major Metabolite of Rebaudioside A, with Selected Drugs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31760750/),μM,0.8,101952,DB01032,Probenecid
,2395126,drug,Excretion of sodium paralleled piretanide excretion throughout the study except after i.v. dosing in the nonhydrated state where changes in drug excretion after probenecid (2.55 versus 1.63 mg/6 h) failed to influence sodium output (167 versus 152 mmol/6 h).,"Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395126/),[mg] / [6·h],2.55,102332,DB01032,Probenecid
,2395126,excretion,Excretion of sodium paralleled piretanide excretion throughout the study except after i.v. dosing in the nonhydrated state where changes in drug excretion after probenecid (2.55 versus 1.63 mg/6 h) failed to influence sodium output (167 versus 152 mmol/6 h).,"Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395126/),[mg] / [6·h],2.55,102333,DB01032,Probenecid
,2395126,excretion,Excretion of sodium paralleled piretanide excretion throughout the study except after i.v. dosing in the nonhydrated state where changes in drug excretion after probenecid (2.55 versus 1.63 mg/6 h) failed to influence sodium output (167 versus 152 mmol/6 h).,"Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395126/),[mg] / [6·h],1.63,102334,DB01032,Probenecid
,2395126,sodium output,Excretion of sodium paralleled piretanide excretion throughout the study except after i.v. dosing in the nonhydrated state where changes in drug excretion after probenecid (2.55 versus 1.63 mg/6 h) failed to influence sodium output (167 versus 152 mmol/6 h).,"Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395126/),[mM] / [6·h],167,102335,DB01032,Probenecid
,2395126,sodium output,Excretion of sodium paralleled piretanide excretion throughout the study except after i.v. dosing in the nonhydrated state where changes in drug excretion after probenecid (2.55 versus 1.63 mg/6 h) failed to influence sodium output (167 versus 152 mmol/6 h).,"Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395126/),[mM] / [6·h],152,102336,DB01032,Probenecid
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],238.8,103008,DB01032,Probenecid
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],109.9,103009,DB01032,Probenecid
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],1297.2,103010,DB01032,Probenecid
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],355.0,103011,DB01032,Probenecid
,24616266,renal clearance,"Geometric mean avibactam renal clearance (158 ml/min) was greater than the product of unbound fraction of drug and glomerular filtration rate (109.5 ml/min), suggesting that active tubular secretion accounted for some renal elimination.",Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24616266/),[ml] / [min],158,103151,DB01032,Probenecid
>,24616266,Km,"Avibactam demonstrated in vitro substrate potential for organic anion transporters 1 and 3 (OAT1 and OAT3) proteins expressed in human embryonic kidney 293 cells (Km > 1000 μM; >10-fold the Cmax of a therapeutic dose), which could account for the active tubular secretion observed in vivo.",Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24616266/),μM,1000,103152,DB01032,Probenecid
,7574510,terminal half-life,Levels of cidofovir in serum following intravenous infusion were dose proportional over the dose range of 1.0 to 10.0 mg/kg of body weight and declined biexponentially with an overall mean +/- standard deviation terminal half-life of 2.6 +/- 1.2 h (n = 25).,Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574510/),h,2.6,105405,DB01032,Probenecid
,7574510,total clearance of the drug from serum,"The overall mean +/- standard deviation total clearance of the drug from serum (148 +/- 25 ml/h/kg; n = 25) approximated renal clearance (129 +/- 42 ml/h/kg; n = 25), which was significantly higher (P < 0.001) than the baseline creatinine clearance in the same patients (83 +/- 21 ml/h/kg; n = 12).",Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574510/),[ml] / [h·kg],148,105406,DB01032,Probenecid
,7574510,renal clearance,"The overall mean +/- standard deviation total clearance of the drug from serum (148 +/- 25 ml/h/kg; n = 25) approximated renal clearance (129 +/- 42 ml/h/kg; n = 25), which was significantly higher (P < 0.001) than the baseline creatinine clearance in the same patients (83 +/- 21 ml/h/kg; n = 12).",Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574510/),[ml] / [h·kg],129,105407,DB01032,Probenecid
,7574510,steady-state volume of distribution,"The steady-state volume of distribution of cidofovir was approximately 500 ml/kg, suggesting that the drug was distributed in total body water.",Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574510/),[ml] / [kg],500,105408,DB01032,Probenecid
,10579144,bioavailability,The mean (+/- SD) bioavailability of R-clinafloxacin was 87.5% +/- 4.8% compared to 86.2% +/- 5.8% for S-clinafloxacin.,Pharmacokinetics of clinafloxacin enantiomers in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),%,87.5,105574,DB01032,Probenecid
,10579144,bioavailability,The mean (+/- SD) bioavailability of R-clinafloxacin was 87.5% +/- 4.8% compared to 86.2% +/- 5.8% for S-clinafloxacin.,Pharmacokinetics of clinafloxacin enantiomers in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),%,86.2,105575,DB01032,Probenecid
,10579144,Cmax,"The mean Cmax of each enantiomer was 1.19 micrograms/mL, with plasma concentrations of each enantiomer remaining above 0.1 microgram/mL for at least 12 hours.",Pharmacokinetics of clinafloxacin enantiomers in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),[μg] / [ml],1.19,105576,DB01032,Probenecid
,10579144,t1/2,"After a single 400 mg intravenous dose of racemic drug, mean (+/- SD) t1/2 was 5.6 +/- 0.3 hours and 5.7 +/- 0.4 hours, plasma Cl was 329 +/- 49 mL/min and 314 +/- 45 mL/min, and Vdss was 138 +/- 18 L and 134 +/- 16 L for R- and S-clinafloxacin, respectively.",Pharmacokinetics of clinafloxacin enantiomers in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),h,5.6,105577,DB01032,Probenecid
,10579144,t1/2,"After a single 400 mg intravenous dose of racemic drug, mean (+/- SD) t1/2 was 5.6 +/- 0.3 hours and 5.7 +/- 0.4 hours, plasma Cl was 329 +/- 49 mL/min and 314 +/- 45 mL/min, and Vdss was 138 +/- 18 L and 134 +/- 16 L for R- and S-clinafloxacin, respectively.",Pharmacokinetics of clinafloxacin enantiomers in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),h,5.7,105578,DB01032,Probenecid
,10579144,plasma Cl,"After a single 400 mg intravenous dose of racemic drug, mean (+/- SD) t1/2 was 5.6 +/- 0.3 hours and 5.7 +/- 0.4 hours, plasma Cl was 329 +/- 49 mL/min and 314 +/- 45 mL/min, and Vdss was 138 +/- 18 L and 134 +/- 16 L for R- and S-clinafloxacin, respectively.",Pharmacokinetics of clinafloxacin enantiomers in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),[ml] / [min],329,105579,DB01032,Probenecid
,10579144,plasma Cl,"After a single 400 mg intravenous dose of racemic drug, mean (+/- SD) t1/2 was 5.6 +/- 0.3 hours and 5.7 +/- 0.4 hours, plasma Cl was 329 +/- 49 mL/min and 314 +/- 45 mL/min, and Vdss was 138 +/- 18 L and 134 +/- 16 L for R- and S-clinafloxacin, respectively.",Pharmacokinetics of clinafloxacin enantiomers in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),[ml] / [min],314,105580,DB01032,Probenecid
,10579144,Vdss,"After a single 400 mg intravenous dose of racemic drug, mean (+/- SD) t1/2 was 5.6 +/- 0.3 hours and 5.7 +/- 0.4 hours, plasma Cl was 329 +/- 49 mL/min and 314 +/- 45 mL/min, and Vdss was 138 +/- 18 L and 134 +/- 16 L for R- and S-clinafloxacin, respectively.",Pharmacokinetics of clinafloxacin enantiomers in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),l,138,105581,DB01032,Probenecid
,10579144,Vdss,"After a single 400 mg intravenous dose of racemic drug, mean (+/- SD) t1/2 was 5.6 +/- 0.3 hours and 5.7 +/- 0.4 hours, plasma Cl was 329 +/- 49 mL/min and 314 +/- 45 mL/min, and Vdss was 138 +/- 18 L and 134 +/- 16 L for R- and S-clinafloxacin, respectively.",Pharmacokinetics of clinafloxacin enantiomers in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579144/),l,134,105582,DB01032,Probenecid
,4018078,plasma clearance,"However, its plasma clearance was significantly higher in NAR (45.7 ml kg-1 min-1) than in normal rats (25.2 ml kg-1 min-1).",Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],45.7,106839,DB01032,Probenecid
,4018078,plasma clearance,"However, its plasma clearance was significantly higher in NAR (45.7 ml kg-1 min-1) than in normal rats (25.2 ml kg-1 min-1).",Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],25.2,106840,DB01032,Probenecid
,4018078,association constant,The mercapturic acid bound to plasma albumin with an association constant of 2.24 X 10(5) M-1 and the number of binding sites was 1.18/mol albumin.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),1/[M],2.24 X 10(5),106841,DB01032,Probenecid
,4018078,number of binding sites,The mercapturic acid bound to plasma albumin with an association constant of 2.24 X 10(5) M-1 and the number of binding sites was 1.18/mol albumin.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),1/[mol],1.18,106842,DB01032,Probenecid
,4018078,plasma clearance,Concomitant administration of this mercapturic acid with equimolar amounts of albumin resulted in a marked decrease in the plasma clearance (26.2 ml kg-1 min-1) and an increase in the urinary secretion of this ligand in NAR.,Role of plasma albumin in renal elimination of a mercapturic acid. Analyses in normal and mutant analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018078/),[ml] / [kg·min],26.2,106843,DB01032,Probenecid
,2351614,serum elimination T1/2,"As is characteristic for most penems, the serum elimination T1/2 of CP-65,207 in rodents was only 13 minutes for mice and 18 minutes for rats.","Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2351614/),min,13,108037,DB01032,Probenecid
,2351614,serum elimination T1/2,"As is characteristic for most penems, the serum elimination T1/2 of CP-65,207 in rodents was only 13 minutes for mice and 18 minutes for rats.","Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2351614/),min,18,108038,DB01032,Probenecid
,2351614,T1/2,The T1/2 in the beagle dog and monkey following intravenous injection was approximately 23 minutes.,"Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2351614/),min,23,108039,DB01032,Probenecid
,2351614,Urinary recovery,"Urinary recovery of CP-65,207 in the dog was 42% compared to 1% for imipenem without RDHP inhibitor.","Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2351614/),%,42,108040,DB01032,Probenecid
,2351614,Urinary recovery,"Urinary recovery of CP-65,207 in the dog was 42% compared to 1% for imipenem without RDHP inhibitor.","Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2351614/),%,1,108041,DB01032,Probenecid
,6395801,Maximal plasma concentrations,"Maximal plasma concentrations of 36, 78, and 150 micrograms/ml appeared after doses of 500, 1,000, and 2,000 mg, respectively.","Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6395801/),[μg] / [ml],36,108374,DB01032,Probenecid
,6395801,Maximal plasma concentrations,"Maximal plasma concentrations of 36, 78, and 150 micrograms/ml appeared after doses of 500, 1,000, and 2,000 mg, respectively.","Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6395801/),[μg] / [ml],78,108375,DB01032,Probenecid
,6395801,Maximal plasma concentrations,"Maximal plasma concentrations of 36, 78, and 150 micrograms/ml appeared after doses of 500, 1,000, and 2,000 mg, respectively.","Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6395801/),[μg] / [ml],150,108376,DB01032,Probenecid
,6395801,terminal elimination half-life,"The mean terminal elimination half-life was 1.8 h (range, 1.4 to 2.3 h), the apparent volume of distribution at steady state was 17 liters, and the total systemic clearance was 150 ml/min.","Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6395801/),h,1.8,108377,DB01032,Probenecid
,6395801,apparent volume of distribution at steady state,"The mean terminal elimination half-life was 1.8 h (range, 1.4 to 2.3 h), the apparent volume of distribution at steady state was 17 liters, and the total systemic clearance was 150 ml/min.","Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6395801/),l,17,108378,DB01032,Probenecid
,6395801,total systemic clearance,"The mean terminal elimination half-life was 1.8 h (range, 1.4 to 2.3 h), the apparent volume of distribution at steady state was 17 liters, and the total systemic clearance was 150 ml/min.","Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6395801/),[ml] / [min],150,108379,DB01032,Probenecid
,17329910,Km,"The Km value of the hOAT3-mediated transport was 847 microM, and the uptake was inhibited by probenecid, p-aminohippurate and benzylpenicillin with Ki values of 3.76, 712, and 202 microM, respectively.","Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329910/),μM,847,111049,DB01032,Probenecid
,17329910,Ki,"The Km value of the hOAT3-mediated transport was 847 microM, and the uptake was inhibited by probenecid, p-aminohippurate and benzylpenicillin with Ki values of 3.76, 712, and 202 microM, respectively.","Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329910/),μM,3.76,111050,DB01032,Probenecid
,17329910,Ki,"The Km value of the hOAT3-mediated transport was 847 microM, and the uptake was inhibited by probenecid, p-aminohippurate and benzylpenicillin with Ki values of 3.76, 712, and 202 microM, respectively.","Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329910/),μM,712,111051,DB01032,Probenecid
,17329910,Ki,"The Km value of the hOAT3-mediated transport was 847 microM, and the uptake was inhibited by probenecid, p-aminohippurate and benzylpenicillin with Ki values of 3.76, 712, and 202 microM, respectively.","Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329910/),μM,202,111052,DB01032,Probenecid
less,3522937,minimal inhibitory concentration (MIC),"The minimal inhibitory concentration (MIC) of flumequine for 249 Salmonella, 126 Escherichia coli, and 22 Pasteurella multocida isolates recovered from clinical cases of neonatal calf diarrhoea, pneumonia and sudden death was less than or equal to 0.78 microgram/ml.",Clinical pharmacokinetics of flumequine in calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),[μg] / [ml],0.78,111124,DB01032,Probenecid
,3522937,distribution half-life (t1/2 alpha),"The distribution half-life (t1/2 alpha) was 13 min, elimination half-life (t1/2 beta) was 2.25 h, the apparent area volume of distribution (Vd(area)), and the volume of distribution at steady state (Vd(ss)) were 1.48 and 1.43 l/kg, respectively.",Clinical pharmacokinetics of flumequine in calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),min,13,111125,DB01032,Probenecid
,3522937,elimination half-life (t1/2 beta),"The distribution half-life (t1/2 alpha) was 13 min, elimination half-life (t1/2 beta) was 2.25 h, the apparent area volume of distribution (Vd(area)), and the volume of distribution at steady state (Vd(ss)) were 1.48 and 1.43 l/kg, respectively.",Clinical pharmacokinetics of flumequine in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),h,2.25,111126,DB01032,Probenecid
,3522937,apparent area volume of distribution (Vd(area)),"The distribution half-life (t1/2 alpha) was 13 min, elimination half-life (t1/2 beta) was 2.25 h, the apparent area volume of distribution (Vd(area)), and the volume of distribution at steady state (Vd(ss)) were 1.48 and 1.43 l/kg, respectively.",Clinical pharmacokinetics of flumequine in calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),[l] / [kg],1.48,111127,DB01032,Probenecid
,3522937,volume of distribution at steady state (Vd(ss)),"The distribution half-life (t1/2 alpha) was 13 min, elimination half-life (t1/2 beta) was 2.25 h, the apparent area volume of distribution (Vd(area)), and the volume of distribution at steady state (Vd(ss)) were 1.48 and 1.43 l/kg, respectively.",Clinical pharmacokinetics of flumequine in calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),[l] / [kg],1.43,111128,DB01032,Probenecid
,3522937,peak serum drug concentration (Cmax),Flumequine was quickly and completely absorbed into the systemic circulation after i.m. administration of a soluble drug formulation; a mean peak serum drug concentration (Cmax) of 6.2 micrograms/ml was attained 30 min after treatment at 10 mg/kg and was similar to the concentration measured 30 min after an equal dose of the drug was injected i.v.,Clinical pharmacokinetics of flumequine in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),[μg] / [ml],6.2,111129,DB01032,Probenecid
,3522937,bioavailability,"On the other hand, the i.m. bioavailability of two injectable oily suspensions of the drug was 44%; both formulations failed to produce serum drug concentrations of potential clinical significance after administration at 20 mg/kg.",Clinical pharmacokinetics of flumequine in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),%,44,111130,DB01032,Probenecid
,3522937,oral bioavailability,The drug was rapidly absorbed after oral administration; the oral bioavailability ranged between 55.7% for the 5 mg/kg dose and 92.5% for the 20 mg/kg dose.,Clinical pharmacokinetics of flumequine in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),%,55.7,111131,DB01032,Probenecid
,3522937,oral bioavailability,The drug was rapidly absorbed after oral administration; the oral bioavailability ranged between 55.7% for the 5 mg/kg dose and 92.5% for the 20 mg/kg dose.,Clinical pharmacokinetics of flumequine in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3522937/),%,92.5,111132,DB01032,Probenecid
,3578325,peak serum concentrations,Intravenous infusions of 200 mg over one-half hour result in peak serum concentrations of 3.80 +/- 0.62 micrograms/ml.,An overview of the pharmacology of intravenously administered ciprofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578325/),[μg] / [ml],3.80,111229,DB01032,Probenecid
,3578325,Serum clearance,"Serum clearance in normal subjects averages 23.7 +/- 5.1 liters/hour/1.73 m2, with renal clearance accounting for 66.6 +/- 11.0 percent of the total serum clearance.",An overview of the pharmacology of intravenously administered ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3578325/),[l] / [1.73·h·m2],23.7,111230,DB01032,Probenecid
,12739770,steady-state ratio,The steady-state ratio of 0.29 +/- 0.07 of unbound morphine concentration in brain to that in blood indicates that morphine is actively effluxed at the BBB.,Morphine blood-brain barrier transport is influenced by probenecid co-administration. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739770/),,0.29,112404,DB01032,Probenecid
,12739770,half-life in brain,The half-life in brain increased from 58 +/- 9 min to 115 +/- 25 min when probenecid was co-administered.,Morphine blood-brain barrier transport is influenced by probenecid co-administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739770/),min,58,112405,DB01032,Probenecid
,12739770,half-life in brain,The half-life in brain increased from 58 +/- 9 min to 115 +/- 25 min when probenecid was co-administered.,Morphine blood-brain barrier transport is influenced by probenecid co-administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739770/),min,115,112406,DB01032,Probenecid
,24419341,peak serum concentration,The peak serum concentration measured at 60 min postinfusion was 28.01 mg/liter at the arterial port.,Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24419341/),[mg] / [l],28.01,112900,DB01032,Probenecid
,24419341,trough serum level,The trough serum level was 19.33 mg/liter at the arterial port after 24 h.,Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24419341/),[mg] / [l],19.33,112901,DB01032,Probenecid
,24419341,area under the concentration-versus-time curve from 0 to 24 h,The value of the area under the concentration-versus-time curve from 0 to 24 h was 543.8 mg·h/liter.,Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24419341/),[h·mg] / [l],543.8,112902,DB01032,Probenecid
,24419341,total body clearance,"The total body clearance was 2.46 ml/h/kg, and the elimination half-life time was 53.32 h.",Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24419341/),[ml] / [h·kg],2.46,112903,DB01032,Probenecid
,24419341,elimination half-life time,"The total body clearance was 2.46 ml/h/kg, and the elimination half-life time was 53.32 h.",Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24419341/),h,53.32,112904,DB01032,Probenecid
,24419341,sieving coefficient,The sieving coefficient was 0.138±0.022.,Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24419341/),,0.138,112905,DB01032,Probenecid
,24419341,Total removal,Total removal of the drug was 30.99% after 24 h.,Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24419341/),%,30.99,112906,DB01032,Probenecid
,6285937,serum concentration,The further of the serum concentration was slower in II than in I: serum concentration 6 h after the injection was 2.6 +/- 0.9 micrograms/ml in I and 4.4 +/- 2 micrograms/ml in II.,[Pharmacokinetics of ceftizoxime with and without probenecid]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285937/),[μg] / [ml],2.6,114200,DB01032,Probenecid
,6285937,serum concentration,The further of the serum concentration was slower in II than in I: serum concentration 6 h after the injection was 2.6 +/- 0.9 micrograms/ml in I and 4.4 +/- 2 micrograms/ml in II.,[Pharmacokinetics of ceftizoxime with and without probenecid]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285937/),[μg] / [ml],4.4,114201,DB01032,Probenecid
,6285937,t/2 beta,t/2 beta was calculated for I with 1.76 h and 2.13 h for II.,[Pharmacokinetics of ceftizoxime with and without probenecid]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285937/),h,1.76,114202,DB01032,Probenecid
,6285937,t/2 beta,t/2 beta was calculated for I with 1.76 h and 2.13 h for II.,[Pharmacokinetics of ceftizoxime with and without probenecid]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285937/),h,2.13,114203,DB01032,Probenecid
,6285937,renal clearance,"The distribution volume was equal, so that the differences in serum concentrations could be explained by the reduced renal clearance: from 2.1 to 1.4 ml/s.",[Pharmacokinetics of ceftizoxime with and without probenecid]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285937/),[ml] / [s],2.1,114204,DB01032,Probenecid
,6285937,renal clearance,"The distribution volume was equal, so that the differences in serum concentrations could be explained by the reduced renal clearance: from 2.1 to 1.4 ml/s.",[Pharmacokinetics of ceftizoxime with and without probenecid]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285937/),[ml] / [s],1.4,114205,DB01032,Probenecid
,10611135,urinary excretions,"The renal clearance of the unchanged drug in males was 21 times lower than that in females, and the urinary excretions in males and females were 2.1 and 39.5% of dose, respectively.",Sex-related differences in urinary excretion of egualen sodium in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611135/),%,2.1,115922,DB01032,Probenecid
,10611135,urinary excretions,"The renal clearance of the unchanged drug in males was 21 times lower than that in females, and the urinary excretions in males and females were 2.1 and 39.5% of dose, respectively.",Sex-related differences in urinary excretion of egualen sodium in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611135/),%,39.5,115923,DB01032,Probenecid
,9951427,clearance (CL),"Mean +/- SD cidofovir clearance (CL) in control subjects (normal renal function; n = 5) was 1.7 +/- 0.1 mL/min/kg, which decreased with declining renal function as indicated by the regression equation: CL (mL/min/kg) = 0.94 x CLCR (mL/min/kg) + 0.064 (r2 = 0.91).",Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951427/),[ml] / [kg·min],1.7,116134,DB01032,Probenecid
,9570004,Plasma clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],198,117110,DB01032,Probenecid
,9570004,Plasma clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],119,117111,DB01032,Probenecid
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],104,117112,DB01032,Probenecid
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],54,117113,DB01032,Probenecid
,9570004,renal clearance,Plasma clearance was reduced by probenecid from 198 +/- 47 to 119 +/- 41 mL min-1 (mean +/- SD.); renal clearance was reduced from 104 +/- 33 to 54 +/- 24 mL min-1 (p < 0.02) by probenecid and to 89 +/- 37 mL min-1 (NS) by cimetidine.,A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[ml] / [min],89,117114,DB01032,Probenecid
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],18.4,117115,DB01032,Probenecid
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],13.6,117116,DB01032,Probenecid
,9570004,Basolateral transport,"Basolateral transport was reduced (from 18.4 +/- 7.8 to 13.6 +/- 10.3 min-1 by cimetidine and 3.9 +/- 3.1 min-1 by probenecid), whereas no effect on brush-border exit was found.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),1/[min],3.9,117117,DB01032,Probenecid
,9570004,inhibition constants,"Estimated inhibition constants of cimetidine and probenecid were 62 and 4 micrograms mL-1, respectively.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[μg] / [ml],62,117118,DB01032,Probenecid
,9570004,inhibition constants,"Estimated inhibition constants of cimetidine and probenecid were 62 and 4 micrograms mL-1, respectively.",A physiologically based kidney model for the renal clearance of ranitidine and the interaction with cimetidine and probenecid in the dog. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570004/),[μg] / [ml],4,117119,DB01032,Probenecid
,9234857,flow-rate,"The mobile phase was a mixture of 0.005 M phosphate buffer (pH 7.0) and methanol (12:1, v/v) with a flow-rate of 1.0 ml/min.",Determination of ticarcillin epimers in plasma and urine with high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234857/),[ml] / [min],1.0,117917,DB01032,Probenecid
,9234857,S/N ratio,1 microg/ml with a S/N ratio of 3.,Determination of ticarcillin epimers in plasma and urine with high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234857/),,3,117918,DB01032,Probenecid
more,9234857,recovery,The recovery was more than 80% for both plasma and urine samples.,Determination of ticarcillin epimers in plasma and urine with high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234857/),%,80,117919,DB01032,Probenecid
,9234857,C.V.,"C.V. values for intra- and inter-day variabilities were 0.9-2.1 and 1.1-6.4%, respectively, at concentrations ranging between 5 and 200 microg/ml.",Determination of ticarcillin epimers in plasma and urine with high-performance liquid chromatography. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234857/),%,0.9-2.1,117920,DB01032,Probenecid
,9234857,C.V.,"C.V. values for intra- and inter-day variabilities were 0.9-2.1 and 1.1-6.4%, respectively, at concentrations ranging between 5 and 200 microg/ml.",Determination of ticarcillin epimers in plasma and urine with high-performance liquid chromatography. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234857/),%,1.1-6.4,117921,DB01032,Probenecid
,1904495,Plasma concentrations,"Plasma concentrations of probenecid averaged 221 +/- 34 micrograms/ml upon termination of the ddl infusion and 258 +/- 34 micrograms/ml (mean +/- S.D., n = 4) 1 hr later.","Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid efflux. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904495/),[μg] / [ml],221,122306,DB01032,Probenecid
,1904495,Plasma concentrations,"Plasma concentrations of probenecid averaged 221 +/- 34 micrograms/ml upon termination of the ddl infusion and 258 +/- 34 micrograms/ml (mean +/- S.D., n = 4) 1 hr later.","Probenecid enhances central nervous system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal fluid efflux. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904495/),[μg] / [ml],258,122307,DB01032,Probenecid
,3080583,IC50,"Ceftriaxone was also a much less potent inhibitor of [14C]penicillin G accumulation by the isolated choroid plexus than penicillin G itself (IC50 = 1.6 vs. 0.07 mM, respectively).",Ceftriaxone pharmacokinetics in the central nervous system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3080583/),mM,1.6,124329,DB01032,Probenecid
,3080583,IC50,"Ceftriaxone was also a much less potent inhibitor of [14C]penicillin G accumulation by the isolated choroid plexus than penicillin G itself (IC50 = 1.6 vs. 0.07 mM, respectively).",Ceftriaxone pharmacokinetics in the central nervous system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3080583/),mM,0.07,124330,DB01032,Probenecid
,24747579,inhibition constant (Ki),"In human kidney slices, probenecid potently inhibited the uptake of both adefovir and benzylpenicillin with inhibition constant (Ki) values of 18.6±5.1 and 12.6±4.2μM, respectively, whereas p-aminohippurate (PAH) preferentially inhibited adefovir uptake.",Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24747579/),μM,18.6,127795,DB01032,Probenecid
,24747579,inhibition constant (Ki),"In human kidney slices, probenecid potently inhibited the uptake of both adefovir and benzylpenicillin with inhibition constant (Ki) values of 18.6±5.1 and 12.6±4.2μM, respectively, whereas p-aminohippurate (PAH) preferentially inhibited adefovir uptake.",Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24747579/),μM,12.6,127796,DB01032,Probenecid
,2729930,peak concentration,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[μg] / [ml],290,127916,DB01032,Probenecid
,2729930,peak concentration,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[μg] / [ml],244,127917,DB01032,Probenecid
,2729930,terminal disposition half-life,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),h,1.50,127918,DB01032,Probenecid
,2729930,terminal disposition half-life,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),h,0.81,127919,DB01032,Probenecid
,2729930,systemic clearance,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],111.7,127920,DB01032,Probenecid
,2729930,systemic clearance,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],279,127921,DB01032,Probenecid
,2729930,renal clearance,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],78.7,127922,DB01032,Probenecid
,2729930,renal clearance,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],221,127923,DB01032,Probenecid
,2729930,steady-state volume of distribution,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),l,10.3,127924,DB01032,Probenecid
,2729930,steady-state volume of distribution,"Compared with cefoxitin, cefmetazole had a significantly (P less than 0.05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1.50 +/- 0.14 versus 0.81 +/- 0.04 h), lower systemic clearance (111.7 +/- 4.7 versus 279 +/- 12 ml/min) and renal clearance (78.7 +/- 4.3 versus 221 +/- 14 ml/min) of intact drug, and a slightly smaller steady-state volume of distribution (10.3 +/- 0.21 versus 12.8 +/- 0.48 liters).",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),l,12.8,127925,DB01032,Probenecid
,2729930,recoveries,"Mean recoveries of cefmetazole and cefoxitin in urine were approximately 71 and 77%, respectively.",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),%,71,127926,DB01032,Probenecid
,2729930,recoveries,"Mean recoveries of cefmetazole and cefoxitin in urine were approximately 71 and 77%, respectively.",Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),%,77,127927,DB01032,Probenecid
,2729930,areas under the concentration-time curve,Mean areas under the concentration-time curve (466 +/- 27 versus 295 +/- 13 micrograms.h/ml) and terminal disposition half-lives (2.27 +/- 0.13 versus 1.50 +/- 0.14 h) of cefmetazole increased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[h·μg] / [ml],466,127928,DB01032,Probenecid
,2729930,areas under the concentration-time curve,Mean areas under the concentration-time curve (466 +/- 27 versus 295 +/- 13 micrograms.h/ml) and terminal disposition half-lives (2.27 +/- 0.13 versus 1.50 +/- 0.14 h) of cefmetazole increased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[h·μg] / [ml],295,127929,DB01032,Probenecid
,2729930,terminal disposition half-lives,Mean areas under the concentration-time curve (466 +/- 27 versus 295 +/- 13 micrograms.h/ml) and terminal disposition half-lives (2.27 +/- 0.13 versus 1.50 +/- 0.14 h) of cefmetazole increased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),h,2.27,127930,DB01032,Probenecid
,2729930,terminal disposition half-lives,Mean areas under the concentration-time curve (466 +/- 27 versus 295 +/- 13 micrograms.h/ml) and terminal disposition half-lives (2.27 +/- 0.13 versus 1.50 +/- 0.14 h) of cefmetazole increased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),h,1.50,127931,DB01032,Probenecid
,2729930,Systemic clearance,Systemic clearance (72.1 +/- 4.0 versus 111.7 +/- 4.7 ml/min) and renal clearance (47.4 +/- 4.0 versus 78.7 +/- 4.3 ml/min) of intact antibiotic decreased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],72.1,127932,DB01032,Probenecid
,2729930,Systemic clearance,Systemic clearance (72.1 +/- 4.0 versus 111.7 +/- 4.7 ml/min) and renal clearance (47.4 +/- 4.0 versus 78.7 +/- 4.3 ml/min) of intact antibiotic decreased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],111.7,127933,DB01032,Probenecid
,2729930,renal clearance,Systemic clearance (72.1 +/- 4.0 versus 111.7 +/- 4.7 ml/min) and renal clearance (47.4 +/- 4.0 versus 78.7 +/- 4.3 ml/min) of intact antibiotic decreased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],47.4,127934,DB01032,Probenecid
,2729930,renal clearance,Systemic clearance (72.1 +/- 4.0 versus 111.7 +/- 4.7 ml/min) and renal clearance (47.4 +/- 4.0 versus 78.7 +/- 4.3 ml/min) of intact antibiotic decreased.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),[ml] / [min],78.7,127935,DB01032,Probenecid
,2729930,recoveries,Mean recoveries (65.9 +/- 3.7 versus 71.0 +/- 3.2%) of intact cefmetazole in urine were not significantly (P > 0.05) different.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),%,65.9,127936,DB01032,Probenecid
,2729930,recoveries,Mean recoveries (65.9 +/- 3.7 versus 71.0 +/- 3.2%) of intact cefmetazole in urine were not significantly (P > 0.05) different.,Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729930/),%,71.0,127937,DB01032,Probenecid
,9056062,peak plasma concentrations,Mean (+/-s.d.) peak plasma concentrations were 904 +/- 65 microM (foscarnet) and 862 +/- 97 microM (foscarnet+probenecid) whilst the plasma AUC values were 3326 +/- 451 microM h and 3133 +/- 476 microM h respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),μM,904,128836,DB01032,Probenecid
,9056062,peak plasma concentrations,Mean (+/-s.d.) peak plasma concentrations were 904 +/- 65 microM (foscarnet) and 862 +/- 97 microM (foscarnet+probenecid) whilst the plasma AUC values were 3326 +/- 451 microM h and 3133 +/- 476 microM h respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),μM,862,128837,DB01032,Probenecid
,9056062,plasma AUC,Mean (+/-s.d.) peak plasma concentrations were 904 +/- 65 microM (foscarnet) and 862 +/- 97 microM (foscarnet+probenecid) whilst the plasma AUC values were 3326 +/- 451 microM h and 3133 +/- 476 microM h respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),h·μM,3326,128838,DB01032,Probenecid
,9056062,plasma AUC,Mean (+/-s.d.) peak plasma concentrations were 904 +/- 65 microM (foscarnet) and 862 +/- 97 microM (foscarnet+probenecid) whilst the plasma AUC values were 3326 +/- 451 microM h and 3133 +/- 476 microM h respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),h·μM,3133,128839,DB01032,Probenecid
,9056062,volumes of distribution at steady state,Terminal elimination half-life remained unchanged at 5.6 +/- 0.7 h and the respective volumes of distribution at steady state were 23 +/- 31 (foscarnet) and 25 +/- 31 (foscarnet+probenecid).,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),,23,128840,DB01032,Probenecid
,9056062,volumes of distribution at steady state,Terminal elimination half-life remained unchanged at 5.6 +/- 0.7 h and the respective volumes of distribution at steady state were 23 +/- 31 (foscarnet) and 25 +/- 31 (foscarnet+probenecid).,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),,25,128841,DB01032,Probenecid
,9056062,total body clearance,Mean total body clearance was 110 +/- 17 ml min-1 (foscarnet) and 113 +/- 13 ml min-1 (foscarnet+probenecid) and the corresponding renal clearances of foscarnet were 102 +/- 5 ml min-1 and 105 +/- 5 ml min-1 respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),[ml] / [min],110,128842,DB01032,Probenecid
,9056062,total body clearance,Mean total body clearance was 110 +/- 17 ml min-1 (foscarnet) and 113 +/- 13 ml min-1 (foscarnet+probenecid) and the corresponding renal clearances of foscarnet were 102 +/- 5 ml min-1 and 105 +/- 5 ml min-1 respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),[ml] / [min],113,128843,DB01032,Probenecid
,9056062,renal clearances,Mean total body clearance was 110 +/- 17 ml min-1 (foscarnet) and 113 +/- 13 ml min-1 (foscarnet+probenecid) and the corresponding renal clearances of foscarnet were 102 +/- 5 ml min-1 and 105 +/- 5 ml min-1 respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),[ml] / [min],102,128844,DB01032,Probenecid
,9056062,renal clearances,Mean total body clearance was 110 +/- 17 ml min-1 (foscarnet) and 113 +/- 13 ml min-1 (foscarnet+probenecid) and the corresponding renal clearances of foscarnet were 102 +/- 5 ml min-1 and 105 +/- 5 ml min-1 respectively.,Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056062/),[ml] / [min],105,128845,DB01032,Probenecid
,6644585,renal clearance of unbound drug,The renal clearance of unbound drug was 0.82 ml/min with a reabsorption ratio (R) of 0.22.,Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644585/),[ml] / [min],0.82,129996,DB01032,Probenecid
,6644585,reabsorption ratio (R),The renal clearance of unbound drug was 0.82 ml/min with a reabsorption ratio (R) of 0.22.,Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644585/),,0.22,129997,DB01032,Probenecid
,8692740,renal clearance,Coadministration of probenecid with zalcitabine resulted in a decrease in mean (%CV) renal clearance of zalcitabine from 310 (28%) ml/min when zalcitabine was given alone to 180 (22%) ml/min with probenecid and a prolonged half-life from 1.7 hours to 2.5 hours.,The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692740/),[ml] / [min],310,134807,DB01032,Probenecid
,8692740,renal clearance,Coadministration of probenecid with zalcitabine resulted in a decrease in mean (%CV) renal clearance of zalcitabine from 310 (28%) ml/min when zalcitabine was given alone to 180 (22%) ml/min with probenecid and a prolonged half-life from 1.7 hours to 2.5 hours.,The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692740/),[ml] / [min],180,134808,DB01032,Probenecid
,8692740,half-life,Coadministration of probenecid with zalcitabine resulted in a decrease in mean (%CV) renal clearance of zalcitabine from 310 (28%) ml/min when zalcitabine was given alone to 180 (22%) ml/min with probenecid and a prolonged half-life from 1.7 hours to 2.5 hours.,The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692740/),h,1.7,134809,DB01032,Probenecid
,8692740,half-life,Coadministration of probenecid with zalcitabine resulted in a decrease in mean (%CV) renal clearance of zalcitabine from 310 (28%) ml/min when zalcitabine was given alone to 180 (22%) ml/min with probenecid and a prolonged half-life from 1.7 hours to 2.5 hours.,The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692740/),h,2.5,134810,DB01032,Probenecid
,8692740,AUCs,Mean AUCs increased from 59 ng.h/ml when zalcitabine was given alone to 91 ng.h/ml when given with probenecid.,The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692740/),[h·ng] / [ml],59,134811,DB01032,Probenecid
,8692740,AUCs,Mean AUCs increased from 59 ng.h/ml when zalcitabine was given alone to 91 ng.h/ml when given with probenecid.,The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692740/),[h·ng] / [ml],91,134812,DB01032,Probenecid
,8692740,half-life,"Considering the short half-life of zalcitabine (1-3 hours) relative to its dosing schedule, the pharmacokinetic changes observed in this study are not expected to result in significant accumulation during chronic dosing.",The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692740/),h,1-3,134813,DB01032,Probenecid
,30417385,inhibition constant (Ki ),"Probenecid inhibition of resveratrol 3-O-glucuronidation was predominantly noncompetitive, with an inhibition constant (Ki ) averaging 3.1 mm.",Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30417385/),mm,3.1,135162,DB01032,Probenecid
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB01032,Probenecid
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB01032,Probenecid
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB01032,Probenecid
,19376665,flow rate,"Chromatography of felbinac and the internal standard probenecid was performed within 2min on a Venusil MP C(18) column (100mmx4.6mm i.d., 5microm) with a mobile phase consisting of acetonitrile-5mM ammonium acetate containing 0.1% formic acid (pH 3.0) (80:20, v/v) at a flow rate of 1.2ml/min.",Validated LC-MS/MS assay for the determination of felbinac: Application to a preclinical pharmacokinetics study of felbinac trometamol injection in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19376665/),[ml] / [min],1.2,142246,DB01032,Probenecid
,2303581,area under the serum famotidine concentration-time curve up to 10 hours,The mean area under the serum famotidine concentration-time curve up to 10 hours was increased by coadministration of probenecid from 424 +/- 19 (SEM) to 768 +/- 39 ng.hr/ml.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[h·ng] / [ml],424,142774,DB01032,Probenecid
,2303581,area under the serum famotidine concentration-time curve up to 10 hours,The mean area under the serum famotidine concentration-time curve up to 10 hours was increased by coadministration of probenecid from 424 +/- 19 (SEM) to 768 +/- 39 ng.hr/ml.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[h·ng] / [ml],768,142775,DB01032,Probenecid
,2303581,tubular secretion clearance,The mean tubular secretion clearance of famotidine was decreased from 196.2 +/- 21.4 to 22.0 +/- 4.2 ml/min.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[ml] / [min],196.2,142776,DB01032,Probenecid
,2303581,tubular secretion clearance,The mean tubular secretion clearance of famotidine was decreased from 196.2 +/- 21.4 to 22.0 +/- 4.2 ml/min.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[ml] / [min],22.0,142777,DB01032,Probenecid
,8061834,F,"The limit of quantitation of F in plasma is 0.007 microgram/ml, Fgluc 0.010 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.007,144155,DB01032,Probenecid
,8061834,Fgluc,"The limit of quantitation of F in plasma is 0.007 microgram/ml, Fgluc 0.010 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.010,144156,DB01032,Probenecid
,8061834,F,"The limits of quantitation in urine are respectively: F 0.10 microgram/ml, Fgluc 0.15 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.10,144157,DB01032,Probenecid
,8061834,Fgluc,"The limits of quantitation in urine are respectively: F 0.10 microgram/ml, Fgluc 0.15 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.15,144158,DB01032,Probenecid
,16679727,S/N ratio,"The quantification limit of probenecid was approximately 50 ng/ml at S/N ratio = 3, by simple procedure with HCl and methanol treatment.","Probenecid: its chromatographic determination, plasma protein binding, and in vivo pharmacokinetics in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679727/),,3,146715,DB01032,Probenecid
,16679727,total body clearance,"The total body clearance was 0.34 +/- 0.04 ml/min/kg, volume of distribution at steady-state was 0.46 +/- 0.07 l/kg, elimination half-life was 18 +/- 6 hr, and mean residence time (MRT) was 23 +/- 6 hr.","Probenecid: its chromatographic determination, plasma protein binding, and in vivo pharmacokinetics in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679727/),[ml] / [kg·min],0.34,146716,DB01032,Probenecid
,16679727,volume of distribution at steady-state,"The total body clearance was 0.34 +/- 0.04 ml/min/kg, volume of distribution at steady-state was 0.46 +/- 0.07 l/kg, elimination half-life was 18 +/- 6 hr, and mean residence time (MRT) was 23 +/- 6 hr.","Probenecid: its chromatographic determination, plasma protein binding, and in vivo pharmacokinetics in dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679727/),[l] / [kg],0.46,146717,DB01032,Probenecid
,16679727,elimination half-life,"The total body clearance was 0.34 +/- 0.04 ml/min/kg, volume of distribution at steady-state was 0.46 +/- 0.07 l/kg, elimination half-life was 18 +/- 6 hr, and mean residence time (MRT) was 23 +/- 6 hr.","Probenecid: its chromatographic determination, plasma protein binding, and in vivo pharmacokinetics in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679727/),h,18,146718,DB01032,Probenecid
,16679727,mean residence time (MRT),"The total body clearance was 0.34 +/- 0.04 ml/min/kg, volume of distribution at steady-state was 0.46 +/- 0.07 l/kg, elimination half-life was 18 +/- 6 hr, and mean residence time (MRT) was 23 +/- 6 hr.","Probenecid: its chromatographic determination, plasma protein binding, and in vivo pharmacokinetics in dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16679727/),h,23,146719,DB01032,Probenecid
,6311785,half-life,"Ceftizoxime half-life was increased by probenecid from 1.7 to 2.3 h in the iv group, and 1.9 to 2.8 h in the im group (P less than 0.05, paired t-test).",Effect of probenecid on the pharmacokinetics of ceftizoxime. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311785/),h,1.7 to 2.3,147710,DB01032,Probenecid
,6311785,half-life,"Ceftizoxime half-life was increased by probenecid from 1.7 to 2.3 h in the iv group, and 1.9 to 2.8 h in the im group (P less than 0.05, paired t-test).",Effect of probenecid on the pharmacokinetics of ceftizoxime. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311785/),h,1.9 to 2.8,147711,DB01032,Probenecid
,2934521,Clearance,"Clearance studies in rats resulted in 2.84 ml/min/100 g for [99mTc]MAG3, 2.17 for OIH, and 1.29 for [125I]iothalamate.",Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2934521/),[ml] / [100·g·min],2.84,148158,DB01032,Probenecid
,2934521,Clearance,"Clearance studies in rats resulted in 2.84 ml/min/100 g for [99mTc]MAG3, 2.17 for OIH, and 1.29 for [125I]iothalamate.",Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2934521/),,2.17,148159,DB01032,Probenecid
,2934521,Clearance,"Clearance studies in rats resulted in 2.84 ml/min/100 g for [99mTc]MAG3, 2.17 for OIH, and 1.29 for [125I]iothalamate.",Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2934521/),[ml] / [100·g·min],1.29,148160,DB01032,Probenecid
,2934521,Extraction efficiencies,"Extraction efficiencies were 85% for [99mTc]MAG3, 69% for OIH and 39% for [125I]iothalamate.",Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2934521/),%,85,148161,DB01032,Probenecid
,2934521,Extraction efficiencies,"Extraction efficiencies were 85% for [99mTc]MAG3, 69% for OIH and 39% for [125I]iothalamate.",Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2934521/),%,69,148162,DB01032,Probenecid
,2934521,Extraction efficiencies,"Extraction efficiencies were 85% for [99mTc]MAG3, 69% for OIH and 39% for [125I]iothalamate.",Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2934521/),%,39,148163,DB01032,Probenecid
,1941624,maximum concentration,"In vivo, plasma concentrations of AW rose only slowly after a dose of 10 mg/kg AGAW i.v. to give a maximum concentration of about 3 micrograms AW/ml at t = 14 to 24 h.",Renal selective N-acetyl-L-gamma-glutamyl prodrugs. N-acetyl-L-gamma-glutamyl-4'-aminowarfarin is not targeted to the kidney but is selectively excreted into the bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941624/),[aw·μg] / [ml],3,148255,DB01032,Probenecid
,1590696,maximum concentration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),[μg] / [ml],1.54,149588,DB01032,Probenecid
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),[μg] / [ml],0.5,149589,DB01032,Probenecid
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),%,27,149590,DB01032,Probenecid
,1590696,penetration,"The maximum concentration and the penetration into the aqueous and vitreous humors were 1.54 and 0.5 micrograms/ml and 27 and 10%, respectively.",Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590696/),%,10,149591,DB01032,Probenecid
,1979522,peak concentrations,"The obtained concentrations were effective against both herpesviruses and HIV: peak concentrations were 197 and 11 mumol/l in serum and CSF, respectively; the CSF:serum ratio of the areas under the curve was 82%.",A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979522/),[μM] / [l],197,149746,DB01032,Probenecid
,1979522,peak concentrations,"The obtained concentrations were effective against both herpesviruses and HIV: peak concentrations were 197 and 11 mumol/l in serum and CSF, respectively; the CSF:serum ratio of the areas under the curve was 82%.",A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979522/),[μM] / [l],11,149747,DB01032,Probenecid
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,121,151323,DB01032,Probenecid
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,859,151324,DB01032,Probenecid
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1888,151325,DB01032,Probenecid
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1880,151326,DB01032,Probenecid
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,117,151327,DB01032,Probenecid
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1207,151328,DB01032,Probenecid
,25710938,Km,"Cellular uptake of tanshinol was mediated by human organic anion transporter 1 (OAT1) (Km, 121 μM), OAT2 (859 μM), OAT3 (1888 μM), and OAT4 (1880 μM) and rat Oat1 (117 µM), Oat2 (1207 μM), and Oat3 (1498 μM).","Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25710938/),μM,1498,151329,DB01032,Probenecid
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,0.0372,151352,DB01032,Probenecid
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,0.190,151353,DB01032,Probenecid
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,30.0,151354,DB01032,Probenecid
,31371478,IC50,"Dotinurad, benzbromarone, lesinurad, and probenecid inhibited urate transporter 1 (URAT1) with IC50 values of 0.0372, 0.190, 30.0, and 165 μM, respectively.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,165,151355,DB01032,Probenecid
,31371478,IC50,"Dotinurad weakly inhibited ATP-binding cassette subfamily G member 2 (ABCG2), organic anion transporter 1 (OAT1), and OAT3, with IC50 values of 4.16, 4.08, and 1.32 μM, respectively, indicating higher selectivity for URAT1.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,4.16,151356,DB01032,Probenecid
,31371478,IC50,"Dotinurad weakly inhibited ATP-binding cassette subfamily G member 2 (ABCG2), organic anion transporter 1 (OAT1), and OAT3, with IC50 values of 4.16, 4.08, and 1.32 μM, respectively, indicating higher selectivity for URAT1.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,4.08,151357,DB01032,Probenecid
,31371478,IC50,"Dotinurad weakly inhibited ATP-binding cassette subfamily G member 2 (ABCG2), organic anion transporter 1 (OAT1), and OAT3, with IC50 values of 4.16, 4.08, and 1.32 μM, respectively, indicating higher selectivity for URAT1.","Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31371478/),μM,1.32,151358,DB01032,Probenecid
less,3302313,MIC,"In the presence of clavulanic acid, the MIC of amoxycillin was reduced to levels less than or equal to 12.5 micrograms/ml for all the Salmonella group B, all the Pasteurella, and for 12 out of the 44 E. coli isolates which were resistant to amoxycillin (MIC greater than or equal to 100.0 micrograms/ml).",Clavulanate-potentiated amoxycillin: in vitro antibacterial activity and oral bioavailability in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302313/),[μg] / [ml],12.5,151720,DB01032,Probenecid
greater,3302313,MIC,"In the presence of clavulanic acid, the MIC of amoxycillin was reduced to levels less than or equal to 12.5 micrograms/ml for all the Salmonella group B, all the Pasteurella, and for 12 out of the 44 E. coli isolates which were resistant to amoxycillin (MIC greater than or equal to 100.0 micrograms/ml).",Clavulanate-potentiated amoxycillin: in vitro antibacterial activity and oral bioavailability in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302313/),[μg] / [ml],100.0,151721,DB01032,Probenecid
less,3302313,MIC,For isolates sensitive to amoxycillin (MIC less than or equal to 1.56 microgram/ml) there was no change in MIC values in the presence of clavulanic acid.,Clavulanate-potentiated amoxycillin: in vitro antibacterial activity and oral bioavailability in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302313/),[μg] / [ml],1.56,151722,DB01032,Probenecid
,6875808,flow rate,Lactated Ringer's solution was administered by vein throughout both treatments at a flow rate of 2 ml/min to avoid fluid and electrolyte depletion.,Determinants of bumetanide response in the dog: effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6875808/),[ml] / [min],2,151848,DB01032,Probenecid
,8818570,alpha,"Concentrations of radioactivity in plasma were described by a three-compartment model with alpha, beta, and gamma half-lives of 0.67, 3.02, and 36.0 hr, respectively (N = 3).",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),h,0.67,151849,DB01032,Probenecid
,8818570,beta,"Concentrations of radioactivity in plasma were described by a three-compartment model with alpha, beta, and gamma half-lives of 0.67, 3.02, and 36.0 hr, respectively (N = 3).",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),h,3.02,151850,DB01032,Probenecid
,8818570,gamma half-lives,"Concentrations of radioactivity in plasma were described by a three-compartment model with alpha, beta, and gamma half-lives of 0.67, 3.02, and 36.0 hr, respectively (N = 3).",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),h,36.0,151851,DB01032,Probenecid
,8818570,clearance,The clearance of cidofovir (211 +/- 16.6 ml/hr/kg) was dependent on dose and exceeded the theoretical glomerular filtration rate.,Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),[ml] / [h·kg],211,151852,DB01032,Probenecid
,8818570,half-life,"Concentrations of cidofovir in kidney declined with a half-life of 23 hr and were > 1,000-fold higher than plasma levels by 120 hr.",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),h,23,151853,DB01032,Probenecid
,8818570,Oral,"Oral and subcutaneous bioavailabilities of cidofovir were 21.8 +/- 9.44 and 98.5 +/- 15.8%, respectively.",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),%,21.8,151854,DB01032,Probenecid
,8818570,subcutaneous bioavailabilities,"Oral and subcutaneous bioavailabilities of cidofovir were 21.8 +/- 9.44 and 98.5 +/- 15.8%, respectively.",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),%,98.5,151855,DB01032,Probenecid
,8818570,urinary recoveries,"After intravenous administration of [14C]cidofovir to cynomolgus monkeys (10 mg/kg, 100 microCi/kg) alone or 1 hr after oral probenecid (30 mg/kg), mean +/- SD (N = 3) urinary recoveries of total radioactive dose were 91.4 +/- 11.3% and 94.4 +/- 29.8%, respectively, at 7 days postdose.",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),%,91.4,151856,DB01032,Probenecid
,8818570,urinary recoveries,"After intravenous administration of [14C]cidofovir to cynomolgus monkeys (10 mg/kg, 100 microCi/kg) alone or 1 hr after oral probenecid (30 mg/kg), mean +/- SD (N = 3) urinary recoveries of total radioactive dose were 91.4 +/- 11.3% and 94.4 +/- 29.8%, respectively, at 7 days postdose.",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),%,94.4,151857,DB01032,Probenecid
,8818570,half-lives of the terminal elimination phases,"The mean +/- SD half-lives of the terminal elimination phases were 33.3 +/- 10.6 and 24.4 +/- 5.0 hr, respectively.",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),h,33.3,151858,DB01032,Probenecid
,8818570,half-lives of the terminal elimination phases,"The mean +/- SD half-lives of the terminal elimination phases were 33.3 +/- 10.6 and 24.4 +/- 5.0 hr, respectively.",Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818570/),h,24.4,151859,DB01032,Probenecid
,8287631,peak (Cmax),Plasma sparfloxacin concentrations reach a peak (Cmax) of approximately 0.7 mg/L at 3 to 5 hours after a 200mg oral dose.,Clinical pharmacokinetics of sparfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),[mg] / [l],0.7,152908,DB01032,Probenecid
,8287631,elimination half-life (t1/2),"This is followed by a monophasic slow decrease, with an elimination half-life (t1/2) of 15 to 20 hours.",Clinical pharmacokinetics of sparfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),h,15 to 20,152909,DB01032,Probenecid
,11168914,t1/2beta,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.14,153369,DB01032,Probenecid
,11168914,AUC,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],6.71,153370,DB01032,Probenecid
,11168914,AUC,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.5,153371,DB01032,Probenecid
,11168914,MRT,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],6.71,153372,DB01032,Probenecid
,11168914,MRT,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.5,153373,DB01032,Probenecid
,11168914,ClB,"The t1/2beta, AUC, MRT and ClB of enrofloxacin in normal animals were determined to be 1.14 h, 6.71 microg .h/mL, 1.5 h and 807 mL/h/kg, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[ml] / [h·kg],807,153374,DB01032,Probenecid
,11168914,Cmax.,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[μg] / [ml],0.45,153375,DB01032,Probenecid
,11168914,t1/2beta,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.79,153376,DB01032,Probenecid
,11168914,t1/2beta,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],1.84,153377,DB01032,Probenecid
,11168914,AUC,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.79,153378,DB01032,Probenecid
,11168914,AUC,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],1.84,153379,DB01032,Probenecid
,11168914,MRT,"The Cmax., t1/2beta, AUC and MRT of ciprofloxacin in normal goats were 0.45 microg /mL, 1.79 h, 1.84 microg .h/mL and 3.34 h, respectively.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,3.34,153380,DB01032,Probenecid
,11168914,t1/2beta,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,1.83,153381,DB01032,Probenecid
,11168914,AUC,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[?·h·μg] / [ml],11.68,153382,DB01032,Probenecid
,11168914,MRT,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,2.13,153383,DB01032,Probenecid
,11168914,ClB,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[ml] / [h·kg],430,153384,DB01032,Probenecid
,11168914,conversion,"As compared with normal goats, the values of t1/2beta (1.83 h), AUC (11.68 microg ? h/mL) and MRT (2.13 h) of enrofloxacin were significantly higher, whereas its ClB (430 mL/h/kg) and metabolite conversion to ciprofloxacin (8.5%) were lower in febrile goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),%,8.5,153385,DB01032,Probenecid
,11168914,Cmax.,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[μg] / [ml],0.18,153386,DB01032,Probenecid
,11168914,AUC,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),[h·μg] / [ml],0.99,153387,DB01032,Probenecid
,11168914,t1/2beta,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,2.75,153388,DB01032,Probenecid
,11168914,MRT,"The Cmax. (0.18 microg /mL) and AUC (0.99 microg .h/mL) of ciprofloxacin were significantly decreased, whereas its t1/2beta (2.75 h) and MRT (4.58 h) were prolonged in febrile than in normal goats.",Effects of endotoxin-induced fever and probenecid on disposition of enrofloxacin and its metabolite ciprofloxacin after intravascular administration of enrofloxacin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11168914/),h,4.58,153389,DB01032,Probenecid
,6352628,Serum half-lives,Serum half-lives were in the range from 1.6 to 1.7 h.,"Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352628/),h,1.6 to 1.7,154052,DB01032,Probenecid
,6352628,peak serum levels,"Following a 1-h intravenous drip infusion of 1 and 2 g, ceftazidime attained peak serum levels of 69.5 and 150.8 mg/l at the end of the infusion.","Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352628/),[mg] / [l],69.5,154053,DB01032,Probenecid
,6352628,peak serum levels,"Following a 1-h intravenous drip infusion of 1 and 2 g, ceftazidime attained peak serum levels of 69.5 and 150.8 mg/l at the end of the infusion.","Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352628/),[mg] / [l],150.8,154054,DB01032,Probenecid
,8285607,half-life at alpha phase,"Plasma clearance of 10 mg of FTC per kg of body weight was biexponential in rats, with a half-life at alpha phase of 4.7 +/- 1.1 min (mean +/- standard deviation) and a half-life at beta phase of 44 +/- 8.8 min (n = 5).","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),min,4.7,154604,DB01032,Probenecid
,8285607,half-life at beta phase,"Plasma clearance of 10 mg of FTC per kg of body weight was biexponential in rats, with a half-life at alpha phase of 4.7 +/- 1.1 min (mean +/- standard deviation) and a half-life at beta phase of 44 +/- 8.8 min (n = 5).","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),min,44,154605,DB01032,Probenecid
,8285607,total body clearance,"The total body clearance of FTC was 1.8 +/- 0.1 liters/h/kg, and the oral bioavailability was 90% +/- 8%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [h·kg],1.8,154606,DB01032,Probenecid
,8285607,oral bioavailability,"The total body clearance of FTC was 1.8 +/- 0.1 liters/h/kg, and the oral bioavailability was 90% +/- 8%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,90,154607,DB01032,Probenecid
,8285607,volume of distribution at steady state (Vss),The volume of distribution at steady state (Vss) was 1.5 +/- 0.1 liters/kg.,"Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [kg],1.5,154608,DB01032,Probenecid
,8285607,clearance,"Increasing the dose to 100 mg/kg slowed clearance to 1.5 +/- 0.2 liters/kg/h, lowered the Vss to 1.2 +/- 0.2 liters/kg, and reduced the oral bioavailability to 65% +/- 15%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [h·kg],1.5,154609,DB01032,Probenecid
,8285607,Vss,"Increasing the dose to 100 mg/kg slowed clearance to 1.5 +/- 0.2 liters/kg/h, lowered the Vss to 1.2 +/- 0.2 liters/kg, and reduced the oral bioavailability to 65% +/- 15%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),[l] / [kg],1.2,154610,DB01032,Probenecid
,8285607,oral bioavailability,"Increasing the dose to 100 mg/kg slowed clearance to 1.5 +/- 0.2 liters/kg/h, lowered the Vss to 1.2 +/- 0.2 liters/kg, and reduced the oral bioavailability to 65% +/- 15%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,65,154611,DB01032,Probenecid
,8285607,urinary,"The urinary and fecal recoveries of unchanged FTC after a 10-mg/kg intravenous dose were 87% +/- 3% and 5% +/- 1.6%, respectively.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,87,154612,DB01032,Probenecid
,8285607,fecal recoveries,"The urinary and fecal recoveries of unchanged FTC after a 10-mg/kg intravenous dose were 87% +/- 3% and 5% +/- 1.6%, respectively.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,5,154613,DB01032,Probenecid
,8285607,urinary,"After a 10-mg/kg oral dose, respective urinary and fecal recoveries were 70% +/- 2.5% and 25% +/- 1.6%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,70,154614,DB01032,Probenecid
,8285607,f,"After a 10-mg/kg oral dose, respective urinary and fecal recoveries were 70% +/- 2.5% and 25% +/- 1.6%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,70,154615,DB01032,Probenecid
,8285607,recoveries,"After a 10-mg/kg oral dose, respective urinary and fecal recoveries were 70% +/- 2.5% and 25% +/- 1.6%.","Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285607/),%,25,154616,DB01032,Probenecid
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,5.19,155201,DB01032,Probenecid
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,3.68,155202,DB01032,Probenecid
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.04,155203,DB01032,Probenecid
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.08,155204,DB01032,Probenecid
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],14,155385,DB01032,Probenecid
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],22,155386,DB01032,Probenecid
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],21,155387,DB01032,Probenecid
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],20,155388,DB01032,Probenecid
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],47,155389,DB01032,Probenecid
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],35,155390,DB01032,Probenecid
,20399996,C(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μg] / [ml],13.45,155548,DB01032,Probenecid
,20399996,C(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μg] / [ml],15.04,155549,DB01032,Probenecid
,20399996,T(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),h,1.58,155550,DB01032,Probenecid
,20399996,T(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),h,1.78,155551,DB01032,Probenecid
,20399996,AUC(0-24),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μ] / [h·ml],50.78,155552,DB01032,Probenecid
,20399996,AUC(0-24),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μ] / [h·ml],57.44,155553,DB01032,Probenecid
,20399996,AUC(0-infinity),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μg] / [h·ml],51.95,155554,DB01032,Probenecid
,20399996,AUC(0-infinity),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μg] / [h·ml],58.74,155555,DB01032,Probenecid
,20399996,C(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μg] / [ml],15.56,155556,DB01032,Probenecid
,20399996,C(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),[μg] / [ml],16.01,155557,DB01032,Probenecid
,20399996,T(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),h,2.85,155558,DB01032,Probenecid
,20399996,T(max),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),h,3.30,155559,DB01032,Probenecid
,20399996,AUC(0-24),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),,129.23,155560,DB01032,Probenecid
,20399996,AUC(0-24),"The mean (SD) C(max), T(max), AUC(0-24), and AUC(0-infinity) after administration of the test and reference formulations, respectively, were as follows: ampicillin, C(max), 13.45 (3.43) versus 15.04 (5.68) microg/mL, T(max), 1.58 (0.49) versus 1.78 (0.55) hours, AUC(0-24), 50.78 (13.39) versus 57.44 (17.27) micro/mL/h, and AUC(0-infinity), 51.95 (13.45) versus 58.74 (17.19) microg/mL/h; probenecid, C(max), 15.56 (2.94) versus 16.01 (2.88) microg/mL, T(max), 2.85 (0.78) versus 3.30 (1.51) hours, AUC(0-24), 129.23 (27.59) versus 127.29 (26.89) microg/mL/h, and AUC(0-infinity) 133.85 (28.80) versus 131.21 (28.25) microg/mL/h.","Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399996/),,127.29,155561,DB01032,Probenecid
,7249794,total systemic clearance,"This resulted in unstable, dose-dependent total systemic clearance (9.7-13.0 ml/min) and volume of distribution (7.0-8.6 litres) values.","Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249794/),[ml] / [min],9.7-13.0,155569,DB01032,Probenecid
,7249794,volume of distribution,"This resulted in unstable, dose-dependent total systemic clearance (9.7-13.0 ml/min) and volume of distribution (7.0-8.6 litres) values.","Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249794/),l,7.0-8.6,155570,DB01032,Probenecid
,7249794,plasma protein binding (fp,The dose-dependent pharmacokinetic changes could be completely explained in terms of the concentration-dependent plasma protein binding (fp ranging from 0.04 to 0.17 in the concentration range from 0.5 to 300 micrograms/ml).,"Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249794/),,0.04 to 0.17,155571,DB01032,Probenecid
,7249794,total clearance,With reference to free (unbound) drug the mean total clearance was 255 ml/min and the mean renal clearance about 160 ml/min.,"Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249794/),[ml] / [min],255,155572,DB01032,Probenecid
,7249794,renal clearance,With reference to free (unbound) drug the mean total clearance was 255 ml/min and the mean renal clearance about 160 ml/min.,"Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249794/),[ml] / [min],160,155573,DB01032,Probenecid
,7249794,plasma half-life,The mean plasma half-life of Rocephin was not influenced by dose and averaged 8 h.,"Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249794/),h,8,155574,DB01032,Probenecid
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,15.6,156588,DB01032,Probenecid
,10411561,half-life,In serum the half-life of MRZ 2/576 (30 mg/kg) was also increased by coadministration of probenecid from 15.6 +/- 1.3 to 40.6 +/- 6.0 min.,The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411561/),min,40.6,156589,DB01032,Probenecid
,32952511,Cmax,"Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of Cmax (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC0-∞ (P = 0.04) and Tmax (P = 0.004).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[ug] / [l],392,156842,DB01032,Probenecid
,32952511,Cmax,"Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of Cmax (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC0-∞ (P = 0.04) and Tmax (P = 0.004).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[ug] / [l],1323,156843,DB01032,Probenecid
,32952511,drug clearance (CL/F),"Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[l] / [h·kg],27,156844,DB01032,Probenecid
,32952511,drug clearance (CL/F),"Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27).",Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32952511/),[l] / [h·kg],16,156845,DB01032,Probenecid
,3609117,maximum free fraction,"The free fraction was found to increase nonlinearly with increasing total probenecid concentration, up to a maximum free fraction of 26%.",Non-linear elimination and protein binding of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),%,26,157113,DB01032,Probenecid
,3609117,absorption rate constant,"The mean absorption rate constant 0.0072 min-1 was dose-independent, and the maximal rate of elimination (mean 1429 micrograms/min) did not differ between doses whether calculated from the total or free concentrations.",Non-linear elimination and protein binding of probenecid. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),1/[min],0.0072,157114,DB01032,Probenecid
,3609117,maximal rate of elimination,"The mean absorption rate constant 0.0072 min-1 was dose-independent, and the maximal rate of elimination (mean 1429 micrograms/min) did not differ between doses whether calculated from the total or free concentrations.",Non-linear elimination and protein binding of probenecid. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),[μg] / [min],1429,157115,DB01032,Probenecid
,3609117,Michaelis-Menten constant constant,"The Michaelis-Menten constant constant decreased significantly from 67.1 to 55.5 micrograms/ml as the dose increased from 1 g to 2 g, while the unbound Michaelis-Menten constant remained unchanged.",Non-linear elimination and protein binding of probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),[μg] / [ml],67.1,157116,DB01032,Probenecid
,3609117,Michaelis-Menten constant constant,"The Michaelis-Menten constant constant decreased significantly from 67.1 to 55.5 micrograms/ml as the dose increased from 1 g to 2 g, while the unbound Michaelis-Menten constant remained unchanged.",Non-linear elimination and protein binding of probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),[μg] / [ml],55.5,157117,DB01032,Probenecid
,3609117,volume of distribution,"The volume of distribution increased only slightly from 9.5 to 11.41 as the dose increased from 0.5 to 2 g, but the unbound volume of distribution decreased significantly from 164 to 99 1.",Non-linear elimination and protein binding of probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),,9.5,157118,DB01032,Probenecid
,3609117,volume of distribution,"The volume of distribution increased only slightly from 9.5 to 11.41 as the dose increased from 0.5 to 2 g, but the unbound volume of distribution decreased significantly from 164 to 99 1.",Non-linear elimination and protein binding of probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),,11.41,157119,DB01032,Probenecid
,3609117,unbound volume of distribution,"The volume of distribution increased only slightly from 9.5 to 11.41 as the dose increased from 0.5 to 2 g, but the unbound volume of distribution decreased significantly from 164 to 99 1.",Non-linear elimination and protein binding of probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),1,164,157120,DB01032,Probenecid
,3609117,unbound volume of distribution,"The volume of distribution increased only slightly from 9.5 to 11.41 as the dose increased from 0.5 to 2 g, but the unbound volume of distribution decreased significantly from 164 to 99 1.",Non-linear elimination and protein binding of probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609117/),1,99,157121,DB01032,Probenecid
,1432614,tubular secretion,"Pharmacokinetic parameters for tubular secretion of DPP, as determined by a single-injection renal clearance method, were 21.25 micrograms/mL for the Michaelis-Menten constant and 102.38 micrograms/min for maximum velocity.",Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [ml],21.25,158005,DB01032,Probenecid
,1432614,Michaelis-Menten constant,"Pharmacokinetic parameters for tubular secretion of DPP, as determined by a single-injection renal clearance method, were 21.25 micrograms/mL for the Michaelis-Menten constant and 102.38 micrograms/min for maximum velocity.",Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [ml],21.25,158006,DB01032,Probenecid
,1432614,maximum velocity,"Pharmacokinetic parameters for tubular secretion of DPP, as determined by a single-injection renal clearance method, were 21.25 micrograms/mL for the Michaelis-Menten constant and 102.38 micrograms/min for maximum velocity.",Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [min],102.38,158007,DB01032,Probenecid
,1432614,competitive inhibition constant,The competitive inhibition constant of probenecid was 15.86 micrograms/mL.,Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432614/),[μg] / [ml],15.86,158008,DB01032,Probenecid
,18193917,steady-state plasma oxypurinol concentrations,"Coadministration of allopurinol and probenecid significantly reduced average steady-state plasma oxypurinol concentrations (mean+/-SD: allopurinol alone 9.7+/-2.1 mg/L vs combination 5.1+/-1.0 mg/L, p<0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mg] / [l],9.7,158464,DB01032,Probenecid
,18193917,steady-state plasma oxypurinol concentrations,"Coadministration of allopurinol and probenecid significantly reduced average steady-state plasma oxypurinol concentrations (mean+/-SD: allopurinol alone 9.7+/-2.1 mg/L vs combination 5.1+/-1.0 mg/L, p<0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mg] / [l],5.1,158465,DB01032,Probenecid
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.16,158466,DB01032,Probenecid
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.13,158467,DB01032,Probenecid
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.09,158468,DB01032,Probenecid
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.30,158469,DB01032,Probenecid
,3348534,Bioavailability,"Bioavailability of probenecid was 117 and 102% for 2 mares after a single intragastric dose, compared with a single IV dose.",Probenecid infusion in mares: effect on para-aminohippuric acid clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348534/),%,117,158918,DB01032,Probenecid
,3348534,Bioavailability,"Bioavailability of probenecid was 117 and 102% for 2 mares after a single intragastric dose, compared with a single IV dose.",Probenecid infusion in mares: effect on para-aminohippuric acid clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348534/),%,102,158919,DB01032,Probenecid
,1770096,flow-rate,The formed diastereomers were chromatographed on a reversed-phase column with a mobile phase of 0.06 M KH2PO4-acetonitrile-triethylamine (65:35:0.1) at a flow-rate of 1 ml/min and a detection wavelength of 275 nm.,Simultaneous determination of ketoprofen enantiomers and probenecid in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770096/),[ml] / [min],1,159489,DB01032,Probenecid
,1770096,minimum quantifiable concentration,The minimum quantifiable concentration was 0.5 micrograms/ml in 100 microliters of rat plasma and urine samples.,Simultaneous determination of ketoprofen enantiomers and probenecid in plasma and urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770096/),[μg] / [ml],0.5,159490,DB01032,Probenecid
,6763208,serum protein binding,"Biopharmaceutical properties include serum protein binding of approximately 70%, 50-60% excretion of intact drug in the urine of patients with normal renal function, and an elimination half-life of approximately one hour.","Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6763208/),%,70,161178,DB01032,Probenecid
,6763208,elimination half-life,"Biopharmaceutical properties include serum protein binding of approximately 70%, 50-60% excretion of intact drug in the urine of patients with normal renal function, and an elimination half-life of approximately one hour.","Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6763208/),h,one,161179,DB01032,Probenecid
,833762,Metabolic clearance,Metabolic clearance was found to decrease from 1.74+/-0.11 ml/min in animals which received furosemide alone to 1.06+/-0.10 ml/min in animals which received both furosemide and probenecid.,Metabolic clearance of furosemide in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833762/),[ml] / [min],1.74,161846,DB01032,Probenecid
,833762,Metabolic clearance,Metabolic clearance was found to decrease from 1.74+/-0.11 ml/min in animals which received furosemide alone to 1.06+/-0.10 ml/min in animals which received both furosemide and probenecid.,Metabolic clearance of furosemide in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833762/),[ml] / [min],1.06,161847,DB01032,Probenecid
,3729355,maximum concentration,"The maximum concentration of ampicillin in serum after oral administration of 400 mg of lenampicillin was 6.5 micrograms/ml at 0.70 h, and that after a equimolar dosage of ampicillin was 2.9 micrograms/ml at 0.87 h.",Pharmacokinetic study of lenampicillin (KBT-1585) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729355/),[μg] / [ml],6.5,162958,DB01032,Probenecid
,3729355,maximum concentration,"The maximum concentration of ampicillin in serum after oral administration of 400 mg of lenampicillin was 6.5 micrograms/ml at 0.70 h, and that after a equimolar dosage of ampicillin was 2.9 micrograms/ml at 0.87 h.",Pharmacokinetic study of lenampicillin (KBT-1585) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729355/),[μg] / [ml],2.9,162959,DB01032,Probenecid
,2257863,AUC,"Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.",The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257863/),μg,295,163054,DB01032,Probenecid
,2257863,AUC,"Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.",The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257863/),μg,157,163055,DB01032,Probenecid
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],26,164283,DB01032,Probenecid
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],12,164284,DB01032,Probenecid
,16026004,hepatic extraction,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),,30,164285,DB01032,Probenecid
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],7.3,164286,DB01032,Probenecid
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],2.1,164287,DB01032,Probenecid
>,16026004,permeability,The in vitro permeability for fluvastatin was high (>10 x 10(-6) cm/s).,Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[cm] / [s],10 x 10(-6),164288,DB01032,Probenecid
,7310644,Apparent terminal plasma half-lives,Apparent terminal plasma half-lives ranged from 18 to 25 min in the absence of probenecid.,Saturable kinetics of intravenous chlorothiazide in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310644/),min,18 to 25,165637,DB01032,Probenecid
,4057054,terminal half-life,"After intravenous dosing, the plasma levels of cefotaxime declined in a biphasic manner with a terminal half-life varying between 0.92 and 1.65 hr.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,0.92 and 1.65,165915,DB01032,Probenecid
,4057054,volume of distribution based on area,"Moreover, the pharmacokinetics were linear up to at least a 2.0 g dose for volume of distribution based on area (23.3-31.3 l), plasma clearance (249-2.88 ml/min), and renal clearance (151-177 ml/min).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),l,23.3-31.3,165916,DB01032,Probenecid
,4057054,plasma clearance,"Moreover, the pharmacokinetics were linear up to at least a 2.0 g dose for volume of distribution based on area (23.3-31.3 l), plasma clearance (249-2.88 ml/min), and renal clearance (151-177 ml/min).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[ml] / [min],249-2.88,165917,DB01032,Probenecid
,4057054,renal clearance,"Moreover, the pharmacokinetics were linear up to at least a 2.0 g dose for volume of distribution based on area (23.3-31.3 l), plasma clearance (249-2.88 ml/min), and renal clearance (151-177 ml/min).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[ml] / [min],151-177,165918,DB01032,Probenecid
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,54,165919,DB01032,Probenecid
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,19,165920,DB01032,Probenecid
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,6,165921,DB01032,Probenecid
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,5,165922,DB01032,Probenecid
,4057054,half-lives,"The observed half-lives of DACM, M2, and M3 were 2.3 +/- 0.4, 2.2 +/- 0.1 and 2.2 hr, respectively.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,2.3,165923,DB01032,Probenecid
,4057054,half-lives,"The observed half-lives of DACM, M2, and M3 were 2.3 +/- 0.4, 2.2 +/- 0.1 and 2.2 hr, respectively.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,2.2,165924,DB01032,Probenecid
,4057054,half-lives,"The observed half-lives of DACM, M2, and M3 were 2.3 +/- 0.4, 2.2 +/- 0.1 and 2.2 hr, respectively.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,2.2,165925,DB01032,Probenecid
,4057054,half-life,"However, when the true half-life of DACM was calculated (0.83 +/- 0.23 hr) it was not only significantly shorter than that observed but also shorter than that for intact cefotaxime.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,0.83,165926,DB01032,Probenecid
,4057054,plasma clearance,The plasma clearance of DACM (744 +/- 226 ml/min) was much higher than that of cefotaxime while the volume of distribution was of a similar order (56 +/- 24 l).,The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[ml] / [min],744,165927,DB01032,Probenecid
,4057054,volume of distribution,The plasma clearance of DACM (744 +/- 226 ml/min) was much higher than that of cefotaxime while the volume of distribution was of a similar order (56 +/- 24 l).,The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),l,56,165928,DB01032,Probenecid
,4057054,maximum plasma levels,"When administered intramuscularly, there was good absorption of cefotaxime from the site of injection (92-94%) giving maximum plasma levels of the drug of between 30 and 35 mg/l at approximately 40 min after dosing.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[mg] / [l],30 and 35,165929,DB01032,Probenecid
,4057054,half-life,"Thereafter, the plasma levels of cefotaxime declined in a monophasic manner with a half-life (1.0-1.2 hr) similar to that of the terminal half-life seen after intravenous administration.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,1.0-1.2,165930,DB01032,Probenecid
,29277663,Km,"The Km values of tazobactam (431 ± 67 μM for hOAT1, 377 ± 63 μM for hOAT3) were significantly higher than those of piperacillin (37 ± 5 μM for hOAT1, 172 ± 28 μM for hOAT3).",OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277663/),μM,431,166063,DB01032,Probenecid
,29277663,Km,"The Km values of tazobactam (431 ± 67 μM for hOAT1, 377 ± 63 μM for hOAT3) were significantly higher than those of piperacillin (37 ± 5 μM for hOAT1, 172 ± 28 μM for hOAT3).",OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277663/),μM,377,166064,DB01032,Probenecid
,29277663,Km,"The Km values of tazobactam (431 ± 67 μM for hOAT1, 377 ± 63 μM for hOAT3) were significantly higher than those of piperacillin (37 ± 5 μM for hOAT1, 172 ± 28 μM for hOAT3).",OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277663/),μM,37,166065,DB01032,Probenecid
,29277663,Km,"The Km values of tazobactam (431 ± 67 μM for hOAT1, 377 ± 63 μM for hOAT3) were significantly higher than those of piperacillin (37 ± 5 μM for hOAT1, 172 ± 28 μM for hOAT3).",OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277663/),μM,172,166066,DB01032,Probenecid
,2197818,Bioavailability,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),%,50 to 70,166086,DB01032,Probenecid
,2197818,half-life,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),h,1-2,166087,DB01032,Probenecid
,2197818,total body clearance,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),[ml] / [kg·min],20-40,166088,DB01032,Probenecid
,2197818,volume of distribution,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),[l] / [kg],1-2,166089,DB01032,Probenecid
,8225127,total clearances (Clt),"Based on plasma concentration-time profiles, the total clearances (Clt) for DA, PAH and inulin were 9.12, 33.17 and 7.50 ml/min/kg body weight, respectively.",Renal clearance of domoic acid in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225127/),[ml] / [body·kg·min·weight],9.12,166165,DB01032,Probenecid
,8225127,total clearances (Clt),"Based on plasma concentration-time profiles, the total clearances (Clt) for DA, PAH and inulin were 9.12, 33.17 and 7.50 ml/min/kg body weight, respectively.",Renal clearance of domoic acid in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225127/),[ml] / [body·kg·min·weight],33.17,166166,DB01032,Probenecid
,8225127,total clearances (Clt),"Based on plasma concentration-time profiles, the total clearances (Clt) for DA, PAH and inulin were 9.12, 33.17 and 7.50 ml/min/kg body weight, respectively.",Renal clearance of domoic acid in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225127/),[ml] / [body·kg·min·weight],7.50,166167,DB01032,Probenecid
,2542469,Metabolism,Metabolism is minimal (ca. 15-20% for ciprofloxacin and norfloxacin).,Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),%,15-20,166231,DB01032,Probenecid
,2542469,serum half-life,"Because the transintestinal route of elimination compensates for loss of renal elimination, the serum half-life of ciprofloxacvin is raised only to 5-10 hours even in total renal failure.",Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),h,5-10,166232,DB01032,Probenecid
,711932,serum half-life,Cinoxacin is a new synthetic organic antibacterial compound which has a serum half-life of approximately 1 hour.,Cinoxacin: pharmacokinetics and the effect of probenecid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711932/),h,1,166981,DB01032,Probenecid
,18838240,flow rate,"The analytes and internal standard, probenecid, were separated on a Venusil XBP-C(8) column using gradient elution with acetonitrile-10 mM ammonium acetate-formic acid at a flow rate of 1.2 mL/min.",Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18838240/),[ml] / [min],1.2,167271,DB01032,Probenecid
,2609014,Maximum concentrations,"Maximum concentrations of the D- and P-adducts were achieved within one day of cessation of dosing, and were 35 +/- SE 1 and 17 +/- SE 1 ng/mg protein respectively.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),[ng] / [mg],35,167660,DB01032,Probenecid
,2609014,Maximum concentrations,"Maximum concentrations of the D- and P-adducts were achieved within one day of cessation of dosing, and were 35 +/- SE 1 and 17 +/- SE 1 ng/mg protein respectively.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),[ng] / [mg],17,167661,DB01032,Probenecid
,2609014,terminal half-life,"The D-protein adduct was eliminated from plasma in a biphasic manner, with a terminal half-life of 10.0 +/- SE 0.9 days.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),d,10.0,167662,DB01032,Probenecid
,2609014,half-life,"In contrast, elimination of the P-protein adduct was monophasic with a half-life of 13.5 +/- SE 0.3 days.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),d,13.5,167663,DB01032,Probenecid
≥,23357838,fm UGT,"To assess the effect of the UGT inhibitor probenecid on the pharmacokinetics of dalcetrapib, an investigational drug whose pharmacologically active thiol form undergoes glucuronidation (fm UGT ≥ 0.25).",In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357838/),,0.25,168497,DB01032,Probenecid
,19564368,K(m),"The estimated K(m) and Vmax for the saturable part of renal elimination were 9.16 mg/liter (20%) and 113 mg/h (21%), respectively.",Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564368/),[mg] / [l],9.16,168500,DB01032,Probenecid
,19564368,Vmax,"The estimated K(m) and Vmax for the saturable part of renal elimination were 9.16 mg/liter (20%) and 113 mg/h (21%), respectively.",Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564368/),[mg] / [h],113,168501,DB01032,Probenecid
,19564368,nonrenal clearance,Probenecid also reduced the nonrenal clearance of gemifloxacin from 25.2 (26%) to 21.0 (23%) liters/h.,Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564368/),[l] / [h],25.2,168502,DB01032,Probenecid
,19564368,nonrenal clearance,Probenecid also reduced the nonrenal clearance of gemifloxacin from 25.2 (26%) to 21.0 (23%) liters/h.,Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564368/),[l] / [h],21.0,168503,DB01032,Probenecid
,17162472,clearance ratio (renal clearance/glomerular filtration rate),"CS-023 showed a clearance ratio (renal clearance/glomerular filtration rate) of around 1, which was not affected by co-administration of probenecid or p-aminohippurate.","Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162472/),,1,168918,DB01032,Probenecid
,17162472,clearance ratio,"On the other hand, meropenem exhibited a clearance ratio of around 3, which was significantly decreased to 1 by co-administration of probenecid.","Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162472/),,3,168919,DB01032,Probenecid
,17162472,renal cortex/plasma concentration ratio,The renal cortex/plasma concentration ratio of CS-023 was around 0.6 with or without probenecid co-administration.,"Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162472/),,0.6,168920,DB01032,Probenecid
,17162472,ratio of meropenem,"This ratio of meropenem was around 3, which was decreased significantly by co-administration of probenecid to around 0.6.","Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17162472/),,3,168921,DB01032,Probenecid
,6795136,half-life,"The half-life of cefadroxil in serum has an average value of 1.13 h, rising to 1.63 h when the antibiotic is associated with probenecid.",The pharmacokinetics of cefadroxil associated with probenecid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795136/),h,1.13,169672,DB01032,Probenecid
,6795136,half-life,"The half-life of cefadroxil in serum has an average value of 1.13 h, rising to 1.63 h when the antibiotic is associated with probenecid.",The pharmacokinetics of cefadroxil associated with probenecid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795136/),h,1.63,169673,DB01032,Probenecid
,6795136,apparent distribution volume,The apparent distribution volume remains unmodified with a value close to 23 liters.,The pharmacokinetics of cefadroxil associated with probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795136/),l,23,169674,DB01032,Probenecid
,6795136,lag time,"The lag time is 0.25 h in the absence of probenecid, rising to 1.029 h in the presence of the uricosuric agent.",The pharmacokinetics of cefadroxil associated with probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795136/),h,0.25,169675,DB01032,Probenecid
,6795136,lag time,"The lag time is 0.25 h in the absence of probenecid, rising to 1.029 h in the presence of the uricosuric agent.",The pharmacokinetics of cefadroxil associated with probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795136/),h,1.029,169676,DB01032,Probenecid
,8785407,total clearance,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],18.65,170562,DB01032,Probenecid
,8785407,urinary,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],7.95,170563,DB01032,Probenecid
,8785407,metabolic clearances,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],7.95,170564,DB01032,Probenecid
,8785407,metabolic clearances,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],10.70,170565,DB01032,Probenecid
,8785407,total clearance,"In anephric rabbits, total clearance was reduced by 85% to 2.69 +/- 0.26 mL/min per kg (P < 0.001), secondary to the abolition of furosemide renal excretion and to the reduction in metabolic clearance from 10.70 +/- 1.11 to 2.69 +/- 0.26 mL/min per kg (P < 0.001).",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],2.69,170566,DB01032,Probenecid
,8785407,metabolic clearance,"In anephric rabbits, total clearance was reduced by 85% to 2.69 +/- 0.26 mL/min per kg (P < 0.001), secondary to the abolition of furosemide renal excretion and to the reduction in metabolic clearance from 10.70 +/- 1.11 to 2.69 +/- 0.26 mL/min per kg (P < 0.001).",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],10.70,170567,DB01032,Probenecid
,8785407,metabolic clearance,"In anephric rabbits, total clearance was reduced by 85% to 2.69 +/- 0.26 mL/min per kg (P < 0.001), secondary to the abolition of furosemide renal excretion and to the reduction in metabolic clearance from 10.70 +/- 1.11 to 2.69 +/- 0.26 mL/min per kg (P < 0.001).",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],2.69,170568,DB01032,Probenecid
,8785407,total clearance,"The pretreatment with probenecid reduced the total clearance of furosemide by 80%, to 3.62 +/- 0.24 mL/min per kg (P < 0.001), because of a reduction of 90 and 75% in urinary and metabolic clearances, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],3.62,170569,DB01032,Probenecid
,7303723,terminal half-life,"After intravenous administration of the non-nutritive sweetener, saccharin (10 mg/kg), to normal volunteers; the plasma concentration--time curve fitted a two-compartment open model with a terminal half-life of 70 min.",The pharmacokinetics of saccharin in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7303723/),min,70,171027,DB01032,Probenecid
,7303723,fraction absorbed,The fraction absorbed was about 0.85 as determined by the recovery in urine and the area under the plasma concentration--time curves.,The pharmacokinetics of saccharin in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7303723/),,0.85,171028,DB01032,Probenecid
,12538836,K(m),CDF uptake in collagen sandwich-cultured rat hepatocytes was temperature-dependent and saturable (K(m) = 22 +/- 10 microM; V(max) = 97 +/- 9 pmol/min/mg protein).,"Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538836/),μM,22,171367,DB01032,Probenecid
,12538836,V(max),CDF uptake in collagen sandwich-cultured rat hepatocytes was temperature-dependent and saturable (K(m) = 22 +/- 10 microM; V(max) = 97 +/- 9 pmol/min/mg protein).,"Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12538836/),[pM] / [mg·min],97,171368,DB01032,Probenecid
,7249487,peak plasma concentrations,"In general, peak plasma concentrations of 2 to 3 microgram/ml are achieved with 1 to 2 hours, but concomitant ingestion of food reduces and delays the peak concentrations without reducing the amount absorbed.",Clinical Pharmacokinetics of indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[μg] / [ml],2 to 3,172594,DB01032,Probenecid
,7249487,biological half-life,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),h,5 to 10,172595,DB01032,Probenecid
,7249487,plasma clearance,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[ml] / [kg·min],1 to 2.5,172596,DB01032,Probenecid
,4020944,biological half-life,"After i.v. injection, the biological half-life was 1.55 h and apparent volume of distribution at the steady state (Vdss) 0.18 l/kg.",Pharmacokinetics of probenecid in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020944/),h,1.55,174577,DB01032,Probenecid
,4020944,apparent volume of distribution at the steady state (Vdss),"After i.v. injection, the biological half-life was 1.55 h and apparent volume of distribution at the steady state (Vdss) 0.18 l/kg.",Pharmacokinetics of probenecid in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020944/),[l] / [kg],0.18,174578,DB01032,Probenecid
,4020944,Body clearance (ClB),"Body clearance (ClB) and renal clearance (ClR) were 0.12 l/h/kg and 0.03 l/h/kg, respectively.",Pharmacokinetics of probenecid in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020944/),[l] / [h·kg],0.12,174579,DB01032,Probenecid
,4020944,renal clearance (ClR),"Body clearance (ClB) and renal clearance (ClR) were 0.12 l/h/kg and 0.03 l/h/kg, respectively.",Pharmacokinetics of probenecid in sheep. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020944/),[l] / [h·kg],0.03,174580,DB01032,Probenecid
,4020944,bioavailability,"The average bioavailability of probenecid given by i.m. and s.c. injection was 46% and 34%, respectively.",Pharmacokinetics of probenecid in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020944/),%,46,174581,DB01032,Probenecid
,4020944,bioavailability,"The average bioavailability of probenecid given by i.m. and s.c. injection was 46% and 34%, respectively.",Pharmacokinetics of probenecid in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020944/),%,34,174582,DB01032,Probenecid
,2792173,half-life,"The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data.",Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792173/),h,6.80,175073,DB01032,Probenecid
,2792173,renal excretion rate constant,"The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance.",Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792173/),1/[h],0.35,175074,DB01032,Probenecid
,3449380,ratio S:R,In man about 40% of the dose was recovered in urine as glucuronides (ratio S:R = 2.2) within 96 hours of p.o. administration of racemic drug.,Influence of probenecid on the urinary excretion rates of the diastereomeric benoxaprofen glucuronides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449380/),,2.2,175181,DB01032,Probenecid
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],0.51,178729,DB01032,Probenecid
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],0.97,178730,DB01032,Probenecid
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],1.59,178731,DB01032,Probenecid
,9420036,maximum concentrations,"The maximum concentrations of R-95867 in serum (C[max]s) after the administration of CS-834 at doses of 50, 100, 200, and 400 mg were 0.51, 0.97, 1.59, and 2.51 microg/ml, respectively.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),[μg] / [ml],2.51,178732,DB01032,Probenecid
,9420036,half-lives (t1/2s),"The half-lives (t1/2s) were almost constant, approximately 0.7 h.","Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),h,0.7,178733,DB01032,Probenecid
,9420036,cumulative recoveries,The cumulative recoveries in urine were approximately 30 to 35% until 24 h after drug administration.,"Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420036/),%,30 to 35,178734,DB01032,Probenecid
,3319507,bioavailabilities,"Among agents that are absorbed from the gastrointestinal tract, those with bioavailabilities of 85 to 90% include cefroxadine, cefadroxil, cefsumide, cephalexin, cephradine, cephacetrile, and cefazaflur.",Pharmacokinetic properties of the cephalosporins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319507/),%,85 to 90,179143,DB01032,Probenecid
,3319507,serum half-lives (t1/2s),"Most cephalosporins are eliminated rapidly, with serum half-lives (t1/2s) of 1 to 2 hours.",Pharmacokinetic properties of the cephalosporins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319507/),h,1 to 2,179144,DB01032,Probenecid
,3319507,t1/2,"Exceptions are cefonicid with a t1/2 of 4.4 hours, cefpiramide with a t1/2 of 5.0 hours, and cefotetan with a t1/2 of 3.5 hours.",Pharmacokinetic properties of the cephalosporins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319507/),h,4.4,179145,DB01032,Probenecid
,3319507,t1/2,"Exceptions are cefonicid with a t1/2 of 4.4 hours, cefpiramide with a t1/2 of 5.0 hours, and cefotetan with a t1/2 of 3.5 hours.",Pharmacokinetic properties of the cephalosporins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319507/),h,5.0,179146,DB01032,Probenecid
,3319507,t1/2,"Exceptions are cefonicid with a t1/2 of 4.4 hours, cefpiramide with a t1/2 of 5.0 hours, and cefotetan with a t1/2 of 3.5 hours.",Pharmacokinetic properties of the cephalosporins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319507/),h,3.5,179147,DB01032,Probenecid
,3319507,t1/2,The longest half-life is shown by ceftriaxone with a t1/2 of 8.5 hours.,Pharmacokinetic properties of the cephalosporins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319507/),h,8.5,179148,DB01032,Probenecid
,1854160,elimination half-life,"GAZT exhibited a kinetic profile similar to that of AZT, with an elimination half-life of approximately 1 h, while AMT was more variable, with an apparent half-life of 1.6 +/- 1.5 h.",Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854160/),h,1,179563,DB01032,Probenecid
,1854160,apparent half-life,"GAZT exhibited a kinetic profile similar to that of AZT, with an elimination half-life of approximately 1 h, while AMT was more variable, with an apparent half-life of 1.6 +/- 1.5 h.",Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854160/),h,1.6,179564,DB01032,Probenecid
,8820422,elimination half-life,The estimated elimination half-life of cidofovir from the kidney was 16 hr in the presence of probenecid and 11 hr without probenecid.,"Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820422/),h,16,181260,DB01032,Probenecid
,8820422,elimination half-life,The estimated elimination half-life of cidofovir from the kidney was 16 hr in the presence of probenecid and 11 hr without probenecid.,"Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820422/),h,11,181261,DB01032,Probenecid
,8820422,Radioactivity,Radioactivity was highest in the kidney (approximately 700 mu g-eq/g at 30 min postdose).,"Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820422/),[g-eq·mu] / [g],700,181262,DB01032,Probenecid
,2362907,CSF/plasma steady-state AZT concentration ratio,The CSF/plasma steady-state AZT concentration ratio was 0.192 +/- 0.003.,Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362907/),,0.192,183518,DB01032,Probenecid
,8157041,clearance,Pretreatment with probenecid caused a significant decrease in paracetamol clearance (6.23 to 3.42 ml.min-1.kg-1).,The effect of probenecid on paracetamol metabolism and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157041/),[ml] / [kg·min],6.23 to 3.42,185228,DB01032,Probenecid
,24820074,Km,"In vitro transporter studies revealed that M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (Km = 28.6 and 54.0 μM, respectively).",Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820074/),μM,28.6,185353,DB01032,Probenecid
,24820074,Km,"In vitro transporter studies revealed that M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (Km = 28.6 and 54.0 μM, respectively).",Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820074/),μM,54.0,185354,DB01032,Probenecid
,6352634,T 1/2 alpha,"Two-compartment pharmacokinetic analysis revealed means (+/- S.D.) T 1/2 alpha, 0.45 (0.20) h; T 1/2 beta, 1.74 (0.63) h; Vd, 270.0 (50.0) ml/kg; Vc, 190.0 (50.0) ml/kg and Cl beta, 133.7 (22.8) ml/min/1.73 m2.",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),h,0.45,185660,DB01032,Probenecid
,6352634,T 1/2 beta,"Two-compartment pharmacokinetic analysis revealed means (+/- S.D.) T 1/2 alpha, 0.45 (0.20) h; T 1/2 beta, 1.74 (0.63) h; Vd, 270.0 (50.0) ml/kg; Vc, 190.0 (50.0) ml/kg and Cl beta, 133.7 (22.8) ml/min/1.73 m2.",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),h,1.74,185661,DB01032,Probenecid
,6352634,Vd,"Two-compartment pharmacokinetic analysis revealed means (+/- S.D.) T 1/2 alpha, 0.45 (0.20) h; T 1/2 beta, 1.74 (0.63) h; Vd, 270.0 (50.0) ml/kg; Vc, 190.0 (50.0) ml/kg and Cl beta, 133.7 (22.8) ml/min/1.73 m2.",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),[ml] / [kg],270.0,185662,DB01032,Probenecid
,6352634,Vc,"Two-compartment pharmacokinetic analysis revealed means (+/- S.D.) T 1/2 alpha, 0.45 (0.20) h; T 1/2 beta, 1.74 (0.63) h; Vd, 270.0 (50.0) ml/kg; Vc, 190.0 (50.0) ml/kg and Cl beta, 133.7 (22.8) ml/min/1.73 m2.",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),[ml] / [kg],190.0,185663,DB01032,Probenecid
,6352634,Cl beta,"Two-compartment pharmacokinetic analysis revealed means (+/- S.D.) T 1/2 alpha, 0.45 (0.20) h; T 1/2 beta, 1.74 (0.63) h; Vd, 270.0 (50.0) ml/kg; Vc, 190.0 (50.0) ml/kg and Cl beta, 133.7 (22.8) ml/min/1.73 m2.",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),[ml] / [1.73·m2·min],133.7,185664,DB01032,Probenecid
,6352634,Urinary excretion,"Urinary excretion was (% of dose) 0 to 2 h, 65.4 (11.1); 2 to 4 h, 14.9 (3.4) and 4 to 8 h, 9.8 (5.8).",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),%,65.4,185665,DB01032,Probenecid
,6352634,Urinary excretion,"Urinary excretion was (% of dose) 0 to 2 h, 65.4 (11.1); 2 to 4 h, 14.9 (3.4) and 4 to 8 h, 9.8 (5.8).",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),%,14.9,185666,DB01032,Probenecid
,6352634,Urinary excretion,"Urinary excretion was (% of dose) 0 to 2 h, 65.4 (11.1); 2 to 4 h, 14.9 (3.4) and 4 to 8 h, 9.8 (5.8).",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),h,4,185667,DB01032,Probenecid
,6352634,Urinary excretion,"Urinary excretion was (% of dose) 0 to 2 h, 65.4 (11.1); 2 to 4 h, 14.9 (3.4) and 4 to 8 h, 9.8 (5.8).",Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6352634/),%,9.8,185668,DB01032,Probenecid
,33435470,Km,"Rosmarinic acid showed organic anion transporter (OAT)1-mediated active transport with a Km of 26.5 μM and a Vmax of 69.0 pmol/min in HEK293 cells overexpressing OAT1, and the plasma concentrations of rosmarinic acid were increased by the co-injection of probenecid because of decreased renal excretion due to OAT1 inhibition.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,26.5,186352,DB01032,Probenecid
,33435470,Vmax,"Rosmarinic acid showed organic anion transporter (OAT)1-mediated active transport with a Km of 26.5 μM and a Vmax of 69.0 pmol/min in HEK293 cells overexpressing OAT1, and the plasma concentrations of rosmarinic acid were increased by the co-injection of probenecid because of decreased renal excretion due to OAT1 inhibition.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),[pM] / [min],69.0,186353,DB01032,Probenecid
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,60.6,186354,DB01032,Probenecid
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,1.52,186355,DB01032,Probenecid
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,74.8,186356,DB01032,Probenecid
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,91.3,186357,DB01032,Probenecid
,8882301,protein binding to serum albumin,A mean protein binding to serum albumin of 42 to 57% is usually reported.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),%,42 to 57,186895,DB01032,Probenecid
,8882301,steady-state volume of distribution,The steady-state volume of distribution is approximately 1 L/kg.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [kg],1,186896,DB01032,Probenecid
,8882301,elimination half-life,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),h,5 to 8,186897,DB01032,Probenecid
,8882301,total body clearance,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [h],4.8 to 7.8,186898,DB01032,Probenecid
,3608350,total clearance,"Although total clearance was the same with all doses (about 0.45 ml/min/kg), renal clearance and the fraction of unchanged drug appearing in the urine decreased with higher doses raising the question of saturable renal secretion.","Clinical pharmacology of torasemide, a new loop diuretic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608350/),[ml] / [kg·min],0.45,188327,DB01032,Probenecid
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],158,188341,DB01032,Probenecid
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],216,188342,DB01032,Probenecid
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],62,188343,DB01032,Probenecid
,2158548,peak serum concentration,"Mean peak serum concentration of enalapril rose from 158 +/- 7 to 216 +/- 1 ng/ml (P less than .01), whereas that of its metabolite, enalaprilat, rose from 62 +/- 6 to 84 +/- 8 ng/ml (P less than .01) in the presence of probenecid pretreatment.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ng] / [ml],84,188344,DB01032,Probenecid
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],229,188345,DB01032,Probenecid
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],61,188346,DB01032,Probenecid
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],108,188347,DB01032,Probenecid
,2158548,renal clearance,The renal clearance of enalapril decreased from 229 +/- 19 to 61 +/- 4 ml/min (P less than .001) and that of enalaprilat from 108 +/- 4 to 66 +/- 2 ml/min (P less than .001).,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[ml] / [min],66,188348,DB01032,Probenecid
,2158548,total drug recovery,The total drug recovery fell from 48 +/- 3 to 38 +/- 2% (P less than .01) of the administered dose with no accompanying changes in plasma elimination half-lives of the parent drug or metabolite.,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),%,48,188349,DB01032,Probenecid
,2158548,total drug recovery,The total drug recovery fell from 48 +/- 3 to 38 +/- 2% (P less than .01) of the administered dose with no accompanying changes in plasma elimination half-lives of the parent drug or metabolite.,Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),%,38,188350,DB01032,Probenecid
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],51,188351,DB01032,Probenecid
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],91,188352,DB01032,Probenecid
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],55,188353,DB01032,Probenecid
,2158548,Absolute urinary excretion of sodium,"Absolute urinary excretion of sodium increased from 51 +/- 5 to 91 +/- 8 mmol/6 hr (P less than .001) after enalapril and from 55 +/- 4 to 113 +/- 13 mmol/6 hr (P less than .01) after enalapril in presence of probenecid pretreatment, despite a significant decrease in the renal excretion of enalapril and enalaprilat over the same interval.",Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2158548/),[mM] / [6·h],113,188354,DB01032,Probenecid
,7400372,t 1/2,"After a single dose of 100 mg, plasma caprofen peaked in 1 to 2 hours, and t 1/2 was estimated to be 4.4 +/- 1.4 hours, based on a monoexponential fit of the data.",Pharmacokinetic and clinical studies of carprofen in gout. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400372/),h,4.4,188947,DB01032,Probenecid
,3989899,plasma half-life,"When given intravenously, probenecid increased significantly (P less than 0.05) the plasma half-life of cefotaxime three-fold (to 0.94 +/- 0.32 h) and the area under the curve (AUC) approximately two-fold (to 41.1 +/- 16.8 micrograms.h/ml), and decreased plasma cefotaxime clearance (ClB) 45% (to 0.648 +/- 0.191 l/h/kg).",Effect of probenecid on the pharmacokinetics of cefotaxime in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989899/),h,0.94,189366,DB01032,Probenecid
,3989899,area under the curve (AUC),"When given intravenously, probenecid increased significantly (P less than 0.05) the plasma half-life of cefotaxime three-fold (to 0.94 +/- 0.32 h) and the area under the curve (AUC) approximately two-fold (to 41.1 +/- 16.8 micrograms.h/ml), and decreased plasma cefotaxime clearance (ClB) 45% (to 0.648 +/- 0.191 l/h/kg).",Effect of probenecid on the pharmacokinetics of cefotaxime in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989899/),[h·μg] / [ml],41.1,189367,DB01032,Probenecid
,3989899,clearance (ClB),"When given intravenously, probenecid increased significantly (P less than 0.05) the plasma half-life of cefotaxime three-fold (to 0.94 +/- 0.32 h) and the area under the curve (AUC) approximately two-fold (to 41.1 +/- 16.8 micrograms.h/ml), and decreased plasma cefotaxime clearance (ClB) 45% (to 0.648 +/- 0.191 l/h/kg).",Effect of probenecid on the pharmacokinetics of cefotaxime in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3989899/),[l] / [h·kg],0.648,189368,DB01032,Probenecid
,1122685,biologic half-life,"The biologic half-life of ticarcillin was slightly longer than that of carbenicillin (72 and 65 min, P smaller than 0.01) and its volume of distribution was larger (15.7 and 12.3 l, P smaller than 0.01).",Ticarcillin vs carbenicillin: clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122685/),min,72,191402,DB01032,Probenecid
,1122685,biologic half-life,"The biologic half-life of ticarcillin was slightly longer than that of carbenicillin (72 and 65 min, P smaller than 0.01) and its volume of distribution was larger (15.7 and 12.3 l, P smaller than 0.01).",Ticarcillin vs carbenicillin: clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122685/),min,65,191403,DB01032,Probenecid
,1122685,volume of distribution,"The biologic half-life of ticarcillin was slightly longer than that of carbenicillin (72 and 65 min, P smaller than 0.01) and its volume of distribution was larger (15.7 and 12.3 l, P smaller than 0.01).",Ticarcillin vs carbenicillin: clinical pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122685/),l,15.7,191404,DB01032,Probenecid
,1122685,volume of distribution,"The biologic half-life of ticarcillin was slightly longer than that of carbenicillin (72 and 65 min, P smaller than 0.01) and its volume of distribution was larger (15.7 and 12.3 l, P smaller than 0.01).",Ticarcillin vs carbenicillin: clinical pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122685/),l,12.3,191405,DB01032,Probenecid
,1122685,steady-state blood levels,An intravenous infusion of 1 gm/hr gave average steady-state blood levels of about 124 mug/ml for both antibiotics.,Ticarcillin vs carbenicillin: clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122685/),[μg] / [ml],124,191406,DB01032,Probenecid
,1122685,Protein binding,"Protein binding in 100 percent human serum was 50 percent and 65 percent for carbenicillin and ticarcillin, respectively.",Ticarcillin vs carbenicillin: clinical pharmacokinetics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122685/),%,50,191407,DB01032,Probenecid
,1122685,Protein binding,"Protein binding in 100 percent human serum was 50 percent and 65 percent for carbenicillin and ticarcillin, respectively.",Ticarcillin vs carbenicillin: clinical pharmacokinetics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122685/),%,65,191408,DB01032,Probenecid
,318227,bioavailability,The bioavailability of intramuscularly administered cefoxitin is equivalent to that of intravenously administered cefoxitin and is 90% complete within 3-4 hr after the dose is given.,Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/318227/),,90,192253,DB01032,Probenecid
,18559644,steady-state apparent oral clearance,"The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),[l] / [h],7.4,193862,DB01032,Probenecid
,18559644,steady-state apparent oral clearance,"The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),[l] / [h],7.19,193863,DB01032,Probenecid
,18559644,steady-state apparent oral clearance,"The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),[l] / [h],9.75,193864,DB01032,Probenecid
,18559644,concentration,"The (arithmetic) mean concentration at 48 h for group 2 was not significantly different from the mean concentration at 24 h for group 1 (42 +/- 76 and 81 +/- 54 ng/ml, respectively; P = 0.194), but the mean concentration at 48 h for group 3 was significantly less than the mean concentration at 24 h for group 1 (23 +/- 26 and 81 +/- 54 ng/ml, respectively; P = 0.012).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),ng,42,193865,DB01032,Probenecid
,18559644,concentration,"The (arithmetic) mean concentration at 48 h for group 2 was not significantly different from the mean concentration at 24 h for group 1 (42 +/- 76 and 81 +/- 54 ng/ml, respectively; P = 0.194), but the mean concentration at 48 h for group 3 was significantly less than the mean concentration at 24 h for group 1 (23 +/- 26 and 81 +/- 54 ng/ml, respectively; P = 0.012).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),ng,23,193866,DB01032,Probenecid
,18559644,concentration,"The (arithmetic) mean concentration at 48 h for group 2 was not significantly different from the mean concentration at 24 h for group 1 (42 +/- 76 and 81 +/- 54 ng/ml, respectively; P = 0.194), but the mean concentration at 48 h for group 3 was significantly less than the mean concentration at 24 h for group 1 (23 +/- 26 and 81 +/- 54 ng/ml, respectively; P = 0.012).",Pharmacokinetics and tolerability of oseltamivir combined with probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18559644/),ng,81,193867,DB01032,Probenecid
less,6573156,plasma half-life,The plasma half-life of N-formimidoyl thienamycin was slightly less than 1 h and did not increase significantly with the coadministration of probenecid.,Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573156/),h,1,194427,DB01032,Probenecid
,6573156,urinary recovery,The urinary recovery of N-formimidoyl thienamycin varied between 6.0 and 38.4% of the dose with a marked intersubject variability.,Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573156/),%,6.0,194428,DB01032,Probenecid
,6573156,decay,In vitro experiments showed that the decay of N-formimidoyl thienamycin in spiked pretreatment urine samples was 2 to 5%/h with more rapid degradation at acidic than at basic pH.,Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573156/),[%] / [h],2 to 5,194429,DB01032,Probenecid
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],893.48,194449,DB01032,Probenecid
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],1123.85,194450,DB01032,Probenecid
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],314.91,194451,DB01032,Probenecid
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],505.74,194452,DB01032,Probenecid
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],2724.97,194453,DB01032,Probenecid
,31325605,AUC,"AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased.",Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325605/),[μg] / [h·l],3096.40,194454,DB01032,Probenecid
,1157572,Urinary recovery,"Urinary recovery of mecillinam after orally administered pivmecillinam was 45% in the first 6 h compared with 55 and 59% after mecillinam given by the intravenous and intramuscular routes, respectively.",Pharmacokinetic studies with mecillinam and pivmecillinam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1157572/),%,45,194936,DB01032,Probenecid
,1157572,Urinary recovery,"Urinary recovery of mecillinam after orally administered pivmecillinam was 45% in the first 6 h compared with 55 and 59% after mecillinam given by the intravenous and intramuscular routes, respectively.",Pharmacokinetic studies with mecillinam and pivmecillinam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1157572/),%,55,194937,DB01032,Probenecid
,1157572,Urinary recovery,"Urinary recovery of mecillinam after orally administered pivmecillinam was 45% in the first 6 h compared with 55 and 59% after mecillinam given by the intravenous and intramuscular routes, respectively.",Pharmacokinetic studies with mecillinam and pivmecillinam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1157572/),%,59,194938,DB01032,Probenecid
,2920479,bioavailability,"Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%.",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),%,100,197116,DB01032,Probenecid
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],1.5,197117,DB01032,Probenecid
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],10.7,197118,DB01032,Probenecid
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],78,197119,DB01032,Probenecid
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],5.5,197120,DB01032,Probenecid
,2920479,apparent volume of distribution,Protein binding is low (less than or equal to 30%) and apparent volume of distribution is between 1.5 and 3.1 liters/kg.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[l] / [kg],1.5 and 3.1,197121,DB01032,Probenecid
,2920479,half-lives,"Norfloxacin and ciprofloxacin have the shortest half-lives (+/- 4h), while fleroxacin and pefloxacin have the longest (10-12h).",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),h,10-12,197122,DB01032,Probenecid
,6275776,half-lives,"The half-lives of moxalactam, ceftazidime, and cefotaxime were 2.34, 1.95, and 1.16 h, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),h,2.34,197143,DB01032,Probenecid
,6275776,half-lives,"The half-lives of moxalactam, ceftazidime, and cefotaxime were 2.34, 1.95, and 1.16 h, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),h,1.95,197144,DB01032,Probenecid
,6275776,half-lives,"The half-lives of moxalactam, ceftazidime, and cefotaxime were 2.34, 1.95, and 1.16 h, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),h,1.16,197145,DB01032,Probenecid
,6275776,volume of distribution,"The volume of distribution averaged 0.20 +/- 0.03, 0.23 +/- 0.02, and 0.25 +/- 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),[l] / [kg],0.20,197146,DB01032,Probenecid
,6275776,volume of distribution,"The volume of distribution averaged 0.20 +/- 0.03, 0.23 +/- 0.02, and 0.25 +/- 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),[l] / [kg],0.23,197147,DB01032,Probenecid
,6275776,volume of distribution,"The volume of distribution averaged 0.20 +/- 0.03, 0.23 +/- 0.02, and 0.25 +/- 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),[l] / [kg],0.25,197148,DB01032,Probenecid
,6275776,total body clearance,"The volume of distribution averaged 0.20 +/- 0.03, 0.23 +/- 0.02, and 0.25 +/- 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),[ml] / [min],84,197149,DB01032,Probenecid
,6275776,total body clearance,"The volume of distribution averaged 0.20 +/- 0.03, 0.23 +/- 0.02, and 0.25 +/- 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),[ml] / [min],131,197150,DB01032,Probenecid
,6275776,total body clearance,"The volume of distribution averaged 0.20 +/- 0.03, 0.23 +/- 0.02, and 0.25 +/- 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),[ml] / [min],328,197151,DB01032,Probenecid
,6275776,urinary recovery,The 24-h urinary recovery was highest for moxalactam (75 +/- 4%) followed by ceftazidime (68 +/- 11%) and cefotaxime (53 +/- 6%).,"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),%,75,197152,DB01032,Probenecid
,6275776,urinary recovery,The 24-h urinary recovery was highest for moxalactam (75 +/- 4%) followed by ceftazidime (68 +/- 11%) and cefotaxime (53 +/- 6%).,"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),%,68,197153,DB01032,Probenecid
,6275776,urinary recovery,The 24-h urinary recovery was highest for moxalactam (75 +/- 4%) followed by ceftazidime (68 +/- 11%) and cefotaxime (53 +/- 6%).,"Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),%,53,197154,DB01032,Probenecid
,6275776,half-life,"After the 0.5- and 2.0- g doses of cefotaxime, desacetyl-cefotaxime activity (determined by high-pressure liquid chromatography) reached a peak of 2.7 and 9.9 mug/ml and declined with a half-life of 1.9 and 1.4 h.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),h,1.9,197155,DB01032,Probenecid
,6275776,half-life,"After the 0.5- and 2.0- g doses of cefotaxime, desacetyl-cefotaxime activity (determined by high-pressure liquid chromatography) reached a peak of 2.7 and 9.9 mug/ml and declined with a half-life of 1.9 and 1.4 h.","Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6275776/),h,1.4,197156,DB01032,Probenecid
<,11082489,brain-to-unbound plasma concentration ratio,Delivery of valproic acid (VPA) to the human brain is relatively inefficient as reflected by a low brain-to-unbound plasma concentration ratio (< or =0.5) at steady state.,Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,0.5,198445,DB01032,Probenecid
,11082489,concentration ratio,"Probenecid co-infusion elevated the ICC-to-ECF concentration ratio to 4.2+/-0.44, which confirms the existence of an efflux transport system in brain parenchymal cells.",Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,4.2,198446,DB01032,Probenecid
below,11082489,-to-unbound plasma concentration ratio,"The ECF-to-unbound plasma concentration ratio was well below unity (0.029), indicating an uphill efflux transport of VPA across the BBB.",Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,unity,198447,DB01032,Probenecid
,11082489,-to-unbound plasma concentration ratio,"The ECF-to-unbound plasma concentration ratio was well below unity (0.029), indicating an uphill efflux transport of VPA across the BBB.",Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,0.029,198448,DB01032,Probenecid
,17655371,oral bioavailability,"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),%,79,200787,DB01032,Probenecid
,17655371,elimination half-life (t((1/2))),"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),h,1.2,200788,DB01032,Probenecid
,17655371,apparent oral clearance (CL/F),"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[ml] / [kg·min],15.8,200789,DB01032,Probenecid
,17655371,apparent volume of distribution after oral administration (V(d)/F),"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[l] / [kg],1.31,200790,DB01032,Probenecid
,17655371,t((1/2)),"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),h,23.3,200791,DB01032,Probenecid
,17655371,CL/F,"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[ml] / [kg·min],0.31,200792,DB01032,Probenecid
,17655371,V(d)/F,"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[l] / [kg],0.59,200793,DB01032,Probenecid
,17655371,renal clearance (CL(R)),"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),,0.19,200794,DB01032,Probenecid
,3049491,peak serum concentrations,"After administration of a 10-mg/kg dose by the intramuscular route to rhesus monkeys, peak serum concentrations of 32-54 micrograms/ml were seen at about 30 minutes, and the half-life was estimated to be 63 minutes.","L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049491/),[μg] / [ml],32-54,201090,DB01032,Probenecid
,3049491,half-life,"After administration of a 10-mg/kg dose by the intramuscular route to rhesus monkeys, peak serum concentrations of 32-54 micrograms/ml were seen at about 30 minutes, and the half-life was estimated to be 63 minutes.","L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049491/),min,63,201091,DB01032,Probenecid
greater,3049491,Urinary recovery of administered dose,Urinary recovery of administered dose was greater than 94% in 6 hours.,"L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049491/),%,94,201092,DB01032,Probenecid
,3049491,peak serum concentration,"In mice given a 20-mg/kg dose by the subcutaneous route, a peak serum concentration of 22.9 microgram/ml was observed at 15 minutes after dosing, and the half-life in serum was about 18 minutes.","L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049491/),[μg] / [ml],22.9,201093,DB01032,Probenecid
,3049491,half-life in serum,"In mice given a 20-mg/kg dose by the subcutaneous route, a peak serum concentration of 22.9 microgram/ml was observed at 15 minutes after dosing, and the half-life in serum was about 18 minutes.","L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049491/),min,18,201094,DB01032,Probenecid
,3049491,Urinary recovery,Urinary recovery of the dose was 59% in 6 hours.,"L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049491/),%,59,201095,DB01032,Probenecid
,3049491,Binding,Binding to human plasma proteins was 30% at drug concentrations from 25-100 micrograms/ml.,"L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049491/),%,30,201096,DB01032,Probenecid
,9462447,MIC90,"Probenecid prolonged the serum cefuroxime half-life by 63% (P < 0.05) with a significant increase in the mean time for which serum cefuroxime concentrations exceeded the MIC90 for common respiratory pathogens (2 mg/L) compared with either 750 mg cefuroxime (2.2 h, P < 0.05) or 1.5 g of cefuroxime (0.9 h, P < 0.05) without probenecid.",Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9462447/),[mg] / [l],2,201385,DB01032,Probenecid
,9462447,MIC90,"Probenecid prolonged the serum cefuroxime half-life by 63% (P < 0.05) with a significant increase in the mean time for which serum cefuroxime concentrations exceeded the MIC90 for common respiratory pathogens (2 mg/L) compared with either 750 mg cefuroxime (2.2 h, P < 0.05) or 1.5 g of cefuroxime (0.9 h, P < 0.05) without probenecid.",Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9462447/),h,2.2,201386,DB01032,Probenecid
,9462447,MIC90,"Probenecid prolonged the serum cefuroxime half-life by 63% (P < 0.05) with a significant increase in the mean time for which serum cefuroxime concentrations exceeded the MIC90 for common respiratory pathogens (2 mg/L) compared with either 750 mg cefuroxime (2.2 h, P < 0.05) or 1.5 g of cefuroxime (0.9 h, P < 0.05) without probenecid.",Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9462447/),h,0.9,201387,DB01032,Probenecid
,4208290,half-life,The half-life of tobramycin in patients with normal renal function (serum creatine [Formula: see text] to 1.5 mg/100) was on the average 3 h.,Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4208290/),h,3,203560,DB01032,Probenecid
,7175716,peak probenecid levels,"Mean peak probenecid levels of 35.3, 69.6, and 148.6 micrograms/ml were obtained at 3-4 hr following the 0.5-, 1.0-, and 2.0-g doses, respectively.",Pharmacokinetics of probenecid following oral doses to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),[μg] / [ml],35.3,203699,DB01032,Probenecid
,7175716,peak probenecid levels,"Mean peak probenecid levels of 35.3, 69.6, and 148.6 micrograms/ml were obtained at 3-4 hr following the 0.5-, 1.0-, and 2.0-g doses, respectively.",Pharmacokinetics of probenecid following oral doses to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),[μg] / [ml],69.6,203700,DB01032,Probenecid
,7175716,peak probenecid levels,"Mean peak probenecid levels of 35.3, 69.6, and 148.6 micrograms/ml were obtained at 3-4 hr following the 0.5-, 1.0-, and 2.0-g doses, respectively.",Pharmacokinetics of probenecid following oral doses to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),[μg] / [ml],148.6,203701,DB01032,Probenecid
,7175716,elimination half-lives,"Probenecid levels from the 0.5- and 1.0-g doses declined in apparent monoexponential fashion, with mean elimination half-lives of 4.2 and 4.9 hr.",Pharmacokinetics of probenecid following oral doses to human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),h,4.2,203702,DB01032,Probenecid
,7175716,elimination half-lives,"Probenecid levels from the 0.5- and 1.0-g doses declined in apparent monoexponential fashion, with mean elimination half-lives of 4.2 and 4.9 hr.",Pharmacokinetics of probenecid following oral doses to human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),h,4.9,203703,DB01032,Probenecid
,7175716,plasma drug half-life,Interpretation of the 2.0-g data by a kinetic model incorporating first-order elimination resulted in a plasma drug half-life of 8.5 hr.,Pharmacokinetics of probenecid following oral doses to human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),h,8.5,203704,DB01032,Probenecid
,7175716,Vm/Km ratios,"When first-order elimination was replaced by a Michaelis-Menten-type function, the mean value of the resulting Vm/Km ratios was 0.20, equivalent to a plasma drug half-life [0.693/(Vm/Km)] of 3.8 hr.",Pharmacokinetics of probenecid following oral doses to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),,0.20,203705,DB01032,Probenecid
,7175716,plasma drug half-life [0.693/(Vm/Km)],"When first-order elimination was replaced by a Michaelis-Menten-type function, the mean value of the resulting Vm/Km ratios was 0.20, equivalent to a plasma drug half-life [0.693/(Vm/Km)] of 3.8 hr.",Pharmacokinetics of probenecid following oral doses to human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175716/),h,3.8,203706,DB01032,Probenecid
,3054149,elimination half-life (t1/2),The elimination half-life (t1/2) was 66.9 +/- 6.9 min (mean +/- SD) after i.v. and 81.0 +/- 10.9 min after i.m. administration.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),min,66.9,204383,DB01032,Probenecid
,3054149,elimination half-life (t1/2),The elimination half-life (t1/2) was 66.9 +/- 6.9 min (mean +/- SD) after i.v. and 81.0 +/- 10.9 min after i.m. administration.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),min,81.0,204384,DB01032,Probenecid
,3054149,t1/2,The t1/2 increased to 125.5 +/- 15.6 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),min,125.5,204385,DB01032,Probenecid
,3054149,total body clearance (ClT),The total body clearance (ClT) was 4.88 +/- 1.71 ml/min/kg and the volume of distribution (Vss) 0.3187 +/- 0.0950 l/kg.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),[ml] / [kg·min],4.88,204386,DB01032,Probenecid
,3054149,volume of distribution (Vss),The total body clearance (ClT) was 4.88 +/- 1.71 ml/min/kg and the volume of distribution (Vss) 0.3187 +/- 0.0950 l/kg.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),[l] / [kg],0.3187,204387,DB01032,Probenecid
,3054149,mean residence time (MRT),The mean residence time (MRT) was 68.2 +/- 12.3 min after i.v. and 118.6 +/- 16.8 min after i.m. injection and increased to 211.5 +/- 16.8 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),min,68.2,204388,DB01032,Probenecid
,3054149,mean residence time (MRT),The mean residence time (MRT) was 68.2 +/- 12.3 min after i.v. and 118.6 +/- 16.8 min after i.m. injection and increased to 211.5 +/- 16.8 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),min,118.6,204389,DB01032,Probenecid
,3054149,mean residence time (MRT),The mean residence time (MRT) was 68.2 +/- 12.3 min after i.v. and 118.6 +/- 16.8 min after i.m. injection and increased to 211.5 +/- 16.8 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),min,211.5,204390,DB01032,Probenecid
,3054149,mean absorption time (MAT),The mean absorption time (MAT) was 50.6 min and the estimated bioavailability (F) of cefoxitin after i.m. administration was 73.8%.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),min,50.6,204391,DB01032,Probenecid
,3054149,bioavailability (F),The mean absorption time (MAT) was 50.6 min and the estimated bioavailability (F) of cefoxitin after i.m. administration was 73.8%.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),%,73.8,204392,DB01032,Probenecid
,3054149,protein binding,The cefoxitin protein binding ranged from 55.0 to 42.0% at concentrations from 2 to 50 micrograms/ml.,Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),%,55.0 to 42.0,204393,DB01032,Probenecid
,3054149,MIC90,"The MIC90 values for cefoxitin were 6.25 micrograms/ml for E. coli and Salmonella group B isolates, 3.13 micrograms/ml for Salmonella group C and D and Pasteurella multocida.",Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),[μg] / [ml],6.25,204394,DB01032,Probenecid
,3054149,MIC90,"The MIC90 values for cefoxitin were 6.25 micrograms/ml for E. coli and Salmonella group B isolates, 3.13 micrograms/ml for Salmonella group C and D and Pasteurella multocida.",Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3054149/),[μg] / [ml],3.13,204395,DB01032,Probenecid
,3447247,renal extractions,The renal extractions of the two substances were closely correlated and averaged 85.9% for PAH and 88.7% for TEA (p less than 0.01).,Superiority of tetraethylammonium to p-aminohippurate as a marker for renal plasma flow during furosemide diuresis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447247/),%,85.9,207219,DB01032,Probenecid
,3447247,renal extractions,The renal extractions of the two substances were closely correlated and averaged 85.9% for PAH and 88.7% for TEA (p less than 0.01).,Superiority of tetraethylammonium to p-aminohippurate as a marker for renal plasma flow during furosemide diuresis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447247/),%,88.7,207220,DB01032,Probenecid
,17725176,renal clearance,"Coadministration of probenecid resulted in a 34% reduction of the renal clearance of 1-MX (mean +/- SD 190 +/- 42 versus 290 +/- 83 ml min(-1), 95% CI on difference 0.2, 200, p = 0.04) with a 41% reduction in its estimated non-glomerular clearance.",Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725176/),[ml] / [min],190,208670,DB01032,Probenecid
,17725176,renal clearance,"Coadministration of probenecid resulted in a 34% reduction of the renal clearance of 1-MX (mean +/- SD 190 +/- 42 versus 290 +/- 83 ml min(-1), 95% CI on difference 0.2, 200, p = 0.04) with a 41% reduction in its estimated non-glomerular clearance.",Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725176/),[ml] / [min],290,208671,DB01032,Probenecid
,8220301,intrinsic t1/2,Under probenecid co-medication the renal glucuronidation of nalidixic acid is reduced from 53% to 16%; the renal clearance of both nalidixic acid and 7-hydroxymethylnalidixic acid are reduced (p < 0.001); the intrinsic t1/2 of the metabolite 7-hydroxymethylnalidixic acid increased from 0.48 h to 4.24 h.,Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220301/),h,0.48,209204,DB01032,Probenecid
,8220301,intrinsic t1/2,Under probenecid co-medication the renal glucuronidation of nalidixic acid is reduced from 53% to 16%; the renal clearance of both nalidixic acid and 7-hydroxymethylnalidixic acid are reduced (p < 0.001); the intrinsic t1/2 of the metabolite 7-hydroxymethylnalidixic acid increased from 0.48 h to 4.24 h.,Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220301/),h,4.24,209205,DB01032,Probenecid
,3380821,plasma half-life,Its plasma half-life was found to be 8.4 hrs.,Renal handling of adriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3380821/),h,8.4,209239,DB01032,Probenecid
,3380821,biliary clearance ratio,The biliary clearance ratio between ADR and creatinine was ranged from 30-100.,Renal handling of adriamycin. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3380821/),,30-100,209240,DB01032,Probenecid
,6641097,diuresis at steady state,Continuous intravenous infusion of bumetanide (200 micrograms/hr) gave an average diuresis at steady state of 15 +/- 3 ml/min.,Coupling between renal tubular secretion and effect of bumetanide. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ml] / [min],15,210441,DB01032,Probenecid
,6641097,plasma,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ng] / [ml],14.3,210442,DB01032,Probenecid
,6641097,urinary excretion rate,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[μg] / [30·min],64,210443,DB01032,Probenecid
,6641097,renal clearance,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ml] / [min],145,210444,DB01032,Probenecid
,6641097,plasma concentration,"Average plasma concentration rose to 41.7 +/- 8.1 ng/ml, whereas renal clearance and urinary excretion rate fell to 15.1% and 29.5% of control.",Coupling between renal tubular secretion and effect of bumetanide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ng] / [ml],41.7,210445,DB01032,Probenecid
,2704066,elimination half-life (t1/2),"The elimination half-life (t1/2) was 69.2 min (harmonic mean) after i.v. and 64.8 min and 64.9 min following i.m. administration of the lower and higher dose, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,69.2,210690,DB01032,Probenecid
,2704066,elimination half-life (t1/2),"The elimination half-life (t1/2) was 69.2 min (harmonic mean) after i.v. and 64.8 min and 64.9 min following i.m. administration of the lower and higher dose, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,64.8,210691,DB01032,Probenecid
,2704066,elimination half-life (t1/2),"The elimination half-life (t1/2) was 69.2 min (harmonic mean) after i.v. and 64.8 min and 64.9 min following i.m. administration of the lower and higher dose, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,64.9,210692,DB01032,Probenecid
,2704066,mean residence time (MRT),"The mean residence time (MRT) was 80.9 +/- 23.5 min (mean +/- SD) after i.v. and 117.8 +/- 9.3 min and 117.7 +/- 5.4 min after i.m. administration of cefuroxime at 10 and 20 mg/kg, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,80.9,210693,DB01032,Probenecid
,2704066,mean residence time (MRT),"The mean residence time (MRT) was 80.9 +/- 23.5 min (mean +/- SD) after i.v. and 117.8 +/- 9.3 min and 117.7 +/- 5.4 min after i.m. administration of cefuroxime at 10 and 20 mg/kg, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,117.8,210694,DB01032,Probenecid
,2704066,mean residence time (MRT),"The mean residence time (MRT) was 80.9 +/- 23.5 min (mean +/- SD) after i.v. and 117.8 +/- 9.3 min and 117.7 +/- 5.4 min after i.m. administration of cefuroxime at 10 and 20 mg/kg, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,117.7,210695,DB01032,Probenecid
,2704066,MRTi.m.,The MRTi.m. following administration of cefuroxime at 10 mg/kg together with probenecid at 40 mg/kg was 140.0 +/- 8.8 min.,Probenecid effect on cefuroxime pharmacokinetics in calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,140.0,210696,DB01032,Probenecid
,2704066,MRTi.m.,"The MRTi.m. values were 132.8 +/- 2.3 min and 150.8 +/- 5.1 min after cefuroxime was given at 20 mg/kg together with probenecid at 40 mg/kg or 80 mg/kg, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,132.8,210697,DB01032,Probenecid
,2704066,MRTi.m.,"The MRTi.m. values were 132.8 +/- 2.3 min and 150.8 +/- 5.1 min after cefuroxime was given at 20 mg/kg together with probenecid at 40 mg/kg or 80 mg/kg, respectively.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),min,150.8,210698,DB01032,Probenecid
,2704066,total body clearance (ClT),The total body clearance (ClT) was 3.56 +/- 1.11 ml/min/kg and the volume of distribution at steady state (Vd(ss] 0.270 +/- 0.051 l/kg.,Probenecid effect on cefuroxime pharmacokinetics in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),[ml] / [kg·min],3.56,210699,DB01032,Probenecid
,2704066,volume of distribution at steady state (Vd(ss],The total body clearance (ClT) was 3.56 +/- 1.11 ml/min/kg and the volume of distribution at steady state (Vd(ss] 0.270 +/- 0.051 l/kg.,Probenecid effect on cefuroxime pharmacokinetics in calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),[l] / [kg],0.270,210700,DB01032,Probenecid
,2704066,MIC90,"The MIC90 values of cefuroxime were 16 micrograms/ml for E. coli and Salmonella isolates, 0.5 microgram/ml for Pasteurella multocida and 2.0 micrograms/ml for P. haemolytica.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),[μg] / [ml],16,210701,DB01032,Probenecid
,2704066,MIC90,"The MIC90 values of cefuroxime were 16 micrograms/ml for E. coli and Salmonella isolates, 0.5 microgram/ml for Pasteurella multocida and 2.0 micrograms/ml for P. haemolytica.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),[μg] / [ml],0.5,210702,DB01032,Probenecid
,2704066,MIC90,"The MIC90 values of cefuroxime were 16 micrograms/ml for E. coli and Salmonella isolates, 0.5 microgram/ml for Pasteurella multocida and 2.0 micrograms/ml for P. haemolytica.",Probenecid effect on cefuroxime pharmacokinetics in calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2704066/),[μg] / [ml],2.0,210703,DB01032,Probenecid
,25589475,total clearance,"Pretreated with probenecid, the systemic exposure of GB was significantly elevated from 8.319 ± 1.646 to 14.75 ± 1.328 µg · mL(-1) ∙h but with reduced total clearance from 1.17 ± 0.331 to 0.596 ± 0.0573 L · h(-1) ∙kg(-1) accompanying no changes in plasma elimination half-lives compared with control group.",The potential drug-drug interactions of ginkgolide B mediated by renal transporters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25589475/),[l] / [h·∙kg],1.17,212018,DB01032,Probenecid
,25589475,total clearance,"Pretreated with probenecid, the systemic exposure of GB was significantly elevated from 8.319 ± 1.646 to 14.75 ± 1.328 µg · mL(-1) ∙h but with reduced total clearance from 1.17 ± 0.331 to 0.596 ± 0.0573 L · h(-1) ∙kg(-1) accompanying no changes in plasma elimination half-lives compared with control group.",The potential drug-drug interactions of ginkgolide B mediated by renal transporters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25589475/),[l] / [h·∙kg],0.596,212019,DB01032,Probenecid
,19317352,Minimum detection level,Minimum detection level of enrofloxacin was 0.01 microg/ml.,Effect of probenecid on kinetics of enrofloxacin in lactating goats after subcutaneous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19317352/),[μg] / [ml],0.01,212503,DB01032,Probenecid
,26612873,volume of distribution,"Mean values for volume of distribution, clearance and elimination half-life were 19.5 L, 5.6 L/h and 2.8 h, respectively.",Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612873/),l,19.5,212994,DB01032,Probenecid
,26612873,clearance,"Mean values for volume of distribution, clearance and elimination half-life were 19.5 L, 5.6 L/h and 2.8 h, respectively.",Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612873/),[l] / [h],5.6,212995,DB01032,Probenecid
,26612873,elimination half-life,"Mean values for volume of distribution, clearance and elimination half-life were 19.5 L, 5.6 L/h and 2.8 h, respectively.",Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612873/),h,2.8,212996,DB01032,Probenecid
,2050827,renal clearance,"In particular, renal clearance was not significantly different (488 +/- 95 mL/min without probenecid vs. 478 +/- 69 mL/min in the presence of probenecid).",Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050827/),[ml] / [min],488,213847,DB01032,Probenecid
,2050827,renal clearance,"In particular, renal clearance was not significantly different (488 +/- 95 mL/min without probenecid vs. 478 +/- 69 mL/min in the presence of probenecid).",Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050827/),[ml] / [min],478,213848,DB01032,Probenecid
,19104028,conversion level,"Oseltamivir phosphate (OS) was rapidly and completely absorbed and converted (median conversion level, 93%) to the active carboxylate metabolite.",Pharmacokinetics of high-dose oseltamivir in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19104028/),%,93,215577,DB01032,Probenecid
,19104028,elimination half-lives,Median elimination half-lives (and 95% confidence intervals [CI]) were 1.0 h (0.9 to 1.1 h) for OS and 5.1 h (4.7 to 5.7 h) for oseltamivir carboxylate (OC).,Pharmacokinetics of high-dose oseltamivir in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19104028/),h,1.0,215578,DB01032,Probenecid
,19104028,elimination half-lives,Median elimination half-lives (and 95% confidence intervals [CI]) were 1.0 h (0.9 to 1.1 h) for OS and 5.1 h (4.7 to 5.7 h) for oseltamivir carboxylate (OC).,Pharmacokinetics of high-dose oseltamivir in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19104028/),h,5.1,215579,DB01032,Probenecid
,8648903,plasma half-life,"The mean values (N = 16) for plasma half-life, plasma clearance and apparent volume of distribution of 5-propyl FPA were 3.6 hours, 2.4 ml . min(-1) . kg(-1) and 0.69 liter . kg(-1), respectively.",Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8648903/),h,3.6,217899,DB01032,Probenecid
,8648903,plasma clearance,"The mean values (N = 16) for plasma half-life, plasma clearance and apparent volume of distribution of 5-propyl FPA were 3.6 hours, 2.4 ml . min(-1) . kg(-1) and 0.69 liter . kg(-1), respectively.",Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8648903/),[ml] / [kg·min],2.4,217900,DB01032,Probenecid
,8648903,apparent volume of distribution,"The mean values (N = 16) for plasma half-life, plasma clearance and apparent volume of distribution of 5-propyl FPA were 3.6 hours, 2.4 ml . min(-1) . kg(-1) and 0.69 liter . kg(-1), respectively.",Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8648903/),[l] / [kg],0.69,217901,DB01032,Probenecid
,20233180,renal clearance,"Addition of probenecid reduced the median renal clearance from 23.8 to 8.25 l h(-1)[65% reduction (59, 71), P < 0.01] for ciprofloxacin and from 20.5 to 8.26 l h(-1) (66% reduction (57, 73), P < 0.01] for M1 (estimated by modelling).",Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233180/),[l] / [h],23,218047,DB01032,Probenecid
,20233180,renal clearance,"Addition of probenecid reduced the median renal clearance from 23.8 to 8.25 l h(-1)[65% reduction (59, 71), P < 0.01] for ciprofloxacin and from 20.5 to 8.26 l h(-1) (66% reduction (57, 73), P < 0.01] for M1 (estimated by modelling).",Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233180/),[l] / [h],20.5 to 8.26,218048,DB01032,Probenecid
,18443035,inhibition constant (K(i)),"Zonampanel inhibited the uptake of typical substrates by Oat1, Oat2, and Oat3 with inhibition constant (K(i)) values of 7.02 to 10.4 microM.","Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443035/),μM,7.02 to 10.4,218835,DB01032,Probenecid
,18443035,Michaelis-Menten constant (K(m)),A time- and saturable concentration-dependent increase in [14C]zonampanel uptake was observed in these cells [Michaelis-Menten constant (K(m)) values: 13.4 to 53.6 microM].,"Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443035/),μM,13.4 to 53.6,218836,DB01032,Probenecid
,15626577,ratio,"The extent of BBB transport, expressed as the ratio between clearance into the brain and clearance out of the brain (CL(in)/CL(out)), was estimated as 0.29 on both days, indicating that efflux transporters act on M6G at the BBB.",Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626577/),,0.29,219750,DB01032,Probenecid
,15626577,clearance into the brain,"The extent of BBB transport, expressed as the ratio between clearance into the brain and clearance out of the brain (CL(in)/CL(out)), was estimated as 0.29 on both days, indicating that efflux transporters act on M6G at the BBB.",Influence of probenecid on the delivery of morphine-6-glucuronide to the brain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626577/),,0.29,219751,DB01032,Probenecid
more,4029016,urine flow,A urine flow of more than 500 ml/h was maintained.,Renal clearance of temocillin in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [h],500,220274,DB01032,Probenecid
,4029016,plasma concentrations,"The mean plasma concentrations were 131.4 and 220.7 mg/L during the lower dose and higher dose infusions, respectively, and protein binding decreased from 83% to 74% with this increase in plasma concentration.",Renal clearance of temocillin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[mg] / [l],131.4,220275,DB01032,Probenecid
,4029016,plasma concentrations,"The mean plasma concentrations were 131.4 and 220.7 mg/L during the lower dose and higher dose infusions, respectively, and protein binding decreased from 83% to 74% with this increase in plasma concentration.",Renal clearance of temocillin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[mg] / [l],220.7,220276,DB01032,Probenecid
,4029016,renal clearance of,"The renal clearance of the total drug increased from 29.0 ml/min (low dose) to 50.5 ml/min (high dose) [p less than 0.001], but after correction for protein binding the renal clearance of the unbound drug only increased from 169.1 to 197.0 ml/min (not statistically significant).",Renal clearance of temocillin in volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],29.0,220277,DB01032,Probenecid
,4029016,renal clearance of,"The renal clearance of the total drug increased from 29.0 ml/min (low dose) to 50.5 ml/min (high dose) [p less than 0.001], but after correction for protein binding the renal clearance of the unbound drug only increased from 169.1 to 197.0 ml/min (not statistically significant).",Renal clearance of temocillin in volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],50.5,220278,DB01032,Probenecid
,4029016,renal clearance of the unbound drug,"The renal clearance of the total drug increased from 29.0 ml/min (low dose) to 50.5 ml/min (high dose) [p less than 0.001], but after correction for protein binding the renal clearance of the unbound drug only increased from 169.1 to 197.0 ml/min (not statistically significant).",Renal clearance of temocillin in volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],169.1,220279,DB01032,Probenecid
,4029016,renal clearance of the unbound drug,"The renal clearance of the total drug increased from 29.0 ml/min (low dose) to 50.5 ml/min (high dose) [p less than 0.001], but after correction for protein binding the renal clearance of the unbound drug only increased from 169.1 to 197.0 ml/min (not statistically significant).",Renal clearance of temocillin in volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],197.0,220280,DB01032,Probenecid
,4029016,renal clearance,Blocking of tubular excretion by probenecid caused a maximum decrease of the renal clearance of temocillin from 34.1 to 22.4 ml/min.,Renal clearance of temocillin in volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],34.1,220281,DB01032,Probenecid
,4029016,renal clearance,Blocking of tubular excretion by probenecid caused a maximum decrease of the renal clearance of temocillin from 34.1 to 22.4 ml/min.,Renal clearance of temocillin in volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],22.4,220282,DB01032,Probenecid
,4029016,maximum effect,This maximum effect of 12.3 ml/min subsided by 1.7 ml/min/h.,Renal clearance of temocillin in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],12.3,220283,DB01032,Probenecid
,4029016,maximum effect,This maximum effect of 12.3 ml/min subsided by 1.7 ml/min/h.,Renal clearance of temocillin in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [h·min],1.7,220284,DB01032,Probenecid
,4029016,renal clearance,"The renal clearance of the free drug decreased to 134.6 ml/min, slightly less than the creatinine clearance (158.1 ml/min).",Renal clearance of temocillin in volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029016/),[ml] / [min],134.6,220285,DB01032,Probenecid
,16756973,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03+/-0.02l/h) than in normal control (0.09+/-0.05l/h), in normal probenecid (0.10+/-0.07l/h) and in TR- control rats (0.13+/-0.07l/h).",Tubular transporters and clearance of adefovir. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16756973/),[l] / [h],0.03,221124,DB01032,Probenecid
,16756973,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03+/-0.02l/h) than in normal control (0.09+/-0.05l/h), in normal probenecid (0.10+/-0.07l/h) and in TR- control rats (0.13+/-0.07l/h).",Tubular transporters and clearance of adefovir. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16756973/),[l] / [h],0.09,221125,DB01032,Probenecid
,16756973,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03+/-0.02l/h) than in normal control (0.09+/-0.05l/h), in normal probenecid (0.10+/-0.07l/h) and in TR- control rats (0.13+/-0.07l/h).",Tubular transporters and clearance of adefovir. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16756973/),[l] / [h],0.10,221126,DB01032,Probenecid
,16756973,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03+/-0.02l/h) than in normal control (0.09+/-0.05l/h), in normal probenecid (0.10+/-0.07l/h) and in TR- control rats (0.13+/-0.07l/h).",Tubular transporters and clearance of adefovir. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16756973/),[l] / [h],0.13,221127,DB01032,Probenecid
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.10,221673,DB01032,Probenecid
,2900730,CLR/fu.,"The CLR/fu.GFR, where fu is the unbound fraction, became 1.10 +/- 0.09 and 1.25 +/- 0.25, respectively.",Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900730/),,1.25,221674,DB01032,Probenecid
,650006,peak concentration,"The mean peak concentration in serum after intramuscular (im) injection of 1 g of cefamandole was 20 microgram/ml at 0.5 hr, whereas the level at 6 hr was 1 microgram/ml.",Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[μg] / [ml],20,223075,DB01032,Probenecid
,650006,peak concentration,"The mean peak concentration in serum after intramuscular (im) injection of 1 g of cefamandole was 20 microgram/ml at 0.5 hr, whereas the level at 6 hr was 1 microgram/ml.",Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[μg] / [ml],1,223076,DB01032,Probenecid
,650006,half-life (t1/2),The half-life (t1/2) of cefamandole after im injection ranged from 1 to 1.5 hr and from 0.45 to 1.2 hr after iv injection.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),h,1 to 1.5,223077,DB01032,Probenecid
,650006,half-life (t1/2),The half-life (t1/2) of cefamandole after im injection ranged from 1 to 1.5 hr and from 0.45 to 1.2 hr after iv injection.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),h,0.45 to 1.2,223078,DB01032,Probenecid
,650006,Rates of serum,Rates of serum and renal clearance of cefamandole ranged from 210 to 300 microliter/min per 1.73 m2.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[μl] / [1.73·m2·min],210 to 300,223079,DB01032,Probenecid
,650006,apparent volume of distribution,The apparent volume of distribution ranged from 12.4 to 17.9 liters/1.73 m2.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[l] / [1.73·m2],12.4 to 17.9,223080,DB01032,Probenecid
,16895698,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03 +/- 0.02 l/hour) than in normal control (0.09 +/- 0.05 l/hour), in normal probenecid (0.10 +/- 0.07 l/hour) and in TR- control rats (0.13 +/- 0.07 l/hour).",[Tubular transporters OAT1 and MRP2 and clearance of adefovir]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895698/),[l] / [h],0.03,223768,DB01032,Probenecid
,16895698,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03 +/- 0.02 l/hour) than in normal control (0.09 +/- 0.05 l/hour), in normal probenecid (0.10 +/- 0.07 l/hour) and in TR- control rats (0.13 +/- 0.07 l/hour).",[Tubular transporters OAT1 and MRP2 and clearance of adefovir]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895698/),[l] / [h],0.09,223769,DB01032,Probenecid
,16895698,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03 +/- 0.02 l/hour) than in normal control (0.09 +/- 0.05 l/hour), in normal probenecid (0.10 +/- 0.07 l/hour) and in TR- control rats (0.13 +/- 0.07 l/hour).",[Tubular transporters OAT1 and MRP2 and clearance of adefovir]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895698/),[l] / [h],0.10,223770,DB01032,Probenecid
,16895698,Renal clearance,"Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03 +/- 0.02 l/hour) than in normal control (0.09 +/- 0.05 l/hour), in normal probenecid (0.10 +/- 0.07 l/hour) and in TR- control rats (0.13 +/- 0.07 l/hour).",[Tubular transporters OAT1 and MRP2 and clearance of adefovir]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16895698/),[l] / [h],0.13,223771,DB01032,Probenecid
≤,34081957,MIC,"As an example, the PTA of total concentrations above the minimum inhibitory concentration required to inhibit methicillin-susceptible Staphylococcus aureus isolates (MIC ≤ 8 mg/L) for 70% of a 6 h dose interval approached 100% for cephalexin + probenecid while for cephalexin alone it was <15%.",Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34081957/),[mg] / [l],8,224885,DB01032,Probenecid
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],1253.9,227490,DB01032,Probenecid
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],1020.7,227491,DB01032,Probenecid
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],137.6,227492,DB01032,Probenecid
,15915352,area under the plasma concentration-time curve (AUC),Probenecid decreased the area under the plasma concentration-time curve (AUC) of CBZ from 1253.9 micromol h/l to 1020.7 micromol h/l (P < 0.001) while increasing that of CBZ-E from 137.6 micromol h/l to 183.5 micromol h/l (P = 0.033).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),[h·μM] / [l],183.5,227493,DB01032,Probenecid
,15915352,AUC ratio,Probenecid increased the AUC ratio of CBZ-E/CBZ from 0.11 to 0.16 (P < 0.001).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),,0.11,227494,DB01032,Probenecid
,15915352,AUC ratio,Probenecid increased the AUC ratio of CBZ-E/CBZ from 0.11 to 0.16 (P < 0.001).,Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915352/),,0.16,227495,DB01032,Probenecid
≤,24214317,plasma unbound inhibition constant,"We demonstrated the practical use of PBPK models to: (1) define transporter-mediated renal secretion, using plasma and urine data; (2) inform a change in the system-dependent parameter (≥10-fold reduction in the functional 'proximal tubule cells per gram kidney') in severe renal impairment that is responsible for the decreased secretory transport activities of test drugs; (3) derive an in vivo, plasma unbound inhibition constant of T up,b by probenecid (≤1 μM), based on observed drug interaction data; and (4) suggest a plausible mechanism of probenecid preferentially inhibiting T up,b in order to alleviate cidofovir-induced nephrotoxicity.","Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24214317/),μM,1,228531,DB01032,Probenecid
,28749581,IC50,Physiologically based pharmacokinetic (PBPK) modeling reproduced the renal clearance of baricitinib and the inhibitory effect of probenecid using the in vitro IC50 value of 4.4 μM.,Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,4.4,231753,DB01032,Probenecid
,28749581,IC50,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,4.4,231754,DB01032,Probenecid
,28749581,IC50,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),μM,3.8,231755,DB01032,Probenecid
,28749581,AUC(0-∞) ratios,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),,1.2,231756,DB01032,Probenecid
,28749581,AUC(0-∞) ratios,"Using ibuprofen and diclofenac in vitro IC50 values of 4.4 and 3.8 μM toward OAT3, 1.2 and 1.0 AUC(0-∞) ratios of baricitinib were predicted.",Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28749581/),,1.0,231757,DB01032,Probenecid
,7602486,Absorption ratios,"Absorption ratios of phenol red in 6 h were determined to be 91.1, 91.8 and 89.9% at a dose of 0.3, 1 and 3 mg, respectively.",Mechanism for drug absorption from rat-liver surface membrane: effect of dose and transport inhibitors on the pharmacokinetics of phenol red. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602486/),%,91.1,233671,DB01032,Probenecid
,7602486,Absorption ratios,"Absorption ratios of phenol red in 6 h were determined to be 91.1, 91.8 and 89.9% at a dose of 0.3, 1 and 3 mg, respectively.",Mechanism for drug absorption from rat-liver surface membrane: effect of dose and transport inhibitors on the pharmacokinetics of phenol red. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602486/),%,91.8,233672,DB01032,Probenecid
,7602486,Absorption ratios,"Absorption ratios of phenol red in 6 h were determined to be 91.1, 91.8 and 89.9% at a dose of 0.3, 1 and 3 mg, respectively.",Mechanism for drug absorption from rat-liver surface membrane: effect of dose and transport inhibitors on the pharmacokinetics of phenol red. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602486/),%,89.9,233673,DB01032,Probenecid
,7602486,rate constant Ka,"The time course of the remaining amount of phenol red in the glass cell obeyed first-order kinetics at a dose of 0.3 mg, and its rate constant Ka was calculated to be 0.0069 min-1.",Mechanism for drug absorption from rat-liver surface membrane: effect of dose and transport inhibitors on the pharmacokinetics of phenol red. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602486/),1/[min],0.0069,233674,DB01032,Probenecid
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],0.873,233694,DB01032,Probenecid
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],1.71,233695,DB01032,Probenecid
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],3.35,233696,DB01032,Probenecid
,8592993,peak concentrations,"In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),[μg] / [ml],5.41,233697,DB01032,Probenecid
,8592993,elimination half-life,"The elimination half-life was 7 to 8 h, independently of the doses.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),h,7 to 8,233698,DB01032,Probenecid
,8592993,fecal recovery,The fecal recovery of the unchanged drug amounted to 5.7% for 72 h after a single oral administration of a 400-mg dose.,"Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),%,5.7,233699,DB01032,Probenecid
,8592993,serum protein binding,"The serum protein binding was 20%, independently of the concentrations in serum.","Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592993/),%,20,233700,DB01032,Probenecid
,2799072,terminal halflife,The terminal halflife of cefoperazone was 127.9 +/- 28.2 min (mean +/- SD) after intravenous and 136.9 +/- 19.6 min after intramuscular administration.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),min,127.9,236899,DB01032,Probenecid
,2799072,terminal halflife,The terminal halflife of cefoperazone was 127.9 +/- 28.2 min (mean +/- SD) after intravenous and 136.9 +/- 19.6 min after intramuscular administration.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),min,136.9,236900,DB01032,Probenecid
,2799072,t1/2,The t1/2 was increased to 257.3 +/- 127.3 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),min,257.3,236901,DB01032,Probenecid
,2799072,total body clearance,The total body clearance was 8.16 +/- 1.60 ml min-1 kg-1 and the volume of distribution at steady state was 0.713 +/- 0.167 litre kg-1.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),[ml] / [kg·min],8.16,236902,DB01032,Probenecid
,2799072,volume of distribution at steady state,The total body clearance was 8.16 +/- 1.60 ml min-1 kg-1 and the volume of distribution at steady state was 0.713 +/- 0.167 litre kg-1.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),[l] / [kg],0.713,236903,DB01032,Probenecid
,2799072,mean residence time,The mean residence time values were 87.2 +/- 10.6 min after intravenous and 140.3 +/- 20.6 min after intramuscular injection and were increased to 264.5 +/- 99.8 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),min,87.2,236904,DB01032,Probenecid
,2799072,mean residence time,The mean residence time values were 87.2 +/- 10.6 min after intravenous and 140.3 +/- 20.6 min after intramuscular injection and were increased to 264.5 +/- 99.8 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),min,140.3,236905,DB01032,Probenecid
,2799072,mean residence time,The mean residence time values were 87.2 +/- 10.6 min after intravenous and 140.3 +/- 20.6 min after intramuscular injection and were increased to 264.5 +/- 99.8 min by the co-administration of probenecid.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),min,264.5,236906,DB01032,Probenecid
,2799072,mean absorption time,The estimated mean absorption time was 53.1 min and the estimated bioavailability after intramuscular administration was 76.3 per cent.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),min,53.1,236907,DB01032,Probenecid
,2799072,bioavailability,The estimated mean absorption time was 53.1 min and the estimated bioavailability after intramuscular administration was 76.3 per cent.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),%,76.3,236908,DB01032,Probenecid
,2799072,minimal inhibitory concentration (MIC90),"The minimal inhibitory concentration (MIC90) values of cefoperazone ranged from 0.5 to 2 micrograms ml-1 for Escherichia coli, salmonella groups C, D and E and Pasteurella multocida isolates.",Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),[μg] / [ml],0.5 to 2,236909,DB01032,Probenecid
greater,2799072,MIC90,Salmonella group B strains appeared to be highly resistant to cefoperazone with MIC90 greater than 32 micrograms ml-1.,Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2799072/),[μg] / [ml],32,236910,DB01032,Probenecid
,24091240,excretions,"The excretions of madecassoside in bile, urine and feces were 7.16% (0-12 h), 0.25% (0-72 h) and 24.68% (0-72 h), respectively.","In vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) Urb. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091240/),%,7.16,237202,DB01032,Probenecid
,24091240,excretions,"The excretions of madecassoside in bile, urine and feces were 7.16% (0-12 h), 0.25% (0-72 h) and 24.68% (0-72 h), respectively.","In vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) Urb. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091240/),%,0.25,237203,DB01032,Probenecid
,24091240,excretions,"The excretions of madecassoside in bile, urine and feces were 7.16% (0-12 h), 0.25% (0-72 h) and 24.68% (0-72 h), respectively.","In vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) Urb. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091240/),%,24.68,237204,DB01032,Probenecid
,7140806,renal clearance,"From the data it was possible to calculate the renal clearance of the penicillin, a mean value of 104 ml/min was observed in the 3 volunteers.",Pharmacokinetics of ticarcillin in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140806/),[ml] / [min],104,238535,DB01032,Probenecid
,7140806,half-life,"Furthermore, the mean half-life of ticarcillin in the serum of the three volunteers was significantly increased from 1.3 h to 2.1 h by predosing with probenecid.",Pharmacokinetics of ticarcillin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140806/),h,1.3,238536,DB01032,Probenecid
,7140806,half-life,"Furthermore, the mean half-life of ticarcillin in the serum of the three volunteers was significantly increased from 1.3 h to 2.1 h by predosing with probenecid.",Pharmacokinetics of ticarcillin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140806/),h,2.1,238537,DB01032,Probenecid
,25264913,flow rate of the mobile phase,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),[μl] / [min],250,239506,DB01032,Probenecid
,25264913,retention times,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),min,1.1,239507,DB01032,Probenecid
,25264913,retention times,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),min,0.8,239508,DB01032,Probenecid
,25264913,retention times,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),min,0.9,239509,DB01032,Probenecid
,6654640,half-life,"The half-life values in the vitreous humor were: carbenicillin 10 hours, cefazolin 7 hours, and gentamicin 33 hours.","Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,10,240229,DB01032,Probenecid
,6654640,half-life,"The half-life values in the vitreous humor were: carbenicillin 10 hours, cefazolin 7 hours, and gentamicin 33 hours.","Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,7,240230,DB01032,Probenecid
,6654640,half-life,"The half-life values in the vitreous humor were: carbenicillin 10 hours, cefazolin 7 hours, and gentamicin 33 hours.","Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,33,240231,DB01032,Probenecid
,6654640,half-life,Concomitant intraperitoneal administration of probenecid prolonged the vitreal half-life of carbenicillin to 20 hours and of cefazolin to 30 hours.,"Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,20,240232,DB01032,Probenecid
,6654640,half-life,Concomitant intraperitoneal administration of probenecid prolonged the vitreal half-life of carbenicillin to 20 hours and of cefazolin to 30 hours.,"Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,30,240233,DB01032,Probenecid
,3125788,elimination half-life,"Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg).","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),h,9 to 10,242057,DB01032,Probenecid
,3125788,maximum concentration,"Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg).","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[μg] / [ml],2.3,242058,DB01032,Probenecid
exceeds,3125788,volume of distribution,The volume of distribution clearly exceeds 1 liter/kg and suggests a good tissue penetration.,"Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[l] / [kg],1,242059,DB01032,Probenecid
,3125788,renal clearance of unbound drug,"The renal clearance of unbound drug was 137 ml/min, and probenecid had no significant effect on renal elimination.","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),[ml] / [min],137,242060,DB01032,Probenecid
,3125788,absolute bioavailability,The absolute bioavailability of the administered tablet was practically 100%.,"Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125788/),%,100,242061,DB01032,Probenecid
,6668557,total body clearance,"Mean total body clearance (from 34.3 to 13.1 ml/min) and mean renal clearance (from 25.6 to 7.6 ml/min) of MTX were found to decrease with increasing steady-state plasma concentrations (from 5.1 to 412 micrograms/ml), whereas nonrenal clearances remained relatively constant.",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[ml] / [min],34.3 to 13.1,242530,DB01032,Probenecid
,6668557,renal clearance,"Mean total body clearance (from 34.3 to 13.1 ml/min) and mean renal clearance (from 25.6 to 7.6 ml/min) of MTX were found to decrease with increasing steady-state plasma concentrations (from 5.1 to 412 micrograms/ml), whereas nonrenal clearances remained relatively constant.",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[ml] / [min],25.6 to 7.6,242531,DB01032,Probenecid
,6668557,steady-state plasma concentrations,"Mean total body clearance (from 34.3 to 13.1 ml/min) and mean renal clearance (from 25.6 to 7.6 ml/min) of MTX were found to decrease with increasing steady-state plasma concentrations (from 5.1 to 412 micrograms/ml), whereas nonrenal clearances remained relatively constant.",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[μg] / [ml],5.1 to 412,242532,DB01032,Probenecid
,6668557,renal clearance,"An essentially steady-state plasma level of 7-OH-MTX was achieved during each MTX infusion, and its renal clearance also decreased (from 37.3 to 6.5 ml/min) with increasing metabolite levels (from 1.8 to 293 micrograms/ml).",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[ml] / [min],37.3 to 6.5,242533,DB01032,Probenecid
,6668557,Plasma protein binding,Plasma protein binding of MTX (56%) and 7-OH-MTX (49%) were independent of concentrations between 0.1 and 300 micrograms/ml.,Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),%,56,242534,DB01032,Probenecid
,6668557,Plasma protein binding,Plasma protein binding of MTX (56%) and 7-OH-MTX (49%) were independent of concentrations between 0.1 and 300 micrograms/ml.,Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),%,49,242535,DB01032,Probenecid
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,96,245576,DB01032,Probenecid
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,95,245577,DB01032,Probenecid
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,65,245578,DB01032,Probenecid
,11695851,CLrf/GFR,The CLrf/GFR for MTX was approximately 2.5 but did not differ significantly between the male and female.,Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),,2.5,245579,DB01032,Probenecid
,1437517,t1/2,"When in one volunteer the dose is increased from 250 to 1,500 mg orally, the t1/2 increased from 3 to 6 h.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),h,3,245809,DB01032,Probenecid
,1437517,t1/2,"When in one volunteer the dose is increased from 250 to 1,500 mg orally, the t1/2 increased from 3 to 6 h.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),h,6,245810,DB01032,Probenecid
,1437517,Cmax,"The Cmax was 14 micrograms/ml with a dosage of 250 mg, 31 micrograms/ml with 500 mg, 70 micrograms/ml with 1,000 mg and 120 micrograms/ml with 1,500 mg.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[μg] / [ml],14,245811,DB01032,Probenecid
,1437517,Cmax,"The Cmax was 14 micrograms/ml with a dosage of 250 mg, 31 micrograms/ml with 500 mg, 70 micrograms/ml with 1,000 mg and 120 micrograms/ml with 1,500 mg.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[μg] / [ml],31,245812,DB01032,Probenecid
,1437517,Cmax,"The Cmax was 14 micrograms/ml with a dosage of 250 mg, 31 micrograms/ml with 500 mg, 70 micrograms/ml with 1,000 mg and 120 micrograms/ml with 1,500 mg.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[μg] / [ml],70,245813,DB01032,Probenecid
,1437517,Cmax,"The Cmax was 14 micrograms/ml with a dosage of 250 mg, 31 micrograms/ml with 500 mg, 70 micrograms/ml with 1,000 mg and 120 micrograms/ml with 1,500 mg.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[μg] / [ml],120,245814,DB01032,Probenecid
,1437517,tmax,The tmax remained 1 h for all four dosages.,Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),h,1,245815,DB01032,Probenecid
,1437517,total body clearance,"The total body clearance declined from 64.5 ml/min for 250 mg to 26.0 ml/min for 1,500 mg.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[ml] / [min],64.5,245816,DB01032,Probenecid
,1437517,total body clearance,"The total body clearance declined from 64.5 ml/min for 250 mg to 26.0 ml/min for 1,500 mg.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[ml] / [min],26.0,245817,DB01032,Probenecid
,1437517,renal clearance,"The renal clearance of probenecid remained constant, 0.6-0.8 ml/min.",Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[ml] / [min],0.6-0.8,245818,DB01032,Probenecid
,1437517,Protein binding,Protein binding of probenecid is high (91%) and independent of the dose.,Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),%,91,245819,DB01032,Probenecid
,1437517,protein binding,The phase I metabolites show lower protein binding values (34-59%).,Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),%,34-59,245820,DB01032,Probenecid
,1437517,protein binding,The protein binding of probenecid glucuronide in vitro (spiked plasma) is 75%.,Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),%,75,245821,DB01032,Probenecid
,1437517,renal excretion rate--time,The renal excretion rate--time profile of probenecid glucuronide shows a plateau value of approximately 700 micrograms/min (46 mg/h) with acidic urine pH.,Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437517/),[μg] / [min],700,245822,DB01032,Probenecid
,4030549,elimination of half-life (T 1/2 beta),"Following both routes of drug administration, the elimination of half-life (T 1/2 beta) was 7 min in rats and 25-32 min in dogs.",Pharmacokinetics of Sch 34343 in rats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030549/),min,7,246851,DB01032,Probenecid
,4030549,elimination of half-life (T 1/2 beta),"Following both routes of drug administration, the elimination of half-life (T 1/2 beta) was 7 min in rats and 25-32 min in dogs.",Pharmacokinetics of Sch 34343 in rats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030549/),min,25-32,246852,DB01032,Probenecid
,4030549,urinary excretion,"After either route of dosing, urinary excretion of total radioactivity ranged from 84 to 93% and that of intact Sch 34343 from 41 to 51% of the dose, respectively.",Pharmacokinetics of Sch 34343 in rats and dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030549/),%,84 to 93,246853,DB01032,Probenecid
,4030549,urinary excretion,"After either route of dosing, urinary excretion of total radioactivity ranged from 84 to 93% and that of intact Sch 34343 from 41 to 51% of the dose, respectively.",Pharmacokinetics of Sch 34343 in rats and dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030549/),%,41,246854,DB01032,Probenecid
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],2.8,246855,DB01032,Probenecid
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],3.5,246856,DB01032,Probenecid
,21864246,renal clearance,The complex showed renal clearance of 71.0� 5.9% ID at 10 min.,Preparation of 99mTc(CO)3-Carboxymethylthioethyl iminodiacetic acid and evaluation as a potential renal imaging agent. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21864246/),,71.0,246968,DB01032,Probenecid
,23318470,Oral bioavailability,Oral bioavailability of each compound ranged from 6% (C-DIM8) to 42% (C-DIM12).,Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318470/),%,6,250570,DB01032,Probenecid
,23318470,Oral bioavailability,Oral bioavailability of each compound ranged from 6% (C-DIM8) to 42% (C-DIM12).,Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318470/),%,42,250571,DB01032,Probenecid
,2679252,terminal half-life,"The mean (+/- SD) terminal half-life was 138.7 +/- 23.6 minutes and 126.3 +/- 10.5 minutes after IV and IM administrations, respectively.",Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),min,138.7,251689,DB01032,Probenecid
,2679252,terminal half-life,"The mean (+/- SD) terminal half-life was 138.7 +/- 23.6 minutes and 126.3 +/- 10.5 minutes after IV and IM administrations, respectively.",Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),min,126.3,251690,DB01032,Probenecid
,2679252,mean residence time,"The mean residence time was 167.3 +/- 21.1 minutes and 201.4 +/- 16.8 minutes after IV and IM administrations, respectively.",Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),min,167.3,251691,DB01032,Probenecid
,2679252,mean residence time,"The mean residence time was 167.3 +/- 21.1 minutes and 201.4 +/- 16.8 minutes after IV and IM administrations, respectively.",Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),min,201.4,251692,DB01032,Probenecid
,2679252,total body clearance,"The total body clearance was 1.75 +/- 0.26 ml/min/kg, and the volume of distribution at steady state was 0.294 +/- 0.064 L/kg.",Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),[ml] / [kg·min],1.75,251693,DB01032,Probenecid
,2679252,volume of distribution at steady state,"The total body clearance was 1.75 +/- 0.26 ml/min/kg, and the volume of distribution at steady state was 0.294 +/- 0.064 L/kg.",Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),[l] / [kg],0.294,251694,DB01032,Probenecid
,2679252,mean absorption time,The estimated mean absorption time was 34.1 minutes.,Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),min,34.1,251695,DB01032,Probenecid
less,2679252,90% minimal inhibitory concentration,"The 90% minimal inhibitory concentration values of ceftazidime determined for Escherichia coli, Salmonella spp, Pasteurella multocida, and P haemolytica isolates ranged from less than 0.01 to 0.1 micrograms/ml.",Pharmacokinetics of ceftazidime given alone and combination with probenecid to unweaned calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2679252/),[μg] / [ml],0,251696,DB01032,Probenecid
,1907783,half-life of elimination (T 1/2 beta),"Pharmacokinetic values after intravenous administration were: half-life of elimination (T 1/2 beta) = 0.90 +/- 0.09 h; volume of distribution at steady state (Vdss) = 456.8 +/- 106.6 ml/kg, total body clearance (CIB) = 614.5 +/- 81.2 ml/h/kg.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),h,0.90,251851,DB01032,Probenecid
,1907783,volume of distribution at steady state (Vdss),"Pharmacokinetic values after intravenous administration were: half-life of elimination (T 1/2 beta) = 0.90 +/- 0.09 h; volume of distribution at steady state (Vdss) = 456.8 +/- 106.6 ml/kg, total body clearance (CIB) = 614.5 +/- 81.2 ml/h/kg.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),[ml] / [kg],456.8,251852,DB01032,Probenecid
,1907783,total body clearance (CIB),"Pharmacokinetic values after intravenous administration were: half-life of elimination (T 1/2 beta) = 0.90 +/- 0.09 h; volume of distribution at steady state (Vdss) = 456.8 +/- 106.6 ml/kg, total body clearance (CIB) = 614.5 +/- 81.2 ml/h/kg.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),[ml] / [h·kg],614.5,251853,DB01032,Probenecid
,1907783,half-life of absorption (T 1/2 ab),Pharmacokinetic and bioavailability values after intramuscular administration were: half-life of absorption (T 1/2 ab) = 8.08 +/- 1.98 min; T 1/2 beta = 0.96 +/- 0.07 h.,Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),min,8.08,251854,DB01032,Probenecid
,1907783,T 1/2 beta,Pharmacokinetic and bioavailability values after intramuscular administration were: half-life of absorption (T 1/2 ab) = 8.08 +/- 1.98 min; T 1/2 beta = 0.96 +/- 0.07 h.,Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),h,0.96,251855,DB01032,Probenecid
,1907783,Peak serum concentration (Cmax),"Peak serum concentration (Cmax) was 31.11 +/- 6.02 micrograms/ml at 0.50 h (Tmax), bioavailability (F) was 0.82 +/- 0.09.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),[μg] / [ml],31.11,251856,DB01032,Probenecid
,1907783,bioavailability (F),"Peak serum concentration (Cmax) was 31.11 +/- 6.02 micrograms/ml at 0.50 h (Tmax), bioavailability (F) was 0.82 +/- 0.09.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),,0.82,251857,DB01032,Probenecid
,1907783,T 1/2 ab,"After ticarcillin was administered IM together with probenecid the T 1/2 ab was 33.9 +/- 13.7 min, the T 1/2 beta 2.66 +/- 0.65 h, Cmax = 44.87 +/- 5.58 at 1.33 +/- 0.44 h, and F = 1.25 +/- 0.23.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),min,33.9,251858,DB01032,Probenecid
,1907783,T 1/2 beta,"After ticarcillin was administered IM together with probenecid the T 1/2 ab was 33.9 +/- 13.7 min, the T 1/2 beta 2.66 +/- 0.65 h, Cmax = 44.87 +/- 5.58 at 1.33 +/- 0.44 h, and F = 1.25 +/- 0.23.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),h,2.66,251859,DB01032,Probenecid
,1907783,Cmax,"After ticarcillin was administered IM together with probenecid the T 1/2 ab was 33.9 +/- 13.7 min, the T 1/2 beta 2.66 +/- 0.65 h, Cmax = 44.87 +/- 5.58 at 1.33 +/- 0.44 h, and F = 1.25 +/- 0.23.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),,44.87,251860,DB01032,Probenecid
,1907783,F,"After ticarcillin was administered IM together with probenecid the T 1/2 ab was 33.9 +/- 13.7 min, the T 1/2 beta 2.66 +/- 0.65 h, Cmax = 44.87 +/- 5.58 at 1.33 +/- 0.44 h, and F = 1.25 +/- 0.23.",Pharmacokinetics of ticarcillin and ticarcillin-probenecid in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1907783/),,1.25,251861,DB01032,Probenecid
,581360,second phase half-disappearance time,Probenecid pretreatment of the animals prolonged the second phase half-disappearance time of MTX from 5.20 +/- 0.89 to 7.086 +/- 0.23 hours (mean +/- SD).,Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,5.20,251913,DB01032,Probenecid
,581360,second phase half-disappearance time,Probenecid pretreatment of the animals prolonged the second phase half-disappearance time of MTX from 5.20 +/- 0.89 to 7.086 +/- 0.23 hours (mean +/- SD).,Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,7.086,251914,DB01032,Probenecid
,581360,half-disappearance times,"Also, the rate of decline of plasma MTX concentrations was slower after treatment with probenecid, with mean half-disappearance times of 7.60 +/- 0.77 and 11.32 +/- 1.08 hours.",Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,7.60,251915,DB01032,Probenecid
,581360,half-disappearance times,"Also, the rate of decline of plasma MTX concentrations was slower after treatment with probenecid, with mean half-disappearance times of 7.60 +/- 0.77 and 11.32 +/- 1.08 hours.",Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,11.32,251916,DB01032,Probenecid
,466384,peak plasma levels,"In a study of eight, healthy adult volunteers given 3 g amoxycillin with or without 1g probenecid, significantly higher peak plasma levels of amoxycilin were recorded in the presence (34.96 microgram/ml) of probenecid than in its absence (22.72 microgram/ml).",Clinical pharmacological studies of amoxycillin: effect of probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/466384/),[μg] / [ml],34.96,252121,DB01032,Probenecid
,466384,peak plasma levels,"In a study of eight, healthy adult volunteers given 3 g amoxycillin with or without 1g probenecid, significantly higher peak plasma levels of amoxycilin were recorded in the presence (34.96 microgram/ml) of probenecid than in its absence (22.72 microgram/ml).",Clinical pharmacological studies of amoxycillin: effect of probenecid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/466384/),[μg] / [ml],22.72,252122,DB01032,Probenecid
,18267365,t(1/2)alpha,"The pharmacokinetic profiles of both MHD and DMD in rats after intravenous doses were linear and best fitted to a two compartment model, characterized with a rapid distribution phase (MHD: t(1/2)alpha, 0.09-0.14 h; DMD: t 1/2 alpha, 0.07-0.11h) and a relatively slow elimination phase (MHD: t 1/2 beta, 2.03-3.20 h; DMD: t 1/2 beta, 2.51-3.20 h).","Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18267365/),h,0.09-0.14,253415,DB01032,Probenecid
,18267365,t 1/2 alpha,"The pharmacokinetic profiles of both MHD and DMD in rats after intravenous doses were linear and best fitted to a two compartment model, characterized with a rapid distribution phase (MHD: t(1/2)alpha, 0.09-0.14 h; DMD: t 1/2 alpha, 0.07-0.11h) and a relatively slow elimination phase (MHD: t 1/2 beta, 2.03-3.20 h; DMD: t 1/2 beta, 2.51-3.20 h).","Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18267365/),h,0.07-0.11,253416,DB01032,Probenecid
,18267365,t 1/2 beta,"The pharmacokinetic profiles of both MHD and DMD in rats after intravenous doses were linear and best fitted to a two compartment model, characterized with a rapid distribution phase (MHD: t(1/2)alpha, 0.09-0.14 h; DMD: t 1/2 alpha, 0.07-0.11h) and a relatively slow elimination phase (MHD: t 1/2 beta, 2.03-3.20 h; DMD: t 1/2 beta, 2.51-3.20 h).","Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18267365/),h,2.03-3.20,253417,DB01032,Probenecid
,18267365,t 1/2 beta,"The pharmacokinetic profiles of both MHD and DMD in rats after intravenous doses were linear and best fitted to a two compartment model, characterized with a rapid distribution phase (MHD: t(1/2)alpha, 0.09-0.14 h; DMD: t 1/2 alpha, 0.07-0.11h) and a relatively slow elimination phase (MHD: t 1/2 beta, 2.03-3.20 h; DMD: t 1/2 beta, 2.51-3.20 h).","Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18267365/),h,2.51-3.20,253418,DB01032,Probenecid
,18267365,distribution volume,The tissue distributions of MHD and DMD in rats were rather limited as evidenced from their low distribution volume (0.75-1.70 L/kg) and the results of tissue distribution study.,"Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18267365/),[l] / [kg],0.75-1.70,253419,DB01032,Probenecid
,18267365,Protein binding,"Protein binding of MHD and DMD were moderate (65.36-89.99% for MHD; 45.43-76.23% for DMD), independent of drug concentrations and similar between human and rat plasma over a concentration range of 0.50-50.0 microg/mL.","Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18267365/),%,65.36-89.99,253420,DB01032,Probenecid
,18267365,Protein binding,"Protein binding of MHD and DMD were moderate (65.36-89.99% for MHD; 45.43-76.23% for DMD), independent of drug concentrations and similar between human and rat plasma over a concentration range of 0.50-50.0 microg/mL.","Pharmacokinetics, tissue distribution and excretion of a new photodynamic drug deuxemether. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18267365/),%,45.43-76.23,253421,DB01032,Probenecid
,1487562,maximum peak plasma concentration (Cmax),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[μg] / [ml],14.0,253528,DB01032,Probenecid
,1487562,time to reach Cmax (tmax),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,1.5,253529,DB01032,Probenecid
,1487562,half-life (t1/2),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,1.24,253530,DB01032,Probenecid
,1487562,area under the concentration (AUC0-infinity),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[h·μg] / [ml],47.3,253531,DB01032,Probenecid
,1487562,mean residence time after oral administration (MRTpo),"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),h,2.9,253532,DB01032,Probenecid
,1487562,CLR,"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),[ml] / [min],219,253533,DB01032,Probenecid
,1487562,percent cumulative urinary excretion in 0-24 hours,"The pharmacokinetics of the cis isomer under the fasting condition were as follows: maximum peak plasma concentration (Cmax), 14.0 +/- 2.7 micrograms/mL; median time to reach Cmax (tmax), 1.5 (range, 1.0-3.5) hours; half-life (t1/2), 1.24 +/- 0.27 hours; area under the concentration (AUC0-infinity), 47.3 +/- 7.7 micrograms.hour/mL; mean residence time after oral administration (MRTpo), 2.9 +/- 0.4 hours; CLR, 219 +/- 60 mL/minute; and Xu% (percent cumulative urinary excretion in 0-24 hours), 68.1 +/- 12.5.(ABSTRACT TRUNCATED AT 250 WORDS)","Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487562/),,68.1,253534,DB01032,Probenecid
,1413433,maximum concentration (Cmax),The plasma concentration of probenecid reached a mean (+/- se) maximum concentration (Cmax) of 188-6 +/- 19.3 micrograms/ml after 120.0 +/- 21.2 minutes and concentrations greater than 15 micrograms/ml were present 25 hours after it was administered.,Effect of probenecid on disposition kinetics of ampicillin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413433/),[μg] / [ml],188-6,254159,DB01032,Probenecid
,1413433,body clearance (ClB,The disposition kinetics of ampicillin were altered by the presence of probenecid and as a result the antibiotic had a slower body clearance (ClB; 109.4 +/- 6.71 ml/kg hours compared with 208.9 +/- 26.2 ml/kg hours) a longer elimination half-life (t1/2 beta 1.198 hours compared with 0.701 hours) and consequently a larger area under the plasma concentration versus time curve (AUC 92.3 +/- 5.09 mg/ml hours compared with 35.95 +/- 3.45 mg/ml hours) when compared with animals to which ampicillin was administered alone.,Effect of probenecid on disposition kinetics of ampicillin in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413433/),[ml] / [h·kg],109.4,254160,DB01032,Probenecid
,1413433,body clearance (ClB,The disposition kinetics of ampicillin were altered by the presence of probenecid and as a result the antibiotic had a slower body clearance (ClB; 109.4 +/- 6.71 ml/kg hours compared with 208.9 +/- 26.2 ml/kg hours) a longer elimination half-life (t1/2 beta 1.198 hours compared with 0.701 hours) and consequently a larger area under the plasma concentration versus time curve (AUC 92.3 +/- 5.09 mg/ml hours compared with 35.95 +/- 3.45 mg/ml hours) when compared with animals to which ampicillin was administered alone.,Effect of probenecid on disposition kinetics of ampicillin in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413433/),[ml] / [h·kg],208.9,254161,DB01032,Probenecid
,1413433,elimination half-life (t1/2 beta,The disposition kinetics of ampicillin were altered by the presence of probenecid and as a result the antibiotic had a slower body clearance (ClB; 109.4 +/- 6.71 ml/kg hours compared with 208.9 +/- 26.2 ml/kg hours) a longer elimination half-life (t1/2 beta 1.198 hours compared with 0.701 hours) and consequently a larger area under the plasma concentration versus time curve (AUC 92.3 +/- 5.09 mg/ml hours compared with 35.95 +/- 3.45 mg/ml hours) when compared with animals to which ampicillin was administered alone.,Effect of probenecid on disposition kinetics of ampicillin in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413433/),h,1.198,254162,DB01032,Probenecid
,1413433,elimination half-life (t1/2 beta,The disposition kinetics of ampicillin were altered by the presence of probenecid and as a result the antibiotic had a slower body clearance (ClB; 109.4 +/- 6.71 ml/kg hours compared with 208.9 +/- 26.2 ml/kg hours) a longer elimination half-life (t1/2 beta 1.198 hours compared with 0.701 hours) and consequently a larger area under the plasma concentration versus time curve (AUC 92.3 +/- 5.09 mg/ml hours compared with 35.95 +/- 3.45 mg/ml hours) when compared with animals to which ampicillin was administered alone.,Effect of probenecid on disposition kinetics of ampicillin in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413433/),h,0.701,254163,DB01032,Probenecid
,1413433,area under the plasma concentration versus time curve (AUC,The disposition kinetics of ampicillin were altered by the presence of probenecid and as a result the antibiotic had a slower body clearance (ClB; 109.4 +/- 6.71 ml/kg hours compared with 208.9 +/- 26.2 ml/kg hours) a longer elimination half-life (t1/2 beta 1.198 hours compared with 0.701 hours) and consequently a larger area under the plasma concentration versus time curve (AUC 92.3 +/- 5.09 mg/ml hours compared with 35.95 +/- 3.45 mg/ml hours) when compared with animals to which ampicillin was administered alone.,Effect of probenecid on disposition kinetics of ampicillin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413433/),[mg] / [h·ml],92.3,254164,DB01032,Probenecid
,1413433,area under the plasma concentration versus time curve (AUC,The disposition kinetics of ampicillin were altered by the presence of probenecid and as a result the antibiotic had a slower body clearance (ClB; 109.4 +/- 6.71 ml/kg hours compared with 208.9 +/- 26.2 ml/kg hours) a longer elimination half-life (t1/2 beta 1.198 hours compared with 0.701 hours) and consequently a larger area under the plasma concentration versus time curve (AUC 92.3 +/- 5.09 mg/ml hours compared with 35.95 +/- 3.45 mg/ml hours) when compared with animals to which ampicillin was administered alone.,Effect of probenecid on disposition kinetics of ampicillin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413433/),[mg] / [h·ml],35.95,254165,DB01032,Probenecid
>,33753216,IC50,"We observed that biapenem could not inhibit the transport activities of OAT1 or OCT2, while mildly inhibited OAT3 (IC50 >500 μM).",Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753216/),μM,500,256428,DB01032,Probenecid
,33753216,maximal unbound plasma concentration,"Among the tested antibiotics and antiviral drugs, the relatively high DDI index values (maximal unbound plasma concentration over IC50, Imax,u/IC50) were found for piperacillin, linezolid and benzylpenicillin, which were 2.84, 1.7 and 0.62, respectively.",Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753216/),,2.84,256429,DB01032,Probenecid
,33753216,Imax,"Among the tested antibiotics and antiviral drugs, the relatively high DDI index values (maximal unbound plasma concentration over IC50, Imax,u/IC50) were found for piperacillin, linezolid and benzylpenicillin, which were 2.84, 1.7 and 0.62, respectively.",Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753216/),,1.7,256430,DB01032,Probenecid
,33753216,Imax,"Among the tested antibiotics and antiviral drugs, the relatively high DDI index values (maximal unbound plasma concentration over IC50, Imax,u/IC50) were found for piperacillin, linezolid and benzylpenicillin, which were 2.84, 1.7 and 0.62, respectively.",Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753216/),,0.62,256431,DB01032,Probenecid
,33753216,u/IC50,"Among the tested antibiotics and antiviral drugs, the relatively high DDI index values (maximal unbound plasma concentration over IC50, Imax,u/IC50) were found for piperacillin, linezolid and benzylpenicillin, which were 2.84, 1.7 and 0.62, respectively.",Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753216/),,0.62,256432,DB01032,Probenecid
,33753216,DD,"Although probenecid had the highest DDI index (27.1) in vitro, no significant impact of it on the pharmacokinetics of biapenem was observed in the rats.",Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753216/),,27.1,256433,DB01032,Probenecid
,11749141,elimination half-life (t(1/2beta)),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,1.39,257768,DB01032,Probenecid
,11749141,area under the plasma concentration-time curve (AUC),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,7.82,257769,DB01032,Probenecid
,11749141,area under the plasma concentration-time curve (AUC),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,2.37,257770,DB01032,Probenecid
,11749141,volume of distribution (V(d(area))),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,7.82,257771,DB01032,Probenecid
,11749141,volume of distribution (V(d(area))),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,2.37,257772,DB01032,Probenecid
,11749141,mean residence time (MRT),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,7.82,257773,DB01032,Probenecid
,11749141,mean residence time (MRT),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,2.37,257774,DB01032,Probenecid
,11749141,total systemic clearance (Cl(B)),"The elimination half-life (t(1/2beta)), area under the plasma concentration-time curve (AUC), volume of distribution (V(d(area))), mean residence time (MRT) and total systemic clearance (Cl(B)) were 1.39 h, 7.82 microg x h x mL, 1.52 L x kg(-1), 2.37 h and 802.9 mL x h(-1) x kg(-1), respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),[ml] / [h·kg],802.9,257775,DB01032,Probenecid
,11749141,t(1/2beta),"The t(1/2beta), AUC and MRT of ciprofloxacin were 1.82 h, 2.55 microg x h x mL and 3.59 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,1.82,257776,DB01032,Probenecid
,11749141,AUC,"The t(1/2beta), AUC and MRT of ciprofloxacin were 1.82 h, 2.55 microg x h x mL and 3.59 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,2.55,257777,DB01032,Probenecid
,11749141,MRT,"The t(1/2beta), AUC and MRT of ciprofloxacin were 1.82 h, 2.55 microg x h x mL and 3.59 h, respectively.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,3.59,257778,DB01032,Probenecid
,11749141,t(1/2beta),"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,3.85,257779,DB01032,Probenecid
,11749141,AUC,"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h·ml·μg,6.29,257780,DB01032,Probenecid
,11749141,MRT,"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),h,7.34,257781,DB01032,Probenecid
,11749141,metabolite ratio,"Co-administration of probenecid did not affect the t(1/2beta), AUC, V(d (area)) and Cl(B) of enrofloxacin, whereas the values of t(1/2beta) (3.85 h), AUC (6.29 microg x h x mL), MRT (7.34 h) and metabolite ratio (0.86) of ciprofloxacin were significantly increased.",Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749141/),,0.86,257782,DB01032,Probenecid
,35605,plasma elimination half-life,Adjustment of urine pH to the alkaline range caused more than an 8-fold lowering of the plasma elimination half-life (from 7.0 to 0.8 hr) and enhanced renal clearance by a factor of 53 compared to control.,Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,7.0,258161,DB01032,Probenecid
,35605,plasma elimination half-life,Adjustment of urine pH to the alkaline range caused more than an 8-fold lowering of the plasma elimination half-life (from 7.0 to 0.8 hr) and enhanced renal clearance by a factor of 53 compared to control.,Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,0.8,258162,DB01032,Probenecid
,35605,elimination half-life,"Acidification of the urine or probenecid administration increased the elimination half-life (to 10.9 and 17.5 hr, respectively), and decreased renal and plasma clearance of zomepirac.",Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,10.9,258163,DB01032,Probenecid
,35605,elimination half-life,"Acidification of the urine or probenecid administration increased the elimination half-life (to 10.9 and 17.5 hr, respectively), and decreased renal and plasma clearance of zomepirac.",Renal handling of zomepirac sodium (McN-2783-21-98) in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/35605/),h,17.5,258164,DB01032,Probenecid
greater,3297363,volume of distribution,"Some common pharmacokinetic parameters: low protein binding (less than 50%); high volume of distribution (greater than 1.5 l/kg) with good attainable tissue concentrations in lymph, blister fluid, renal tissue, prostate, bronchial secretions, saliva, aqueous humor, CSF, bone, bile; good intracellular penetration in macrophages, polynuclear neutrophils; high peak urinary concentrations markedly exceeding the MIC for virtually all bacterial urinary tract pathogens, even accounting for the increase in MIC in the urine, especially at lower (acidic) pH; low extraction ratio dialysis; similar adverse reactions; CNS, gastro-intestinal, photosensitivity, tendo-articular and cartilage toxicity.",Comparative pharmacokinetic parameters of new systemic fluoroquinolones: a review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3297363/),[l] / [kg],1.5,258450,DB01032,Probenecid
,8786954,CLin,"The estimated values of CLin and keff were 0.00157 +/- 0.00076 ml/min/g of brain and 0.0872 +/- 0.0252 min-1, respectively.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g·min],0.00157,262741,DB01032,Probenecid
,8786954,keff,"The estimated values of CLin and keff were 0.00157 +/- 0.00076 ml/min/g of brain and 0.0872 +/- 0.0252 min-1, respectively.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),1/[min],0.0872,262742,DB01032,Probenecid
,8786954,efflux clearance (CLout),"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g],0.816,262743,DB01032,Probenecid
,8786954,efflux clearance (CLout),"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [brain·g·min],0.0712,262744,DB01032,Probenecid
,8786954,keff,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g],0.816,262745,DB01032,Probenecid
,8786954,keff,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [brain·g·min],0.0712,262746,DB01032,Probenecid
,8786954,Vd,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [g],0.816,262747,DB01032,Probenecid
,8786954,Vd,"The efflux clearance (CLout) calculated by multiplying keff by Vd (0.816 +/- 0.559 ml/g of brain) was 0.0712 +/- 0.0529 ml/min/g of brain, and it was significantly 40-fold greater than the CLin value and fully greater than the convective flow in ISF.",Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786954/),[ml] / [brain·g·min],0.0712,262748,DB01032,Probenecid
,1356724,formation clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],3.65,264096,DB01032,Probenecid
,1356724,formation clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],1.94,264097,DB01032,Probenecid
,1356724,renal clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],9.32,264098,DB01032,Probenecid
,1356724,renal clearance,Probenecid significantly decreased the formation clearance of AG from 3.65 +/- 0.434 to 1.94 +/- 0.441 ml/min/kg and the renal clearance of AS from 9.32 +/- 2.26 to 3.15 +/- 1.21 ml/min/kg.,Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356724/),[ml] / [kg·min],3.15,264099,DB01032,Probenecid
,949172,peak serum concentrations,"Mean peak serum concentrations of 14.8, 25.7, 34.6, and 40.0 mug/ml were assayed at 29 to 45 min, and measurable levels were present 8 h after the 0.5-g and higher doses.",Cefuroxime: human pharmacokinetics.. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),[μg] / [ml],14.8,264153,DB01032,Probenecid
,949172,peak serum concentrations,"Mean peak serum concentrations of 14.8, 25.7, 34.6, and 40.0 mug/ml were assayed at 29 to 45 min, and measurable levels were present 8 h after the 0.5-g and higher doses.",Cefuroxime: human pharmacokinetics.. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),[μg] / [ml],25.7,264154,DB01032,Probenecid
,949172,peak serum concentrations,"Mean peak serum concentrations of 14.8, 25.7, 34.6, and 40.0 mug/ml were assayed at 29 to 45 min, and measurable levels were present 8 h after the 0.5-g and higher doses.",Cefuroxime: human pharmacokinetics.. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),[μg] / [ml],34.6,264155,DB01032,Probenecid
,949172,peak serum concentrations,"Mean peak serum concentrations of 14.8, 25.7, 34.6, and 40.0 mug/ml were assayed at 29 to 45 min, and measurable levels were present 8 h after the 0.5-g and higher doses.",Cefuroxime: human pharmacokinetics.. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),[μg] / [ml],40.0,264156,DB01032,Probenecid
,949172,ultimate serum half-life,"The antibiotic has a mean ultimate serum half-life of 70 min, a mean serum protein binding of 33%, a metabolic stability of greater than 95%, an apparent distribution volume of 11.1 to 15.8 liters/1.73 m(2) depending on dose, and a mean urinary recovery of at least 95% for all parenteral doses.",Cefuroxime: human pharmacokinetics.. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),min,70,264157,DB01032,Probenecid
,949172,serum protein binding,"The antibiotic has a mean ultimate serum half-life of 70 min, a mean serum protein binding of 33%, a metabolic stability of greater than 95%, an apparent distribution volume of 11.1 to 15.8 liters/1.73 m(2) depending on dose, and a mean urinary recovery of at least 95% for all parenteral doses.",Cefuroxime: human pharmacokinetics.. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),%,33,264158,DB01032,Probenecid
,949172,apparent distribution volume,"The antibiotic has a mean ultimate serum half-life of 70 min, a mean serum protein binding of 33%, a metabolic stability of greater than 95%, an apparent distribution volume of 11.1 to 15.8 liters/1.73 m(2) depending on dose, and a mean urinary recovery of at least 95% for all parenteral doses.",Cefuroxime: human pharmacokinetics.. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),[1.73·l] / [m(2],11.1 to 15.8,264159,DB01032,Probenecid
,949172,urinary recovery,"The antibiotic has a mean ultimate serum half-life of 70 min, a mean serum protein binding of 33%, a metabolic stability of greater than 95%, an apparent distribution volume of 11.1 to 15.8 liters/1.73 m(2) depending on dose, and a mean urinary recovery of at least 95% for all parenteral doses.",Cefuroxime: human pharmacokinetics.. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/949172/),%,95,264160,DB01032,Probenecid
,3383987,total systemic clearance (CLTS),"Probenecid increased the total systemic clearance (CLTS) from 0.244 to 0.312 ml/min/kg, whereas the terminal half-life (t1/2T (beta)) fell from 8.1 to 6.5 h.",Effect of probenecid on the elimination and protein binding of ceftriaxone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383987/),[ml] / [kg·min],0.244 to 0.312,265065,DB01032,Probenecid
,3383987,terminal half-life (t1/2T (beta)),"Probenecid increased the total systemic clearance (CLTS) from 0.244 to 0.312 ml/min/kg, whereas the terminal half-life (t1/2T (beta)) fell from 8.1 to 6.5 h.",Effect of probenecid on the elimination and protein binding of ceftriaxone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383987/),h,8.1 to 6.5,265066,DB01032,Probenecid
,3383987,renal clearance,"In contrast, the renal clearance of free ceftriaxone (CLFR) was decreased from 2.09 to 1.67 ml/min/kg, confirming a small but significant contribution of tubular secretion to the renal elimination of ceftriaxone.",Effect of probenecid on the elimination and protein binding of ceftriaxone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383987/),[ml] / [kg·min],2.09,265067,DB01032,Probenecid
,3383987,renal clearance,"In contrast, the renal clearance of free ceftriaxone (CLFR) was decreased from 2.09 to 1.67 ml/min/kg, confirming a small but significant contribution of tubular secretion to the renal elimination of ceftriaxone.",Effect of probenecid on the elimination and protein binding of ceftriaxone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383987/),[ml] / [kg·min],1.67,265068,DB01032,Probenecid
,3383987,non-renal clearance,"The final value of CLFR was attained with the lower dose probenecid, whereas the non-renal clearance of free ceftriaxone (CLFNR) fell progressively from 2.78 to 1.90 ml/min/kg with the increasing probenecid dose.",Effect of probenecid on the elimination and protein binding of ceftriaxone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383987/),[ml] / [kg·min],2.78,265069,DB01032,Probenecid
,3383987,non-renal clearance,"The final value of CLFR was attained with the lower dose probenecid, whereas the non-renal clearance of free ceftriaxone (CLFNR) fell progressively from 2.78 to 1.90 ml/min/kg with the increasing probenecid dose.",Effect of probenecid on the elimination and protein binding of ceftriaxone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383987/),[ml] / [kg·min],1.90,265070,DB01032,Probenecid
,3383987,systemic clearance,The total decrease in the systemic clearance of free ceftriaxone (CLFS) after the higher dose of probenecid was about 30% (4.87 to 3.57 ml/min/kg).,Effect of probenecid on the elimination and protein binding of ceftriaxone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383987/),[ml] / [kg·min],4.87 to 3.57,265071,DB01032,Probenecid
,3730524,half-lives,The half-lives of sulfatroxazole and its metabolites 5-hydroxysulfatroxazole and N4-acetylsulfatroxazole are approximately 22 h after administration of sulfatroxazole.,"Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730524/),h,22,265781,DB01032,Probenecid
,3730524,initial elimination half-life,"The initial elimination half-life of N4-acetylsulfatroxazole is 4.5 h, which later increases to 70 h as the result of the acetylation-deacetylation equilibrium.","Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730524/),h,4.5,265782,DB01032,Probenecid
,3730524,initial elimination half-life,"The initial elimination half-life of N4-acetylsulfatroxazole is 4.5 h, which later increases to 70 h as the result of the acetylation-deacetylation equilibrium.","Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730524/),h,70,265783,DB01032,Probenecid
,3730524,T 1/2,"Inhibition of the N4-acetyl metabolite favours the deacetylation, which results in an increase of the T 1/2 of sulfatroxazole from 20 to 30 h.","Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730524/),h,20,265784,DB01032,Probenecid
,3730524,T 1/2,"Inhibition of the N4-acetyl metabolite favours the deacetylation, which results in an increase of the T 1/2 of sulfatroxazole from 20 to 30 h.","Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730524/),h,30,265785,DB01032,Probenecid
,3730524,protein binding,"The protein binding value of sulfatroxazole is 84 per cent, that of N4-acetylsulfatroxazole is 37 per cent.","Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730524/),%,84,265786,DB01032,Probenecid
,3730524,protein binding,"The protein binding value of sulfatroxazole is 84 per cent, that of N4-acetylsulfatroxazole is 37 per cent.","Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730524/),%,37,265787,DB01032,Probenecid
,19378467,IC50,All three drugs exhibited high affinity for hOAT3 (PF1 exhibited the lowest IC50 of 6M) but only weakly interacted with hOAT1 (with no interaction found for PF2).,Assessment of the renal toxicity of novel anti-inflammatory compounds using cynomolgus monkey and human kidney cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19378467/),M,6,266291,DB01032,Probenecid
,3108520,elimination half-life (t1/2 beta),"After i.v. injection, the drug was distributed rapidly in the body, the elimination half-life (t1/2 beta) was 34 min and the apparent volume of distribution at steady-state (Vd ss) was 0.30 l/kg.",Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),min,34,266776,DB01032,Probenecid
,3108520,apparent volume of distribution at steady-state (Vd ss),"After i.v. injection, the drug was distributed rapidly in the body, the elimination half-life (t1/2 beta) was 34 min and the apparent volume of distribution at steady-state (Vd ss) was 0.30 l/kg.",Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),[l] / [kg],0.30,266777,DB01032,Probenecid
,3108520,peak serum drug concentrations,"Mean peak serum drug concentrations were directly related to the oral dose administered, i.e. 0.22 microgram/ml, 1.06 micrograms/ml and 2.14 micrograms/ml after dosing at 10, 20 and 40 mg/kg, respectively.",Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),[μg] / [ml],0.22,266778,DB01032,Probenecid
,3108520,peak serum drug concentrations,"Mean peak serum drug concentrations were directly related to the oral dose administered, i.e. 0.22 microgram/ml, 1.06 micrograms/ml and 2.14 micrograms/ml after dosing at 10, 20 and 40 mg/kg, respectively.",Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),[μg] / [ml],1.06,266779,DB01032,Probenecid
,3108520,peak serum drug concentrations,"Mean peak serum drug concentrations were directly related to the oral dose administered, i.e. 0.22 microgram/ml, 1.06 micrograms/ml and 2.14 micrograms/ml after dosing at 10, 20 and 40 mg/kg, respectively.",Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),[μg] / [ml],2.14,266780,DB01032,Probenecid
,3108520,elimination t1/2,"The elimination t1/2 of the drug after oral dosing varied between 90 and 110 min, and the oral bioavailability was approximately 30% of the dose.",Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),min,90 and 110,266781,DB01032,Probenecid
,3108520,oral bioavailability,"The elimination t1/2 of the drug after oral dosing varied between 90 and 110 min, and the oral bioavailability was approximately 30% of the dose.",Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),%,30,266782,DB01032,Probenecid
,3108520,percentage of drug bound to,The percentage of drug bound to serum proteins was 78.8% +/- 8.2%.,Pharmacokinetics of phenoxymethyl penicillin (penicillin V) in calves. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108520/),%,78.8,266783,DB01032,Probenecid
,1888643,plasma clearance,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),[ml] / [min],255,267366,DB01032,Probenecid
,1888643,plasma clearance,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),[ml] / [min],266,267367,DB01032,Probenecid
,1888643,renal clearance,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),[ml] / [min],166,267368,DB01032,Probenecid
,1888643,renal clearance,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),[ml] / [min],155,267369,DB01032,Probenecid
,1888643,biliary clearance,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),[ml] / [min],106,267370,DB01032,Probenecid
,1888643,biliary clearance,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),[ml] / [min],111,267371,DB01032,Probenecid
,1888643,elimination half-life,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),h,34.4,267372,DB01032,Probenecid
,1888643,elimination half-life,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),h,35.2,267373,DB01032,Probenecid
,1888643,volume of distribution,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),l,538,267374,DB01032,Probenecid
,1888643,volume of distribution,"3. Probenecid did not affect the plasma clearance (mean +/- s.d.: 255 +/- 80 vs 266 +/- 40 ml min-1), renal clearance (166 +/- 17 vs 155 +/- 10 ml min-1), biliary clearance (106 +/- 40 vs 111 +/- 50 ml min-1), elimination half-life (34.4 vs 35.2 h) or volume of distribution (538 +/- 241 vs 566 +/- 60 l) of digoxin.",No effect of probenecid on the renal and biliary clearances of digoxin in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888643/),l,566,267375,DB01032,Probenecid
,9423165,maximum transport capacity,"The estimated maximum transport capacity and dissociation constant were 3.5 micrograms/min kg and 127 micrograms/mL, respectively.",Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),[μg] / [kg·min],3.5,268098,DB01032,Probenecid
,9423165,dissociation constant,"The estimated maximum transport capacity and dissociation constant were 3.5 micrograms/min kg and 127 micrograms/mL, respectively.",Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),[μg] / [ml],127,268099,DB01032,Probenecid
,9423165,total linear elimination clearance from CSF,The total linear elimination clearance from CSF was 0.0073 mL/min kg.,Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),[ml] / [kg·min],0.0073,268100,DB01032,Probenecid
,9423165,brain to plasma efflux rate constant,This analysis yielded a brain to plasma efflux rate constant of 0.040/min.,Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),1/[min],0.040,268101,DB01032,Probenecid
greater,2050085,plasma binding,"Despite extensive plasma binding (greater than 95%), the uncorrected renal clearance of BaP-7,8-dihydrodiol exceeded the glomerular filtration rate (GFR) by more than 20-fold.",Relative roles of metabolism and renal excretory mechanisms in xenobiotic elimination by fish. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050085/),%,95,269819,DB01032,Probenecid
,848932,serum half-life,The serum half-life of cefamandole in patients with normal renal function was approximately 1.5 h and increased in patients along with increasing impairment of renal function.,Pharmacokinetics of cefamandole in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/848932/),h,1.5,269969,DB01032,Probenecid
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271646,DB01032,Probenecid
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271647,DB01032,Probenecid
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271648,DB01032,Probenecid
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271649,DB01032,Probenecid
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],231,271650,DB01032,Probenecid
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],135,271651,DB01032,Probenecid
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],225,271652,DB01032,Probenecid
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],141,271653,DB01032,Probenecid
,3317582,MIC90,"The MIC90 values for cephalexin, cephradine and cefadroxil ranged between 3.12 micrograms ml-1 and 12.5 micrograms ml-1, whereas those of cefatrizine and cefaclor were 3.12 micrograms ml-1 and 0.78 microgram ml-1, respectively.",Clinical pharmacokinetics of five oral cephalosporins in calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317582/),[μg] / [ml],3.12,272654,DB01032,Probenecid
,3317582,MIC90,"The MIC90 values for cephalexin, cephradine and cefadroxil ranged between 3.12 micrograms ml-1 and 12.5 micrograms ml-1, whereas those of cefatrizine and cefaclor were 3.12 micrograms ml-1 and 0.78 microgram ml-1, respectively.",Clinical pharmacokinetics of five oral cephalosporins in calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317582/),[μg] / [ml],12.5,272655,DB01032,Probenecid
,3317582,MIC90,"The MIC90 values for cephalexin, cephradine and cefadroxil ranged between 3.12 micrograms ml-1 and 12.5 micrograms ml-1, whereas those of cefatrizine and cefaclor were 3.12 micrograms ml-1 and 0.78 microgram ml-1, respectively.",Clinical pharmacokinetics of five oral cephalosporins in calves. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317582/),[μg] / [ml],0.78,272656,DB01032,Probenecid
,3317582,elimination half-life values (t1/2 beta),The drugs showed rapid absorption into the systemic circulation after oral administration to pre-ruminating calves but the elimination half-life values (t1/2 beta) varied between three hours (cefaclor and cefadroxil) and nine hours (cefatrizine).,Clinical pharmacokinetics of five oral cephalosporins in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317582/),h,three,272657,DB01032,Probenecid
,3317582,elimination half-life values (t1/2 beta),The drugs showed rapid absorption into the systemic circulation after oral administration to pre-ruminating calves but the elimination half-life values (t1/2 beta) varied between three hours (cefaclor and cefadroxil) and nine hours (cefatrizine).,Clinical pharmacokinetics of five oral cephalosporins in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317582/),h,nine,272658,DB01032,Probenecid
,3317582,bioavailability,The bioavailability of the drugs was about 35 per cent of the administered dose.,Clinical pharmacokinetics of five oral cephalosporins in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317582/),%,35,272659,DB01032,Probenecid
,2802305,concentrations,Highest mean serum cephapirin concentrations were 16.1 +/- 2.16 micrograms/ml at 0.5 hour after the 5th cephapirin dose [postinjection (initial) hour (PIH) 48.5] in mares not given probenecid and 23.7 +/- 1.30 micrograms/ml at 1.5 hours after the 5th cephapirin dose (PIH 49.5) in mares given probenecid.,Effect of probenecid administration on cephapirin pharmacokinetics and concentrations in mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802305/),μ,16,272970,DB01032,Probenecid
,2802305,concentrations,Highest mean serum cephapirin concentrations were 16.1 +/- 2.16 micrograms/ml at 0.5 hour after the 5th cephapirin dose [postinjection (initial) hour (PIH) 48.5] in mares not given probenecid and 23.7 +/- 1.30 micrograms/ml at 1.5 hours after the 5th cephapirin dose (PIH 49.5) in mares given probenecid.,Effect of probenecid administration on cephapirin pharmacokinetics and concentrations in mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802305/),,23,272971,DB01032,Probenecid
,2802305,peak peritoneal fluid,"Mean peak peritoneal fluid and synovial fluid cephapirin concentrations were 6.2 +/- 0.57 micrograms/ml and 6.6 +/- 0.58 micrograms/ml, respectively, without probenecid administration and 12.3 +/- 0.46 micrograms/ml and 10 +/- 0.78 micrograms/ml, respectively, with concurrent probenecid administration.",Effect of probenecid administration on cephapirin pharmacokinetics and concentrations in mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802305/),[μg] / [ml],6.2,272972,DB01032,Probenecid
,2802305,peak peritoneal fluid,"Mean peak peritoneal fluid and synovial fluid cephapirin concentrations were 6.2 +/- 0.57 micrograms/ml and 6.6 +/- 0.58 micrograms/ml, respectively, without probenecid administration and 12.3 +/- 0.46 micrograms/ml and 10 +/- 0.78 micrograms/ml, respectively, with concurrent probenecid administration.",Effect of probenecid administration on cephapirin pharmacokinetics and concentrations in mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802305/),[μg] / [ml],12.3,272973,DB01032,Probenecid
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB01032,Probenecid
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB01032,Probenecid
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB01032,Probenecid
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB01032,Probenecid
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB01032,Probenecid
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB01032,Probenecid
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB01032,Probenecid
